Nephrology Dialysis Transplantation

Official Publication of the European Dialysis and Transplant Association–European Renal Association

Incorporating Proceedings of the European Dialysis and Transplant Association—European Renal Association

VOLUME 5: 1990

Editor-in-Chief:
Alex M. Davison, Leeds, UK

Editors:
H. Brynger, Göteborg, Sweden
V. Cambi, Parma, Italy
J. S. Cameron, London, UK
T. Drüeke, Paris, France
J. P. Grünfeld, Paris, France
L. Hernando, Madrid, Spain
K. Hierholzer, Berlin, FRG
H. Klinkmann, Rostock, GDR
H. Kreis, Paris, France
E. Ritz, Heidelberg, FRG
C. Van Ypersele, Bruxelles, Belgium

Advisory Editors:
J. F. Bach, Paris, France
R. S. Barsoum, Cairo, Egypt
J. Bergstrom, Stockholm Sweden
J. Botella, Madrid, Spain
J. D. Briggs, Glasgow, UK
M. Broyer, Paris, France
A. Dal Canton, Catanzaro, Italy
G. D'Amico, Milano, Italy
R. A. Donckerwolcke, Utrecht, The Netherlands
J. F. Donohoe, Dublin, Ireland
P. Druet, Paris, France
J. Egido, Madrid, Spain
H. Eliahou, Tel Hashomer, Israel
D. Falkenhagen, Rostock, GDR
M. Goldman, Bruxelles, Belgium
R. Greger, Frankfurt, FRG
P. Hayry, Helsinki, Finland
P. J. Hoedemaeker, Leiden, The Netherlands
C. Jacobs, Paris, France
R. A. P. Koene, Nijmegen, The Netherlands
F. Kokot, Katowice, Poland
N. H. Lameire, Gent, Belgium
R. Maiorca, Brescia, Italy
N. P. Mallick, Manchester, UK
June Mason, Basel, Switzerland
J. Ph. Méry, Paris, France
C. Mion, Montpellier, France
K. Olgaard, Copenhagen, Denmark
G. Opelz, Heidelberg, FRG
A. Pasternack, Tampere, Finland
R. Pichlmayr, Hannover, FRG
M. Polenaković, Skopje, Yugoslavia
C. Ponticelli, Milano, Italy
A. T. Raftery, Sheffield, UK
G. Remuzzi, Bergamo, Italy
L. Revert, Barcelona, Spain
G. F. Rizzoni, Padova, Italy
G. Sieberth, Aachen, FRG
I. Taraba, Budapest, Hungary
G. Thiel, Basel, Switzerland
D. W. Thoenes, Mainz, FRG
D. Thomson, Edinburgh, UK
A. Valek, Praha, Czechoslovakia
L. A. Van Es, Leiden, The Netherlands
A. J. Wing, London, UK
P. Zucchelli, Bologna, Italy

Editorial Assistant:
Helen Beddow, Leeds, UK

Springer International

Author Index to Volume 5

Aarseth H P, Ganss R: Removal of Chelated Aluminium During Haemodialysis Using Polysulphone High-Flux Dialysers 942
Abassi Z (abst) 658
Abdel Dayem M K (abst) 711
Abdulhadi M H, Fouad-Tarazi F M, Thomas T, Bravo E L, Paganini E P: The Haemodynamic Effects of Correction of Anaemia in Haemodialysis Patients Using Recombinant Human Erythropoietin S102
Abe M (abst) 745
Abel H (abst) 696
Abendroth K (abst) 713
Abraam I (abst) 711
Abramowicz D (abst) 677
Abu-Romeh S H (abst) 744
(letter) 834
Acerbo S: *See* Ghiggeri G M et al.
Ackrill P (abst) 716
Adami S: *See* Graziani G et al.
Adamiec R (abst) 467, 674
Adu D (abst) 683
Agazia B: *See* Ronco C et al.
Agishi T (abst) 663, 745, 757
Agroyannis B (abst) 650
Ahmad R (abst) 744
Aimo G (abst) 724
Airaghi C (abst) 642, 645
Akçahuseyin E: *See* Vincent H H et al.
Akçahuseyin E (abst) 898–9
Akira Nishida (abst) 741
Akizawa T (abst) 732
Ala-Houhala I, Oksa H, Pasanen M, Pasternack A: Interralations of Blood Pressure, Glomerular Filtration Rate, Protein Clearances and Sodium Excretion in Patients with Glomerulonephritis and Diabetic Nephropathy 337
Alaa El-din M (abst) 654
Alamartine E (abst) 745
Alarabi A A, Wahlberg J, Danielson B G, Tufveson G, Wadström J, Wikström B: Experience with the Hemasite Device in Haemodialysis and Haemofiltration Patients with Vascular Access Problems 508
Alaupovic P (abst) 663
Albarracin C (abst) 646
Albert F W: *See* Seyfert U T et al.
Albertazzi A, Del Rosso G, Di Paolo B, Capelli P, Palmieri P F: Computerised Non-Invasive Monitoring of Cardiovascular Stress in Haemodialysis Patients S133
Albertazzi A (abst) 666
Alberti D: *See* Maschio G et al.
Alberto W (abst) 644
Aldridge C (abst) 319
Alessi D (abst) 655
Alexopoulos E: *See* Serón D et al.
Al-Haidary A D, Mackay I G, Bhoola K D, Millar N D, Watson M L, Mackenzie J C: Electrolyte and Humoral Responses of Renal Transplant Patients to Head-Out Water Immersion 535
Al Jamal H (letter) 238
Aljama P: *See* Quesada J M et al.
Aljama P (abst) 705, 717, 723, 750
Allain P (abst) 645
Allaouchiche B (abst) 657, 661
Allegri L, Celendo M T, Ferrari C, Savazzi G, Ronco P, Verroust P: Role of a 90-kD Glycoprotein in Heymann's Nephritis S60
Allen A C (abst) 680
Alloatti S (abst) 697
Almeida M (abst) 697
Almirall J (abst) 757
Almirall J (letter) 903
Al-Nawab M D: *See* Wang Y et al.
Alsina J (abst) 753, 756
Altmann P (abst) 729
Alvarez de Lara M A (abst) 723
Alvarez J (abst) 652
Alvarez M A (abst) 705
Alvarez V (abst) 696
Alvarez-Grande J (abst) 748–9
Alvestrand A (abst) 672
Amado J A: *See* De Francisco A L M et al.
Amado J A (abst) 730
Amaya L (abst) 644
Amdisen A: *See* Sørensen S S et al.
Ameno Y (abst) 725
Amiel C: *See* Friedlander G et al.
Amiel C, Blanchet F, Friedlander G, Nitenberg A: Renal Functional Reserve 763
Amore A (abst) 675, 683
Amorim J P (letter) 320
Amoroso A (abst) 754
Amorosol L (abst) 666
Amprimo M C (abst) 724
Anastasio P (abst) 665, 670
Anastassiades E, Ireland H, Flynn A, Lane D A, Curtis J R: A Low-Molecular-Weight Heparin (Kabi 2165, Fragmin) in Repeated Use for Haemodialysis: Prevention of Clotting and Prolongation of the Venous Compression Time (abst) 135
Anastassiades E (abst) 736
Anção M S: *See* Sesso R et al.
Anders H (abst) 709

Andersen C B, Ladefoged S D, Lauritsen H K, Hansen P R, Larsen S: Detection of CMV DNA and CMV Antigen in Renal Allograft Biopsies by *In Situ* Hybridisation and Immunohistochemistry 1045
Andersen C B (abst) 676, 829
Andersen M J F (abst) 830
Anderson V E R (abst) 306
Anderton J L: *See* Bunney M H et al.
Andrassy H (abst) 706
Andrassy K (letter) 901
Andreae A (abst) 693
Andrejeak M (abst) 660
Andres A (abst) 653, 749
Andrés E (abst) 756
Andres G: *See* Queluz T T
Andreu J (abst) 746, 751, 755, 757
Andreu J (letter) 903
Andreucci V E: *See* Capuano A et al.; Sabbatini et al.
Andreucci V E (book review) 476
Androjna C (abst) 312, 700
Ang K S (abst) 643
Angelini D (abst) 691
Angerpointer T A (book review) 404
Angielski S (abst) 470
Angoletta F (abst) 708
Anteby E Y, Wald H, Popovtzer M M: Glycerol-Induced Acute Renal Failure in the Rat: The Protective Effect of Unilateral Nephrectomy 118
Antignani A (abst) 698
Anton P (abst) 664
Antonangeli L (abst) 669
Antonelli A (abst) 691
Antoniadis A (abst) 733
Antoniou A (abst) 733
Antonov S (letter) 475
Antonucci F (abst) 658
Aparicio M (abst) 646, 663–4
Apostoli P: *See* Ravelli M et al.
Apperl A (abst) 713, 719, 753
Apperloo A J (abst) 894
Aquado S (abst) 748–9
Ardaillou R (abst) 470, 692, 696
Arias M: *See* De Francisco A L M et al.
Arias M (abst) 730
Arici C (letter) 903
Arisz L: *See* Buysen J G M et al.
Arisz L (abst) . . . 299, 313, 649, 718, 721–2, 894–5, 897–8
Arné P (abst) 646
Arnold J (abst) 758
Arnoux B (abst) 723
Aroldi A: *See* Graziani G et al.
Arrizabalaga P (abst) 703
Arrobas M (abst) 729
Arrojo F (abst) 720
Asmus G (abst) 734
Assan R: *See* Friedlander G et al.
Assmann K J M (abst) 295–6, 307
Aswad S (abst) 669
Aten J (abst) 296, 306
Athanasou N A, Chaplin A J, Oliver D O: Subcutaneous Deposition of Beta$_2$-Microglogulin Amyloid in a Long-Term Haemodialysis Patient . . 878
Attman P O (abst) 663
Aurell M (abst) 740
Ausejo M (abst) 721
Ausserwinkler M (letter) 555
Autuly V (abst) 643
Averbukh Z: *See* Modai D et al.
Avram M M (abst) 698
Aznar-Salatti J (abst) 664
Baatard R (abst) 747
Bab I (abst) 710
Babloyan A (abst) 731
Baccega M (abst) 683
Bachmann S (abst) 686
Baehr R V: *See* Schmidtmann S et al.
Baelde J J (abst) 303
Bahlmann J: *See* Nonnast-Daniel B et al.
Bahner U (abst) 693
Bailey R R (abst) 309, 316
Baillod R (abst) 298
Baker F (abst) 303
Bakir N: *See* Hussein M M et al.
Bakker M A H (abst) 295
Bakker W W (abst) 305
Balcke P (abst) 685, 690, 713, 719, 723, 743, 753
Baldamus C A (abst) 684
Baldari G (abst) 686
Baldrati L: *See* Docci D et al.
Baldwin D (abst) 314
Ballardie F W: *See* Mistry C D et al.
Ballardie F W (abst) 298, 304
Baller J F W (abst) 305
Balletta M (abst) 678
Ballocchi S: *See* Bergonzi G et al.
Ballocchi S (abst) 722
Balow J E: Treatment and Monitoring of Patients with Lupus Nephritis S58
Banfi G (letter) 473
Bar-Haim Y (abst) 710
Barakat A Y (book review) 556
Barata J (abst) 697
Barba G (abst) 665, 670
Barbano G: *See* Ginevri F et al.
Barbas J M (letter) 474
Barbatsi A (abst) 733
Barbera G: *See* Sturniolo A et al.
Barbiano di Belgiojoso G: *See* Genderini A et al.
Barbiano di Belgiojoso G, Genderini A, Vago L, Parravicini C, Bertoli S, Landriani N: Absence of HIV Antigens in Renal Tissue from Patients with HIV-Associated Nephropathy 489
Barbiano di Belgiojoso G (abst) 717
Baretta A (abst) 730
Barna I (abst) 691
Baró P (letter) 237
Barone M T (abst) 717
Barr B B: *See* Bunney M H et al.
Barratt T M (abst) 639
Barrera J M (abst) 751
Barrientos A (abst) 666, 704, 735
Barril G (abst) 696
Barrio V: *See* Quesada J M et al.
Barrio V (abst) 717, 750
Barron J H (abst) 716
Barron J L (abst) 650
Barsotti G, Cupisti A, Morelli E, Ciardella F, Giovannetti S: Vegan Supplemented Diet in Nephrotic Syndrome S75
Bartalena L (abst) 669
Barth H P: *See* Bommer J et al.
Barth H P (abst) 737

Bartoli R (abst) . . . 699
Baschieri L (abst) . . . 669
Basiakou S (abst) . . . 733
Basile C: *See* Casino F G et al.
Bassett A H: *See* El Nahas A M et al.; Wight J P et al.
Bassett A H (abst) . . . 316, 671
Batlle D C (abst) . . . 689
Batsford S: *See* Vogt A et al.
Baumelou A (abst) . . . 659, 745
Bautembach S (abst) . . . 469, 742
Bayrou B (abst) . . . 707
Baz M: *See* Monti J P et al.
Baz M (abst) . . . 689
Bazzato G: *See* Scanferla F et al.
Beastall G H: *See* Van der Merwe W M et al.
Becquemont L: *See* Meyrier A et al.
Bedogna V: *See* Maschio G et al.
Beermann E M (abst) . . . 897–8
Begaud B (abst) . . . 707
Behme T C (abst) . . . 706
Belechri A (abst) . . . 733
Bell P R F: *See* Donnelly P K et al.
Bell P R F (abst) . . . 756
Bellavita P (letter) . . . 903
Beltrame G (abst) . . . 665, 710
Beltrandi E (abst) . . . 651, 680
Benazzi E (abst) . . . 712
Bending M R (abst) . . . 650
Beneton M N C (abst) . . . 311
Bengtsson B-Å (abst) . . . 688
Benhmida M (abst) . . . 745
Benjelloun A S (abst) . . . 664
Bennhold I (abst) . . . 696, 752
Benton E C: *See* Bunney M H et al.
Berden J H M (abst) . . . 295, 303, 310
Bereiter-Hahn J (abst) . . . 706
Bererhi L: *See* Losekann A et al.
Berg K J (abst) . . . 748
Berg U (abst) . . . 657
Berger H: *See* Seyfert U T et al.
Bergesio F (abst) . . . 670
Bergia R (abst) . . . 665
Bergonzi G, Paties C, Vassallo G, Zangrandi A, Poisetti P G, Ballocchi S, Fontana F, Scarpioni L: Dextran Deposits in Tissues of Patients Undergoing Haemodialysis . . . 54
Bergonzi G (abst) . . . 722
Bergstrom C, Tufveson G, Broyer M, Brunner F P, Brynger H, Ehrich J H H, Fassbinder W, Geerlings W, Rizzoni G, Selwood N H, Wing A J: Transplant Co-ordination Services in Europe 1989: A Survey by the EDTA Registry . . . 559
Bergström J (abst) . . . 672
Berland Y: *See* Monti J P et al.
Berland Y, Boistelle R, Olmer M: Urinary Supersaturation with Respect to Brushite in Patients Suffering Calcium Oxalate Lithiasis . . . 179
Berland Y (abst) . . . 689
Berman S: *See* Modai D et al.
Bernard T: *See* Innes A et al.
Bernat A (abst) . . . 668, 741
Bernheim J: Effects of Different Converting-Enzyme Inhibitors on the Course of Non-Diabetic Glomerulopathies . . . 837
Bernheim J (abst) . . . 642, 662, 710
Bernheim J (letter) . . . 553
Bernieh B: *See* Bindi P et al.
Bernieh B (abst) . . . 700
Bernis C (abst) . . . 696
Bernstein J (book review) . . . 907
Beroniade V (abst) . . . 641
Bertani T: *See* Genderini A et al.
Bertelli R: *See* Ginevri F et al.
Berthoux F (abst) . . . 745
Bertoli S: *See* Barbiano di Belgiojoso G et al.; Genderini A et al.
Bertoli S (abst) . . . 717
Bertolissii M (abst) . . . 658
Bertoux F: *See* Guerin C.
Bertoux P (abst) . . . 745
Berzlanovich A (abst) . . . 694
Betriu M A (abst) . . . 739
Better O S (abst) . . . 658
Beutler J J (abst) . . . 317
Bewick M (abst) . . . 306
Bewick M (letter) . . . 320
Bezian J H (abst) . . . 663
Bfarna I (abst) . . . 692
Bhoola K D: *See* Al-Haidary A D et al.; Figueroa C D et al.
Bianchi A M: *See* Di Bello V et al.
Bianchi M (abst) . . . 655
Bianchi M L (abst) . . . 664, 738
Bianchi S (abst) . . . 686
Biasioli S, Petrosino L, Cavallini L, Cesaro A, Fazion S, Zambello A, Foroni R, Mazzali A: Cardiovascular Stability During the Haemodialysis Session: Relationship Between Modelling and Impedance Parameters . . . S137
Biddlestone L R (abst) . . . 677
Bier V (abst) . . . 737
Biesenbach G (abst) . . . 643
Bieth J G (abst) . . . 702
Bigazzi R (abst) . . . 686
Bijlsma J A (abst) . . . 318
Billis A (abst) . . . 733, 749
Bilo H J G (abst) . . . 308, 640, 687
Bindi P, Lavaud S, Bernieh B, Toupance O, Chanard J: Early and Late Occurrences of Destructive Spondyloarthropathy in Haemodialysed Patients . . . 199
Binswanger U: *See* Hess B.; Probst W et al.; von Kiparski A et al.
Binswanger U (abst) . . . 702, 711, 749
Birk H-W (abst) . . . 637, 662, 715
Biro A (abst) . . . 649
Bispo J (abst) . . . 697
Bitker M O (abst) . . . 745
Björck S (abst) . . . 660, 740
Blaehr H (abst) . . . 676, 828
Bláha J: *See* Mareckova O et al.
Blanchet F: *See* Amiel C et al.
Blanchet-Benqué F: *See* Friedlander G et al.
Blaškovičová H (abst) . . . 397
Błaszczyk J (abst) . . . 469
Błaszczyk K (abst) . . . 468
Blatsoukasm G (abst) . . . 733
Bloemena E (abst) . . . 307
Blohmé I: *See* Friman S et al.
Bloom S R: *See* Warrens A N et al.
Bloom S E (abst) . . . 676
Blossei N: *See* Neumayer H-H et al.
Blum M (abst) . . . 697

Blum W F (abst) 652, 754
Bobrow M (letter) 900
Boehler T (abst) 737
Boelaert J R, Cantinieaux B F, Hariga C F, Fondu P G: Recombinant Erythropoietin Reverses Polymorphonuclear Granulocyte Dysfunction in Iron-Overloaded Dialysis Patients 504
Boelaert J R, Daneels R F, Schurgers M L, Matthys E G, Gordts B Z, Van Landuyt HW: Iron Overload in Haemodialysis Patients Increases the Risk of Bacteraemia: A Prospective Study 130
Boer J (abst) 469
Boer P (abst) 302
Boer W H (abst) 317–18
Boero R (abst) 691
Boeschoten E W (abst) 313, 718, 721, 894–5, 898
Bogman M J J T (abst) 307
Bohdanecká (abst) 398
Bohle A: *See* Markovic-lipkovski J et al.
Böhler K (abst) 697
Boistelle R: *See* Berland Y et al.
Boitard C: *See* Hannedouche T et al.
Boji P (abst) 701
Boltzmann L (abst) 693
Bombardini T: *See* Stefoni S et al.
Bommer G (abst) 737
Bommer J: *See* Ruffmann K et al.
Bommer J (abst) 737
Bommer J, Kugel M, Schwöbel B, Ritz E, Barth H P, Seelig R: Improved Sexual Function During Recombinant Human Erythropoietin Therapy . . . 204
Bommer J, Weinreich T, Lovett D H, Bouillon R, Ritz E, Gemsa D: Particles From Dialysis Tubing Stimulate Interleukin-1 Secretion by Macrophages . 208
Bonal J: *See* Serra A et al.
Bonaudo R (abst) 655
Bone J M (abst) 311, 674, 755
Bonello F (abst) 665, 710, 720
Boner G (abst) 710
Bonet J: *See* Serra A et al.
Bonino F (abst) 752
Bono M (abst) 687
Bonomini M (abst) 666
Bonomini V: *See* Vangelista A et al
Bonomini V, Gozzetti G: Is Living Donation Still Justifiable? 407
Bonta I L (abst) 313, 718
Bonzel K (abst) 656
Borca M (abst) 691
Borgatti P P: *See* Soliani F et al.
Borque N (abst) 735
Borries M (abst) 695
Borris L C (abst) 831
Bortel L V (abst) 708
Bosch A (abst) 737
Bosticardo G M (abst) 697
Botey A (abst) 687
Bouchet J L (abst) 663
Boudagjan A (abst) 731
Boudailliez B (letter) 553
Bougatsos G (abst) 714
Bouillon R: *See* Bommer J et al.
Bouillon R (abst) 736
Boulton-Jones J M: *See* Fox J G et al.
Boulton-Jones J M (abst) 301, 315, 639, 654
Bourbigot B (abst) 745
Bourdon R: *See* Losekann A et al.
Bourgeois V (letter) 1055
Boussema E (abst) 643
Bouw A (letter) 552
Bouw M J (letter) 552
Bover J (abst) 753, 756
Braendle E, Kindler J, Sieberth H G: Effects of an Acute Protein Load in Comparison to an Acute Load of Essential Amino Acids on Glomerular Filtration Rate, Renal Plasma Flow, Urinary Albumin Excretion and Nitrogen Excretion 572
Bragantini L: *See* Ronco C et al.
Bramley P N (abst) 312
Brandis A (abst) 726
Bravi M (abst) 699
Bravo E L: *See* Abdulhadi M H et al.
Bren A (abst) 643
Brenchley P E C (abst) 298, 304
Brendolan A: *See* Ronco C et al.
Bridges J M: *See* Brown J H et al.
Briggs J D: *See* Van der Merwe W M et al.
Briggs J D (abst) 718
Brillet G (abst) 659
Brini M: *See* Soliani F et al.
Briz E (abst) 730
Brodahl U (abst) 748
Brown A L: *See* Tucker B et al.
Brown A L (abst) 691
Brown A L, Greenwood R N, Cattell W R: Successful Medical Management of Presumed Spontaneous Decapsulation of a Transplant Kidney 75
Brown C B (abst) 311
Brown E A (abst) 312
Brown H (abst) 640, 664
Brown J H (abst) 745
Brown J H, Lappin T R J, Elder G E, Bridges J M, McGeown M G: The Metabolism of Erythropoietin in the Normal and Uraemic Rabbit 855
Brown J H (letter) 554
Brown S C W (abst) 638
Brownjohn A M: *See* Lipkin G W et al.
Brownjohn A M (abst) 310
Brownlee A (abst) 309
Broyer M: *See* Bergstrom C et al.; Laouari D et al.; Rizzoni G et al.
Broyer M, Brunner F P, Brynger H, Dykes S R, Ehrich J H H, Fassbinder W, Geerlings W, Rizzoni G, Selwood N H, Tufveson G, Wing A J: Kidney Transplantation in Primary Oxalosis: Data From the EDTA Registry 332
Brú C (abst) 647, 757
Bruggeman C A (abst) 758
Bruguera M (abst) 751
Bruijn J A: *See* Hogendoorn P C W et al.
Bruijn J A (abst) 296, 303–4, 677
Brunati C (abst) 737
Brunkhorst R: *See* Nonast-Daniel B et al.
Brunkhorst R (abst) 648, 671
Brunner F P: *See* Bergstrom C et al.; Broyer M et al.
Brunner F P, Brynger H, Ehrich J H H, Fassbinder W, Geerlings W, Rizzoni G, Selwood N H, Tufveson G, Wing A J: Case Control Study on Dialysis Arthropathy: The Influence of Two Different Dialysis Membranes: Data from the EDTA Registry 432
Brunner R P: *See* Rizzoni G et al.

Bruno M (abst) . . . 665
Brunori G (abst) . . . 698
Bruyn J A (abst) . . . 296–7
Brynger H: *See* Bergstrom C et al.; Broyer M et al.; Brunner F P et al.; Rizzoni G et al.
Bubić-Filipi Lj (abst) . . . 662
Buccianti G (abst) . . . 664, 738
Buchholz B (abst) . . . 746
Bucht H (abst) . . . 672
Buczyński A (abst) . . . 468–9
Bulla M (abst) . . . 656
Bunker D (abst) . . . 659
Bunney M H, Benton E C, Barr B B, Smith I W, Anderton J L, Hunter J A A: The Prevalence of Skin Disorders in Renal Allograft Recipients Receiving Cyclosporin A Compared with Those Receiving Azathioprine . . . 379
Bunzendahl H: *See* Vogt P et al.
Burchert W (abst) . . . 726
Burden R P: *See* Innes A et al.; Morgan L J et al.
Burden R P (abst) . . . 704, 752
Burdiel L G (abst) . . . 705, 717, 723, 750
Burger H, Zijlstra J J, Kluchert S A, Scholten A P, Kootstra G: Percutaneous Transluminal Angioplasty Improves Longevity in Fistulae and Shunts for Haemodialysis . . . 608
Burgos J (abst) . . . 716
Burns A (abst) . . . 297
Burrell D (abst) . . . 698
Burrichter H (abst) . . . 684
Burtin M: *See* Laouari D et al.
Burtorin N (abst) . . . 705
Butkowski R: *See* Segelmark M et al.
Butlen D (abst) . . . 317
Buturović J (abst) . . . 643
Buur T, Timpka T, Lundberg M, Urea Kinetics and Clinical Evaluation of the Haemodialysis Patient . . 347
Buxbaum M (abst) . . . 686
Buysen J G M, Houthoff H J, Krediet R T, Arisz L: Acute Interstitial Nephritis: A Clinical and Morphological Study in 27 Patients . . . 94
Buzio C (abst) . . . 644
Cabré C (abst) . . . 746
Cacace G (abst) . . . 683
Caglioti A (abst) . . . 644, 677
Cagnoli L, Viglietta G, Madia G, Gattiani A, Orsi C, Rigotti A, Zuccelli A: Acute Bilateral Renal Vein Thrombosis Superimposed on Calcified Thrombus of the Inferior Vena Cava in a Patient with Membranous Lupus Nephritis . . . S71
Cairns H S (abst) . . . 300
Cairns T (abst) . . . 307, 314
Caix J (abst) . . . 663
Caizzi V (abst) . . . 700
Çakmakçi M (abst) . . . 704
Čala S (abst) . . . 698
Čala S, Mažuran R, Kordić D: Negative Effect of Uraemia and Cuprophane Haemodialysis on Natural Killer Cells . . . 437
Calandri C: *See* Saggi S et al.
Calemard E (abst) . . . 726
Callard P (abst) . . . 651
Callea F: *See* Sandrini S et al.
Calò L (abst) . . . 658
Cam G (abst) . . . 643
Cambar J (abst) . . . 664
Cambon-Thomsen A (abst) . . . 656
Cameron J S: How Can We Treat Glomerulonephritis? S16
Cameron J S: *See* Frampton G et al.; Serón D et al.
Cameron J S (abst) . . . 678, 683, 721
Cameron J S (letter) . . . 78, 900, 981
Campagna K D (letter) . . . 400
Campbell E (letter) . . . 321
Campbell I T (abst) . . . 311
Campese V M: Autonomic Nervous System Dysfunction in Uraemia . . . S98
Campise M: *See* Casati S et al.
Campise M (abst) . . . 738
Campistol J M (abst) . . . 647, 724, 746, 751, 755, 757
Campistol J M (letter) . . . 158, 237, 903
Campos C (abst) . . . 653, 749
Camps J (letter) . . . 902
Canaud B (abst) . . . 723
Candiano G: *See* Ghiggeri G M et al.; Ginervri F et al.
Canga E (abst) . . . 730
Cannella G (abst) . . . 737–8
Cantalamessa L (abst) . . . 738
Cantaluppi A (abst) . . . 717, 726
Cantaravich D (abst) . . . 746–7
Cantaro S (abst) . . . 658
Cantarovich F (abst) . . . 644, 658
Cantarovich F (book review) . . . 635
Cantarovich M (abst) . . . 644, 658
Cantinieaux B F: *See* Boelaert J R et al.
Canto C G (abst) . . . 696
Capasso G (abst) . . . 665, 670
Cappelli D (abst) . . . 722
Cappelli P: *See* Albertazzi A et al.
Cappelli P (abst) . . . 666
Cappellini M D (abst) . . . 737
Capuano A, Sepe V, Cianfrone P, Castellano T, Andreucci V E: Cardiovascular Impairment, Dialysis Strategy and Tolerance in Elderly and Young Patients on Maintenance Haemodialysis . . 1023
Caputo M T: *See* Di Bello V et al.
Caralps A: *See* Serra A et al.
Caravaca F (abst) . . . 729
Carayon A (abst) . . . 692
Cardelli R (abst) . . . 665
Caress A (abst) . . . 716
Carlini A (abst) . . . 691
Carmichael D J S: *See* Foster G R et al.; Gopal Rao G et al.
Carmichael D J S (letter) . . . 633
Carmody M (letter) . . . 320
Carneiro J (abst) . . . 703
Carothers A D (abst) . . . 653
Carozzi S (abst) . . . 717, 726
Carr E C (abst) . . . 650
Carr S J (abst) . . . 644
Carrera F (abst) . . . 703
Carrera M (abst) . . . 703, 753
Carvalho F (letter) . . . 552
Casadevall N: *See* Losekann A et al.
Casanova D (abst) . . . 730
Casati S: *See* Graziani G et al.
Casati S (abst) . . . 738
Casati S, Castelnovo C, Campise M, Ponticelli C: Aluminium Interference in the Treatment of Haemodialysis Patients with Recombinant Human Erythropoietin . . . 441
Cascone C (abst) . . . 714

Cases A (abst) . . . 664, 687, 723
Cashman S J (abst) . . . 304
Casiere D (abst) . . . 671
Casino F G, Basile C, Gaudiano V, Lopez T: A Modified Algorithm of the Single Pool Urea Kinetic Model . . . 214
Cassidy M J D: *See* Warrens A N et al.
Cassidy M J D (abst) . . . 676
Castelao A M (abst) . . . 756
Castell J (abst) . . . 687
Castellano T: *See* Capuano A et al.
Castellanos G (abst) . . . 749
Castellino P (abst) . . . 665, 671
Castelnovo C: *See* Casati S et al.; Graziani G et al.
Castelnovo C (abst) . . . 738
Castillo D: *See* Quesada J M et al.
Castillo D (abst) . . . 705, 717, 750
Castillo R (abst) . . . 723
Castro L (abst) . . . 644, 658
Castro M C G (abst) . . . 751
Catalano C (abst) . . . 644
Catalano C, Postorino M, Kelly P J, Fabrizi F, Enia G, Goodship T H, Fulcher G R, Maggiore Q: Diabetes Mellitus and Renal Replacement Therapy in Italy: Prevalence, Main Characteristics and Complications 788
Catelao A M (abst) . . . 753
Cattell V: *See* Foster G R et al.
Cattell V (abst) . . . 676
Catchl W R: *See* Brown A L et al.; Tucker B et al.
Cattell W R (abst) . . . 691
Cattell W R (book review) . . . 477
Catto G R D (abst) . . . 295, 756, 757
Catucci G (abst) . . . 666
Caudwell V (abst) . . . 726
Cavalli P L (abst) . . . 720
Cavallini L: *See* Biasioli S et al.
Cavill I: *See* Macdougall I C et al.
Cecchin E (abst) . . . 645, 739
Celendo M T: *See* Allergri L et al.
Celma M L (abst) . . . 714
Cerrai T (abst) . . . 710
Cesaro A: *See* Biasioli S et al.
Chan M K: *See* Cheng I K P et al.
Chan P C K: *See* Cheng I K P et al.
Chanard J: *See* Bindi P et al.
Chanard J (abst) . . . 700, 726, 728, 755
Chantler C (letter) . . . 320, 900
Chaplin A J : *See* Athanasou N A et al.
Chapuis C (abst) . . . 699
Charra B (abst) . . . 726
Chastang C (abst) . . . 707
Chauveau P (abst) . . . 699
Chavis C (abst) . . . 723
Chazot C (abst) . . . 726
Cheng I K P, Chan P C K, Chan M K: The Effect of Fish-Oil Dietary Supplement on the Progression of Mesangial IgA Glomerulonephritis . . . 241
Chiappini M G (abst) . . . 699
Chiaramonte S: *See* Ronco C et al.
Chochrad D (abst) . . . 894
Choi H: *See* Saggi S et al.
Choy A M (abst) . . . 694
Christensen H K: *See* Otte K E et al.
Christensen H K (abst) . . . 709
Christians U (abst) . . . 752
Chugh K S: *See* Gupta K L et al.
Ciacci C (abst) . . . 665, 671
Cianciolo G: *See* Stefoni S et al.
Cianfrone P: *See* Capuano A et al.
Ciardella F: *See* Barsotti G et al.
Čiderová A (abst) . . . 393
Cidoncha A (abst) . . . 666
Cimadeville R (abst) . . . 748
Cirillo D (abst) . . . 671
Ciuti R (abst) . . . 670
Civati G (abst) . . . 712, 737
Cledes J (abst) . . . 645, 745
Clement C (abst) . . . 700
Clement J P: *See* D'Haese P C et al.
Clutterbuck E J, Evans D J, Pusey C D: Renal Involvement in Churg-Strauss Syndrome . . . 161
Clyne N (abst) . . . 665
Cocchi R: *See* Fabbri A et al.
Cocco G (abst) . . . 708
Cochat N: *See* Cochat P et al.
Cochat P, Cochat N, Jouvenet M, Floret D, Wright C, Martin X, Vallon J J, David L: Ceftriaxone-Associated Nephrolithiasis . . . 974
Coelho A (letter) . . . 552
Coen G: (abst) Spallone V et al.
Cohen J H M (abst) . . . 726, 728
Cohen N A (abst) . . . 750, 758
Cohen Solal M E (abst) . . . 736
Cohen Tervaert J W (abst) . . . 298
Cohn M: *See* Modai D et al.
Colantonio G (abst) . . . 664
Colasanti G (book review) . . . 907
Coles G A: *See* Macdougall I C et al.
Coles G A (abst) . . . 759
Coli L: *See* Stefoni S et al.
Colina F (abst) . . . 749
Collado A (abst) . . . 755
Collart F (abst) . . . 894
Colleoni N (abst) . . . 700
Colombe B W (abst) . . . 750, 758
Colombo P (abst) . . . 665
Colon S (abst) . . . 643
Colussi G (abst) . . . 642, 645, 712
Combe C (abst) . . . 646
Comi N (abst) . . . 678
Concepción T (abst) . . . 731
Concesi C (abst) . . . 722
Conte G: *See* Sabbatini M et al.
Conte G (abst) . . . 644
Conteau M (abst) . . . 303
Conz P: *See* Ronco C et al.
Cook T (abst) . . . 676
Coppo R (abst) . . . 655, 675, 683, 724
Coppola S (abst) . . . 665, 670
Cordonnier D (abst) . . . 669
Corigliano C (abst) . . . 700
Cornu C (letter) . . . 1057
Cornu Ch (abst) . . . 705
Coronel F (abst) . . . 666
Corradi B (abst) . . . 700
Coscarella G (abst) . . . 665, 670
Cosci P (abst) . . . 700
Costa A M (letter) . . . 552
Costanzi S: *See* Sturniolo A et al.
Cosyns J P: *See* Peten E et al.
Cotorruelo J G: *See* De Francisco A L M et al.
Cotorruelo J G (abst) . . . 730

Cotter L (abst) 300
Cotton R E: *See* Innes A et al.
Coupes B M (abst) 304
Couroucé A M (abst) 699
Cowan R A: *See* Van der Merwe W M et al.
Cozma G (letter) 238
Cozma M C (letter) 238
Cozzi G (abst) 716
Crabtree J (abst) 312, 700
Crastes de Paulet A (abst) 723
Crellin D M (abst) 679
Cremagnani L (abst) 738
Crepaldi C: *See* Ronco C et al.
Cresseri D (abst) 664
Creutzig A: *See* Nonnast-Daniel B et al.
Crevat A: *See* Monti J P et al.
Crevat A (abst) 689
Cristinelli L: *See* Sandrini S et al.
Cristol J P (abst) 723
Cruceira A (abst) 735
Cruickshank K (abst) 674
Crusius J B A (abst) 318
Cubero J (abst) 729
Cunningham J (abst) 729
Cunningham S (abst) 754
Cupisti A: *See* Barsotti G et al.
Curatola A (abst) 654–5
Curatola G (abst) 654
Curtis J R: *See* Anastassiades E et al.
Cusson J R (abst) 641
Cuzzola F (abst) 654, 690
Cuzzola P (abst) 655
Czekalski S (abst) 470, 692, 696
Czyżewska K (abst) 470
Daelemans R A (abst) 701
Dag P (abst) 709, 748
Daha M R (abst) 297, 758
Dahl E, Nordal K P, Halse J, FlatmarkA: The Early Effects of Aluminium Deposition and Dialysis on Bone in Chronic Renal Failure: A Cross-Sectional Bone-Histomorphometric Study 449
Dahl H B (abst) 828
Dahl K, Walstad R A, Widere T-E: The Effect of Peritonitis on the Transperitoneal Transport of Cefuroxime in Patients on CAPD Treatment 275
Dal Canton A: *See* Sabbatini M et al.
Dal Canton A (abst) 644, 677–8
Dal Canton A (book review) 476
Dall'Omo A (abst) 752
D'Amico G (abst) 681–2, 700
D'Amico G and Sinico R A: Treatment and Monitoring of Systemic Vasculitis S53
D'Amico G (book review) 635, 907
Damon M (abst) 723
Daneels R P: *See* Boelaert J R et al.
Daniel W G (abst) 708
Danielsen H: *See* Jespersen B et al.
Danielsen H (abst) 694
Danielson B G: *See* Alarabi A A et al.
Danielson B G (abst) 733, 742
Dantal J (abst) 747
d'Ardenne A J: *See* Tucker B et al.
Darvill A (abst) 298
Das A K: *See* Wang Y et al.
Daugaard H (abst) 829, 831
Davenport A (abst) . . . 306, 312, 646, 658, 700, 739, 747
Davenport A, Will E J, Davison A M: Early Changes in Intracranial Pressure During Haemofiltration Treatment in Patients with Grade 4 Hepatic Encephalopathy and Acute Oliguric Renal Failure . 192
Davenport A, Will E J, Davison A M: Paradoxical Increase in Arterial Hydrogen Ion Concentration in Patients with Hepatorenal Failure Given Lactate-Based Fluids 342
David C (abst) 755
David L: *See* Cochat P et al.
Davies D R: *See* Wang Y et al.
Davies M E (abst) 759
Davies M E: *See* Macdougall I C et al.
Davies S P (abst) 312
Davison A M : *See* Davenport A et al.
Davison A M: Steroid Therapy in Primary Glomerulonephritis S23
Davison A M (abst) 306, 312, 646, 658, 679, 685, 700, 739, 747
Davoli V: *See* Soliani F et al.
Day J P (abst) 716
de Bakker J (abst) 898
de Bonis E (abst) 730
De Broe M E: *See* D'Haese P C et al.; Van de Vyver F L et al.
De Broe M E (abst) 311, 66l, 667, 731, 735
de Caestecker M P, Hall C L, MacIver A G: Atypical Antiglomerular Basement Membrane Disease Associated with Thin Membrane Nephropathy . . . 909
de Châtel R (abst) 691–2
De Cristofaro V (abst) 730
De Dominicas E: *See* Ronco C et al.
De F L (abst) 715
De Ferrari M E (abst) 642
de Fijter C W H (abst) 313, 895
de Fijter C W H (letter) 78
de Francisco A L M (abst) 729–30
De Francisco A L M, Cotorruelo J G, Riancho J A, Amado J A, Sanz De Castro S, Zubimendi A, Arias M: Psoriasis, 1, 25$(OH)_2$ Vitamin D3 and Renal Failure 293
de Graeff A (abst) 648
de Heer E (abst) 296, 306, 677
de Jong G M Th (letter) 78
de Jong M C J W (abst) 308, 897
de Jong P E: *See* Dofferhoff A S M et al.; Kremer Hovinga T K et al.
de Jong P E (abst) 297, 301, 315
De Marchi S (abst) 645, 739
De Maria G: *See* Ravelli M et al.
De Monte A (abst) 658
De Negri F (abst) 669
De Nicola L: *See* Sabbatini M et al.
de Oña M (abst) 748–9
De Paepe M (abst) 667
De Plaen J F: *See* Ghysen J et al.
de Precigout V (abst) 646
De Raedt H (abst) 701
de Rooy-Roggekamp M C (abst) 897
De Santo N G (abst) 665
De Smet R (abst) 701, 736
De Vecchi A: *See* Graziani G et al.
de Vries P M J M: Fluid Balance During Haemodialysis and Haemofiltration: The Effect of Dialysate Sodium S158
de Vries P M J M (abst) 715, 895–6

De Zeeuw D: *See* Kremer Hovinga T K et al.
de Zeeuw D (abst) 297, 301, 315
Deabate M C (abst) 691
Deane C (abst) 314, 747
Debatin K M (abst) 737
Debska-Slizien A (abst) 742
Debure A (abst) 707
Deelder A (abst) 684
Defronzo R A (abst) 665
Degli Esposti E: *See* Fabbri A et al.
Deja A (abst) 468
Delgado A: *See* Hannedouche T et al.
Dell Orto A (abst) 648
Dell'Aquila R: *See* Ronco C et al.
Delons S (abst) 699
Del Rosso G: *See* Albertazzi A et al.
Deltz E (abst) 468
Delvecchio C: *See* Docci D et al.
Demant T (abst) 654
Demeš M (abst) 397
Deminière C (abst) 664
Demšar M (abst) 643
Denis M C (abst) 669
Dennis M J S (abst) 747, 752
Dennoroy L (abst) 728
Depierreux M (letter) 1055
Deppisch R (abst) 734
Deramond H (abst) 727
Deray G (abst) 659, 692, 745
Derfler K (abst) 703, 723
Derry C J (abst) 305
DeSanto N G (abst) 670
Deschodt G: *See* Nonnast-Daniel B et al.
Deulofeu R (abst) 724
DeWitt D (abst) 685
D'Haese P C: *See* Van de Vyver F L et al.
D'Haese P C (abst) 311, 731, 735
D'Haese P C, Clement J P, Elseviers M M, Lamberts L V, Van de Vyver F L, Visser W J, De Broe M E: Value of Serum Aluminium Monitoring in Dialysis Patients: A Multicentre Study 45
Diacinti D: *See* Spallone V et al.
Díaz C (abst) 753, 756
De Bello V, Bianchi A M, Caputo M T, Santoro G, Panichi V, Parrini M, Giusti C, Palla R: Fractional Shortening/End-Systolic Stress Correlation in the Evaluation of Left Ventricular Contractility in Patients S115
Di Carlo M: *See* Manno C et al.
Di Cillo M (abst) 677
Dietl K H (abst) 746
Díez J: *See* Maduell F et al.; Pardo-Mindán F J et al.
Diez-Baylon J C (abst) 666
Díez-Marqúes M L: *See* Sevillano G et al.
Di Filippo S: *See* Locatelli F et al.
Dimkovíc N (abst) 701
Dinarello C A (abst) 713
Di Paolo B: *See* Albertazzi A et al.
Di Paolo B (abst) 666
Dische F E (abst) 306
Diskin C J (letter) 400
Dissegna D: *See* Ronco C et al.
Dittmar A: *See* Ebel H et al.
Dittrich P (abst) 651, 680
Docci D, Maldini M, Delvecchio C, Baldrati L, Turci F, Gilli P: Urinary Red Blood Cell Volume Analysis in the Investigation of Haematuria S69
Dofferhoff A S M, Sluiter H E, Geerlings W, De Jong P E: Complications of Liver Cysts in Patients with Adult Polycystic Kidney Disease 882
Doherty C (abst) 664
Doherty C C (letter) 554
Dolejšová (abst) 704
Donker A J M (abst) 301–2, 308, 313, 318, 640, 687, 753, 895
Donker A J M (letter) 906
Donnelly P K (abst) 756
Donnelly P K, Simpson A R, Milner A D, Nicholson M L, Horsburgh T, Veitch P S, Bell P R F: Age-Matching Improves the Results of Renal Transplantation with Older Donors 808
Donohoe J (letter) 321
Donovan K (abst) 759
Dooper Ph M M (abst) 307
Dorhout Mees E J (abst) 302, 309, 314, 317–18
Dort J (abst) 395
Douglas J (abst) 664
Doutrelepont J-M (abst) 677
Drab M (abst) 471–2
Draibe S A: *See* Sesso R et al.
Dratwa M (abst) 894
Drescher P (abst) 667
Drinovec J (abst) 643
Drobisz M (abst) 471–2
Drücke T: *See* Losekann A et al.
Drücke T (abst) 743
Druet P (abst) 685
Dugo M (abst) 714
Dujśin M (abst) 662
Duława J (abst) 471–2
Dumann H (abst) 679
Dupas B: *See* Esnault V et al.
Dupont P (letter) 1055
Duque I: *See* Sevillano G et al.
Dussaule J C (abst) 470, 692, 696
Dussol B (abst) 689
Dvořáková J (abst) 395–6
Dykes S R: *See* Broyer M et al.; Rizzoni G et al.
Dzúrik R (abst) 391, 666, 669
Dzúriková K (abst) 391, 669
Ebel H, Saure B, Laage Ch, Dittmar A, Keuchel M, Stellwaag M, Lange H: Influence of Computer-Modulated Profile Haemodialysis on Cardiac Arrhythmias S165
Eberle H (abst) 651
Ebner F (letter) 555
Eckardt K U (abst) 743
Eckhardt T (abst) 662
Egfjord M (abst) 828–9, 831
Egido J (abst) 679
Ehrich J H H: *See* Bergstrom C et al.; Broyer M et al.; Brunner F P et al.; Rizzoni G et al.
Eidemark I (abst) 830, 831
Eisenbach G-M (abst) 708
Eisenhauer T (abst) 695
Ekholm J (abst) 665
Eklöf O (abst) 655
Elder G E: *See* Brown J H et al.
El Esper N (abst) 727
Elisaf M (abst) 701
El-Khatib D (abst) 744
Ellory J C: *See* Fervenza F C et al.

Ellory J C (abst) 667
El Nahas A M: *See* Wight J P et al.
El Nahas A M (abst) 316, 638–9, 659, 671
El Nahas A M, Le Carpentier J E, Bassett A H: Compensatory Renal Growth: Role of Growth Hormone and Insulin-Like Growth Factor-I 123
El-Sayed A A (abst) 638–9, 659
Elsen R: *See* Monti J P et al.
Elsen R (abst) 689
Elseviers M M: *See* D'Haese P C et al.
Elseviers M M (abst) 661, 667
Emancipator S N (abst) 675, 677
Emery P (abst) 683
Encabo B: *See* Serra A et al.
Endre Z H: *See* Higgins R M et al.
Engliš M (abst) 398
Enia G: *See* Catalano C et al.
Enia G (abst) 644, 702, 731
Erben J (abst) 391–2, 396
Ericzon B-G (abst) 832
Escassi A (abst) 723
Escobedo J M (abst) 741
Escolar G (abst) 664, 723
Esmatjes E (abst) 672
Esnault V, Testa A, Dupas B, Guenel J: Major Muscle Calcifications of the Neck after Non-Traumatic Rhabdomyolysis with Acute Renal Failure 461
Esparrago J (abst) 729
Esparza N: *See* Pardo-Mindán F J et al
Evans B: *See* Wang Y et al.
Evans D B (abst) 309
Evans D J: *See* Clutterbuck E J et al.; Isaacs J D et al.
Evans D J (abst) 304
Evans L J A (abst) 716
Fabbri A, Cocchi R, Degli Esposti E, Lucatello A, Sturani A, Tampieri G, Fusaroli M: Antiproteinuric Effect of Angiotensin-Converting-Enzyme Inhibitors in Patients with Primary Glomerular Disease and Normal Renal Function S81
Fabris A: *See* Ronco C et al.
Fabrizi F: *See* Catalano C et al.
Fabrizi F (abst) 644
Facchini M G: *See* Stefoni S et al.
Faccini G *See* Panzetta G et al.
Fagel W J (letter) 903
Fahr A (abst) 758
Falardeau P (abst) 641
Faranna P (abst) 716
Farrell A M (abst) 704
Farshidfar G (abst) 711
Fass G (abst) 674
Fassbinder W: *See* Bergstrom C et al.; Broyer M et al.; Brunner F P et al.; Rizzoni G et al.
Favre H (abst) 650
Fazion S: *See* Biasioli S et al.
Feber J (abst) 399
Feehall J (abst) 660
Feehally J: *See* Layward L et al.; McNally P G et al.
Feehally J (abst) 303, 309, 680
Feest T G: *See* Thomas D M et al.
Feest T G (abst) 654
Feigel D (abst) 649
Feio S (letter) 552
Feliciangeli G: *See* Stefoni S et al.
Feller P: *See* Ravelli M et al.
Fellstrom B (abst) 733
Ferguson C J, Hillis A N, Williams J D, Griffin P J A, Salaman J R: Calcium-Channel Blockers and Other Factors Influencing Delayed Function in Renal Allografts 816
Feriani M: *See* Ronco C et al.
Ferluga D (abst) 643
Fernandez A (abst) 702
Fernández E, Frutos J L, Pérez L, Montoliu J: Cephalic to External Jugular Vein Bypass to Preserve Arteriovenous Fistula for Haemodialysis After Subclavian Vein Thrombosis 977
Fernández E (abst) 739
Fernández E (letter) 237
Fernández F (abst) 720
Fernandez J: *See* Maduell F et al.
Fernando O N: *See* Scoble J E et al.
Fernando R: *See* Wheeler D C et al.
Ferrari C: *See* Allergri L et al.
Ferrari G (abst) 716
Ferreira A (letter) 552
Ferrer J (abst) 672
Ferrone S (abst) 677–8
Fervenza F C, Meredith D, Ellory J C, Hendry B M: A Study of the Membrane Transport of Aminoacids in Erythrocytes from Patients on Haemodialysis . . . 594
Fessel V (abst) 396
Fidelio T (abst) 707
Fieren M W J A (abst) 313, 718
Figueiredo C E P (abst) 667
Figueroa C D, Lewis H M, MacIver A G, Mackenzie J C, Bhoola K D: Cellular Localisation of Atrial Natriuretic Factor in the Human Kidney 25
Fiklocki C (abst) 702
Fillastre J P: *See* Hannedouche T et al.
Filler G (abst) 639
Finn R: *See* Yaqoob M et al.
Finnemore A-M (abst) 680
Finocchi G: *See* Ronco C et al.
Finocchiaro P (abst) 702
Fiorini I (abst) 691
Fischer J A: *See* Probst W et al.
Fixa P (abst) 392, 396
Fjeldborg O: *See* Povlsen J V et al
Flatmark A: *See* Dahl E et al.
Fleming S (abst) 677
Fleuren G J: *See* Hogendoorn P C W et al.
Fleuren G J (abst) 304
Flinter F A (letter) 900
Floege J (abst) 685, 726
Floret D: *See* Cochat P et al.
Florquin S (abst) 677
Flynn A: *See* Anastassiades E et al.
Fogazzi G B (abst) 646
Fogazzi G B (letter) 473
Fogh-Andersen N (abst) 831
Foidart J-M (abst) 303
Földes J (abst) 692
Fondu P G: *See* Boelaert J R et al.
Fontana F: *See* Bergonzi G et al.
Fontana F: (abst) 722
Ford M (letter) 555
Formica M (abst) 724
Fornasieri A (abst) 678
Forneris G (abst) 691
Foroni R: *See* Biasioli S et al.
Forslund T (abst) 693

Förstermann U (abst) . . . 641
Fort J (letter) . . . 902
Foster G R, Carmichael D J S, Kermode A, Hulme B, Gabriel J R T, Cattell V: Extensive Crescent Formation with Antifibrinolytic Therapy in a Case of Diffuse Endocapillary Glomerulonephritis . . . 152
Fouad-Tarazi F M: *See* Abdulhadi M H et al.
Fouissou F (abst) . . . 656
Fournier A (abst) . . . 660, 707, 710, 727, 736
Fournier A (letter) . . . 553
Fox J G, Sutcliffe N P, Boulton-Jones J M, Imrie C W: Acute Pancreatitis and Renal Cortical Necrosis . . 542
Fox J G (abst) . . . 301, 639
Fracasso A: *See* Scanferla F et al.
Fraile M (abst) . . . 687
Frampton G, Walker R G, Perry G J, Harada T, Cameron J S: IgA Affinity to ssDNA or Endothelial Cells and its Deposition in Glomerular Capillary Walls in IgA Nephropathy . . . 841
Frampton G (abst) . . . 678, 683
Franco V: *See* Soliani F et al.
Frandsen H (abst) . . . 831
Franz M (abst) . . . 754, 756
Frascà G M: *See* Vangelista A et al.
Freestone A: *See* Scoble J E et al.
Frei D: *See* von Kiparski A et al.
Frei U: *See* Vogt P et al.
Frei U (abst) . . . 648, 708, 742
Frenken L A M (abst) . . . 308
Friedberg M (abst) . . . 830–1
Friedlander G: *See* Amiel C et al.
Friedlander G, Blanchet-Benqué F, Nitenberg A, Laborie C, Assan R, Amiel C: Glucagon Secretion is Essential for Aminoacid-Induced Hyperfiltration in Man . . . 110
Friedman D: *See* Simoni G et al.
Friman S, Nyberg G, Blohmé I: Erythrocytosis After Renal Transplantation; Treatment by Removal of the Native Kidneys . . . 969
Frizzi V (abst) . . . 670
Frohnert P P (abst) . . . 748
Frölich J C (abst) . . . 641
Frommherz K (abst) . . . 702
Frostick S P: *See* Higgins R M et al.
Frutos J L: *See* Fernández E et al.
Fuertes A (abst) . . . 749
Fuhrmann G F (abst) . . . 740
Fuiano G (abst) . . . 677–8
Fujikawa H (abst) . . . 663
Fulcher G R: *See* Catalano C et al.
Fulignati P: *See* Sturniolo A et al.
Fulle H-J: *See* Lauster F et al.
Fünfstük R (abst) . . . 679
Fusaroli M: *See* Fabbri A et al.
Gabriel J R T: *See* Foster G R et al.
Gaggiotti M (abst) . . . 737–8
Gago E (abst) . . . 748
Gahl G (abst) . . . 718, 724
Gaido M (abst) . . . 655
Gaio G (abst) . . . 714
Gajdoš M (abst) . . . 391, 669
Gakis D (abst) . . . 733
Galan A (abst) . . . 646
Galiński J (abst) . . . 466
Gallice P (abst) . . . 689
Gamez C (abst) . . . 714
Gammelgaard B (abst) . . . 830
Gans R O B (abst) . . . 687
Ganss R: *See* Aarseth H P and Ganss R
Ganten D (abst) . . . 686
Ganten D (book review) . . . 635
Garberi A: *See* Ghiggeri G M et al.
Garces L (abst) . . . 741
Garcia A (letter) . . . 158
Garcia Castro C: *See* Gonzalez-Posada J M et al.
García García M (abst) . . . 647, 672, 703
Gardner K D Jr (book review) . . . 907
Garella S: Pathophysiology and Clinical Implications of Proteinuria . . . S10
Garev L: *See* Hannedouche T et al.
Garovoy M R (abst) . . . 750, 758
Garrido M C (abst) . . . 667
Gattiani A: *See* Cagnoli L et al.
Gaudiano V: *See* Casino F G et al.
Gavalli G (abst) . . . 724
Gayová E (abst) . . . 392–3
Geary C G (abst) . . . 736
Geberth St (abst) . . . 688
Geerlings W: *See* Bergstrom C et al.; Broyer M et al.; Brunner F P et al.; Dofferhoff A S M et al.; Rademaker P et al.; Rizzoni G et al.
Geerlings W (abst) . . . 894
Geiger H (abst) . . . 693
Geissler D (abst) . . . 680
Gelok E W A: *See* Hogendoorn P C W et al.
Gemsa D: *See* Bommer J et al.
Genderini A: *See* Barbiano di Belgiojoso G et al.
Genderini A, Bertani T, Bertoli S, Scorza D, Barbiano di Belgiojoso G: HIV-Associated Nephropathy: A New Entity. A Study of 12 Cases . . . S84
Genderini A (abst) . . . 717
Gerlag P G G (abst) . . . 715, 895–6
Gerqari I (abst) . . . 832
Gerzer R: *See* Lauster F et al
Gesualdo L (abst) . . . 640, 677
Getino M A (abst) . . . 751
Ghatei M A: *See* Warrens A N et al.
Ghatei M A (abst) . . . 676
Ghiggeri G M: *See* Ginevri F et al.
Ghiggeri G M, Candiano G, Ginevri F, Garberi A, Acerbo S, Perfumo F, Gusmano R: Hypertension and Renal Selectivity Properties in Diabetic Microalbuminuria . . . S66
Ghoneim A (abst) . . . 684
Ghoneim M (abst) . . . 654
Ghysen J, De Plaen J F, van Ypersele de Strihou C: The Effect of Membrane Characteristics on Tumour Necrosis Factor Kinetics During Haemodialysis . . 270
Giachino G (abst) . . . 697, 720
Giangrande M: *See* Manno C et al.
Gianoglio B (abst) . . . 655, 675, 724
Gil C (abst) . . . 751
Giles G R: *See* Ubhi C S et al.
Giles G R: (abst) . . . 306
Gilli P: *See* Docci D et al.
Gilvernet S (abst) . . . 756
Giménez M (abst) . . . 668
Gin H (abst) . . . 663
Ginevri F: *See* Ghiggeri G M et al.
Ginevri F, Ghiggeri G M, Oleggini R, Barbano G, Bertelli R, Candiano G, Perfumo F, Gusmano R: Low-Protein Diet and Xanthine-Metabolising

Enzymes in Adriamycin Nephrosis S63
Giordano C (abst) 665, 671
Giordano F (abst) 658
Giovannetti S: *See* Barsotti G et al.
Giusti C: *See* Di Bello V et al.
Giusti R (abst) 691
Gladziwa U: *See* Mann H et al.
Gladziwa U (abst) 688
Glancey G R (abst) 721
Glancey G R (letter) 78
Glaros D (abst) 670
Glavaš Boras S (abst) 662
Glud T K: *See* Sørensen S S et al
Gmelin H (abst) 706
Gnant M (abst) 703, 748, 753–4
Go J (abst) 894
Godin M: *See* Hannedouche T et al.
Goffin E (letter) 1057
Gokal R: *See* Mistry C D et al.
Gokal R (abst) 298–300, 736
Goldfarb B: *See* Sultan Y et al.
Goldman M (abst) 677
Goldschmeding R (abst) 298
Goldwasser P (abst) 698
Gomboš V (abst) 393
Gómez E (abst) 748–9
Gomez J M (abst) 750
Gömez-Chiarri M (abst) 679
Gonick H C (book review) 477
González C (abst) 756
González E (abst) 658, 679
Gonzalez M (abst) 730
Gonzalez-Posada J M, Garcia Castro C, Losada M, Lorenzo V, Torres A, Hernandez D, Maceira B, Salido E: Monoclonal Analysis of Fine-Needle Aspiration Biopsy in Kidney Allografts 226
Gonzalo A (abst) 647
Goode N P (abst) 679, 685
Goodship T H: *See* Catalano C et al.
Gopal Rao G, Short A, Carmichael D J S: CAPD Peritonitis Caused by Vancomycin-Resistant Lactobacilli 235
Gopalakrishnan G: *See* Ninan V T et al.
Gordge M P (abst) 674
Gordon A McD (abst) 716
Gordon C (abst) 683
Gordts B Z: *See* Boelaert J R et al.
Gorostidi M (abst) 652
Gotdzik J (abst) 696
Gould F K (letter) 555
Gouldesbrough D R (abst) 755
Gózdzik J (abst) 692
Gozzetti G: *See* Bonomini V.
Graça Silva J (abst) 703
Graf H (abst) 693
Grafinger P (abst) 643
Granolleras C (abst) 742
Granqvist S: *See* Tranaeus A et al.
Grant A C: *See* Van der Merwe W M et al.
Grant A C (abst) 718
Gratacos J (abst) 755
Grateau G: *See* Hannedouche T et al.
Grave W (abst) 647
Graziani G, Castelnovo C, Aroldi A, Adami S, Viganò E, Casati S, De Vecchi A: Response of Renal Transplanted Patients to Oral Calcium Load 531
Graziani G (abst) 648
Green A (letter) 321
Green C J (abst) 311
Greenwood R N: *See* Brown A L et al.
Greenwood R N (abst) 319
Gregis G P (letter) 903
Grégoire S (abst) 641
Gregor V (abst) 394
Gregorek H (abst) 467
Gretz N (abst) 657, 667
Griffen S: *See* Steger A C et al.
Griffin P J A: *See* Ferguson C J et al.
Grinblat (letter) 1056
Grinó J M (abst) 753, 756
Groeneveld A B J (abst) 310
Grönhagen-Riska C (abst) 672–724
Groshong T (abst) 719
Gross A J (book review) 403
Gross S (abst) 695
Grünfeld J P: *See* Hannedouche T et al.
Grünfeld J P (abst) 640, 648
Grunze M (abst) 652
Grzeszczak W (abst) 744
Guarena C (abst) 691
Guastoni C (abst) 712
Guenel J: *See* Esnault V et al.
Guerin C (abst) 745
Guerin C, Berthoux F: Prognostic Factors in Malignant Hypertension Selected by Multivariate Analysis . . 563
Gueris J (abst) 736
Guerrero R (abst) 705, 723
Guillodo M P (abst) 645
Guindy R (abst) 711
Guinot Ph (abst) 723
Gülay H (abst) 704
Gumbel W: *See* Seyfert U T et al.
Günther K (abst) 713, 734
Gupta K L, Sakhuja V, Radotra B D, Singh P P, Chugh K S: Necrotising Glomerulonephritis and Non-Hodgkin's Lymphoma Associated with Rheumatoid Arthritis 385
Gurreri G: *See* Simoni G et al.
Gusmano R: *See* Ghiggeri G M et al.; Ginevri F et al.
Gutierrez A (abst) 672
Guttierrez E (abst) 686
Gyr K (abst) 732
Haalboom J (abst) 648
Haas H G (abst) 732
Haberal M (abst) 704
Hackenthal E (book review) 403
Hadj-Aïssa A (abst) 661
Haimovitz C (abst) 710
Hain H (abst) 718
Hájek M (abst) 392
Hajek-Rosenmayr A (abst) 756
Hájková B (abst) 392, 396
Halbhuber K J (abst) 679
Hall C L: *See* de Caestecker M P et al.
Halse J: *See* Dahl E et al.
Ham K C L (abst) 296
Hamdy N A T (abst) 311
Hamilton G (abst) 756
Hammer M (abst) 676
Hampl H (abst) 679, 711
Hamulyak K (abst) 899
Handt S (abst) 732

Hanicki Z (abst) . . . 743
Hannan S F (abst) . . . 309
Hannedouche T (abst) . . . 640
Hannedouche T, Grateau G, Nöel L H, Godin M, Fillastre J P, Grünfeld J P, Jungers P: Renal Granulomatous Sarcoidosis: Report of Six Cases . . . 18
Hannedouche T, Natov S, Garev L, Marquez L P, Delgado A, Boitard C, Lacour B, Grünfeld J P: Renal Haemodynamic Effects of Short Term Cyclosporin A Administration in Patients with Insulin-Dependent Diabetes Mellitus . . . 168
Hannedouche T, Natov S, Ikeni A, Schmitt F, Lacour B, Grünfeld J-P: Does Lithium Affect Renal Sodium Handling and Renal Haemodynamics in Normal Man? . . . 1007
Hansen H E: *See* Povlsen J V et al.
Hansen J M (abst) . . . 831
Hansen M A (abst) . . . 832
Hansen P R: *See* Andersen C B et al.
Harada T: *See* Frampton G et al.
Harding G B (abst) . . . 725
Hardonk M J (abst) . . . 305
Hariga C F: *See* Boelaert J R et al.
Harper S J (abst) . . . 680
Harris K (abst) . . . 302, 317, 659
Harris S (abst) . . . 311
Hartley B: *See* Serón D et al.
Hartley B (abst) . . . 721
Hartter E (abst) . . . 693–4, 755
Hartung R (abst) . . . 673
Hasslacher Ch: *See* Ritz E.
Hattersley J M: *See* Layward L et al.
Hattersley J M (abst) . . . 309
Haubitz M, Schulze M, Koch K-M: Increase of C-Reactive Protein Serum Values Following Haemodialysis . . . 500
Haubitz M (abst) . . . 648, 667
Hauser A C (abst) . . . 723
Havard C W H: *See* Scoble J E et al.
Hayashi T (abst) . . . 663
Haycock G B (letter) . . . 320
Haylor J (abst) . . . 638–9, 659
Hdez D (abst) . . . 751
Heatley R V (abst) . . . 646
Heaton A (abst) . . . 309
Heeg J E (abst) . . . 297, 315
Heidenreich S (abst) . . . 739
Heidland A: *See* Lemke H-D et al.
Heidland A (abst) . . . 673, 693, 742
Heimburger N (abst) . . . 702
Heimbürger O: *See* Tranaeus A et al.
Heinrich U (abst) . . . 754
Heinz G (abst) . . . 685
Hem G v d: *See* Rademaker P et al.
Henckes M (abst) . . . 701
Hendry B M: *See* Fervenza F C et al.
Hendry B M (abst) . . . 667
Hené R J (abst) . . . 298
Henning H V (abst) . . . 695
Henzen-Logmans S C (abst) . . . 310
Herfarth C: *See* Schürmann G et al.
Herlitz H (abst) . . . 688
Herman P (abst) . . . 644
Hernandez D: *See* Gonzalez-Posada J M et al.
Hernandez D (abst) . . . 731
Hernández E (abst) . . . 653
Hernando L (abst) . . . 679
Herout V (abst) . . . 392, 396
Herrero J A (abst) . . . 704
Hertz J M (abst) . . . 830
Hervas F: *See* Quesada J M et al.
Herve J P (abst) . . . 645
Hess B, Binswanger U: Long-Term Administration of Calcium Acetate Efficiently Controls Severe Hyperphosphataemia in Haemodialysis Patients . . . 630
Hicks J A (abst) . . . 678
Hidalgo L (abst) . . . 666, 735
Hiestand P (abst) . . . 758
Higgins R M, Richardson A J, Endre Z H, Frostick S P, Morris P J: Hypophosphataemia After Renal Transplantation: Relationship to Immunosuppressive Drug Therapy and Effects on Muscle Detected by ^{31}P Nuclear Magnetic Resonance Spectroscopy . . . 62
Hijazi A (abst) . . . 744
Hillis A (abst) . . . 661
Hillis A N: *See* Ferguson C J et al.
Hilson A J W (book review) . . . 477
Hilton P J (abst) . . . 641, 662
Hiltunen U (abst) . . . 724
Himmighofen U (abst) . . . 653
Hinglais N: *See* Laouari D et al.
Hiroshi Nihei (abst) . . . 741
Hiroyuki Ohtsuka (abst) . . . 741
Hitman G (abst) . . . 681–2
Hobby P (abst) . . . 303
Hochman B (abst) . . . 649
Hodsman A E: *See* Muirhead N.
Hoedemaeker P (abst) . . . 677
Hoek F J (abst) . . . 313
Hoek J A (abst) . . . 708
Hoffmann G (abst) . . . 758
Hoffmann H G (abst) . . . 737
Hogendoorn P C W, Bruijn J A, Gelok E W A, Van Den Broek L J C M, Fleuren G J: Development of Progressive Glomerulosclerosis in Experimental Chronic Serum Sickness . . . 100
Hohoff A (abst) . . . 653
Hoitsma A J: *See* Wetzels J F M et al.
Hoitsma A J (abst) . . . 307–8
Holstein-Rathlou N-H (abst) . . . 829
Homan van der Heide J J (abst) . . . 308
Honkanen E (abst) . . . 672, 724
Horák J (abst) . . . 393
Hořejš J (letter) . . . 238
Hořejší A (abst) . . . 394
Horina J H (abst) . . . 712
Horký K (abst) . . . 394–5
Hörl W H: *See* Wanner C et al.
Hörl W H (abst) . . . 663, 702
Horoszek-Maziarz S (abst) . . . 466
Horsburgh T: *See* Donnelly P K et al.
Horská M (abst) . . . 392
Hortal L (abst) . . . 702
Hortling L: *See* Sipila R et al.
Hory B (abst) . . . 707
Houhou S (abst) . . . 660
Houllier S (abst) . . . 727
Hourant M (abst) . . . 747
Houthoff H J: *See* Buysen J G M et al.
Hovi T: *See* Sipila R et al.
Howarth D (abst) . . . 736
Howarth J (abst) . . . 736

Howie A J (letter) . . . 552
Howie C (abst) . . . 718
Hoylaerts M F (abst) . . . 661
Hsu C (abst) . . . 736
Hugel U (abst) . . . 732
Huisman R M (letter) . . . 906
Hulme B: *See* Foster G R et al.
Humhal J (abst) . . . 704
Hundeshagen H (abst) . . . 726
Hunt L (abst) . . . 298, 300
Hunter J A A: *See* Bunney M H et al.
Huraib S (abst) . . . 669
Hussein M M, Bakir N, Roujouleh H: Tuberculosis in Patients Undergoing Maintenance Dialysis . . . 584
Hutchinson S (abst) . . . 755
Huther W: *See* Mall G et al.
Hutton R D: *See* Macdougall I C et al.
Hyde K (abst) . . . 736
Iaina A (abst) . . . 697
Iellamo D (abst) . . . 655
Iino S (abst) . . . 707
Ikeni A: *See* Hannedouche T et al.
Ikeni A (abst) . . . 640
Ilan Z(abst) . . . 697
Imbasciati E (abst) . . . 730
Imiela J (abst) . . . 468
Imrie C W: *See* Fox J G et al.
Innes A, Bernard T, Cotton R E, Burden R P: Recurrent Haemolytic Uraemic Syndrome in the Elderly Associated with Metastatic Carcinoma . . . 886
Innes A (abst) . . . 704, 747
Innocenti M (abst) . . . 649
Ionova D (abst) . . . 705
Ireland H: *See* Anastassiades E et al.
Irons L (abst) . . . 674
Ironside J (abst) . . . 739
Isaacs J D, Evans D J, Pusey C D: Mesangial IgA Disease with Crescent Formation During Pregnancy: Postpartum Treatment with Immunosuppression . . 619
Iscovici E (abst) . . . 697
Ise M (abst) . . . 668
Islam M S (abst) . . . 745
Ittel T H, Köppe B K, Sieberth H G: Differential Effect of Steroids and Chloroquine on the Intestinal Absorption of Aluminium and Calcium . . . 860
Ittel T H (abst) . . . 732
Iversen B M (abst) . . . 690
Jacob C K: *See* Ninan V T et al.
Jacobs C (abst) . . . 659, 692, 745
Jacobsen B A (abst) . . . 831
Jacobson S H (abst) . . . 649, 655
Jacquiaud C (abst) . . . 659
Jadoul M (abst) . . . 705, 727–8
Jahn C (abst) . . . 743
Jakubowksi C (abst) . . . 298
Jakubowski Z (abst) . . . 471
Jamart J (abst) . . . 728
Janata V (abst) . . . 397–8
Janda J (abst) . . . 399
Janicka L (abst) . . . 740
Jankovič N (abst) . . . 705
Janssen W M T (abst) . . . 301
Jaraba M (abst) . . . 705
Jaudon C (abst) . . . 659
Javies J (abst) . . . 667
Jayne D (abst) . . . 309
Jedička H (abst) . . . 740
Jedlicka J (abst) . . . 394–5
Jelkmann W (book review) . . . 403
Jensen B N (abst) . . . 831
Jensen G (abst) . . . 740
Jensen I W (abst) . . . 830
Jensen J D (abst) . . . 830
Jespersen B, Danielsen H, Pederson E B: Atrial Natriuretic Peptide and Blood Volume in Patients with Chronic Glomerulonephritis: Effects of Albumin and Frusemide Administration . . . 997
Jespersen B (abst) . . . 694, 830
Jimenez A (abst) . . . 717
Jirásková M (abst) . . . 394
Jirka J (abst) . . . 398
Jirsa M (abst) . . . 714
Jirsová E (abst) . . . 395
Jofre R (abst) . . . 646
Jogestrand T (abst) . . . 665
Johansson A C (abst) . . . 660
John W G: *See* Morgan L J et al.
Joles J A (abst) . . . 314
Jones D H (abst) . . . 639
Jones J M (abst) . . . 759
Jones M C (abst) . . . 684, 757
Jonkman E J (abst) . . . 897
Jonsson O (abst) . . . 688
Jørgensen K A (abst) . . . 830
Jorno A: *See* Rizzuto G et al.
Jörres A (abst) . . . 718, 724
Jouvenet M: *See* Cochat P et al.
Juloski T (abst) . . . 701
Jungers P: *See* Hannedouche T et al.
Junor B J R: *See* Van der Merwe W M et al.
Junor B J R (abst) . . . 718
Juquel J P (abst) . . . 743
Juul-Nielsen O (abst) . . . 740
Kačić M (abst) . . . 662
Kaeyer V (abst) . . . 685
Kahn T: *See* Saggi S et al.
Kaiser W (abst) . . . 643
Kaji D: *See* Saggi S et al.
Kakavas J (abst) . . . 714
Kellenberg C G M (abst) . . . 298
Kallinowski B (abst) . . . 706
Kallivretakis N (abst) . . . 714
Kalra P A (abst) . . . 317
Kamper A-L (abst) . . . 672, 829
Kandt M (abst) . . . 695
Kanfer A (abst) . . . 470
Kang M S (abst) . . . 727
Kanis J A (abst) . . . 311
Kapranos N (abst) . . . 682
Kapras J (abst) . . . 394
Karakelleoglu S (abst) . . . 660
Karamouzis M (abst) . . . 733
Karlberg I (abst) . . . 750
Karlo O (letter) . . . 555
Karmali A (letter) . . . 552
Kasalický J (abst) . . . 704
Kashgarian M (abst) . . . 681
Kashiwagi S (abst) . . . 709
Kašlíková J (abst) . . . 392
Katzir Z (abst) . . . 649
Kawai T (abst) . . . 663
Kazuo Kubo (abst) . . . 741

Keane S J (abst) . . . 306
Kędziora J (abst) . . . 468–9
Keiding S (abst) . . . 832
Keller E (abst) . . . 697
Keller F: *See* Wenzel-Seifert K et al.
Keller F, Seemann J, Preuschof L, Offermann G: Risk Factors of System Clotting in Heparin-Free Haemodialysis . . . 802
Keller F (abst) . . . 752
Keller R (abst) . . . 468
Kelly P J: *See* Catalano C et al.
Kelly P J (abst) . . . 644
Kemp E (abst) . . . 680
Kemperman F A W (abst) . . . 718, 895
Kendall R G (abst) . . . 310
Kendall R G: *See* Lipkin G W et al.
Kennedy L (abst) . . . 307
Kermode A: *See* Foster G R et al.
Kesselheim C (abst) . . . 640
Keuchel M: *See* Ebel H et al.
Keur I (abst) . . . 895
Keusch G (abst) . . . 749
Khan L (letter) . . . 834
Khan-Blouki K (abst) . . . 740
Khanna S K (abst) . . . 739
Khiraoui F: *See* Losekann A et al.
Kiersztejn M (abst) . . . 471, 744
Kindler J: *See* Braendle E et al.
King J (abst) . . . 298
King R (abst) . . . 739
Kinugasa E (abst) . . . 732
Kiriakrov S (abst) . . . 705
Kirijakov Z (letter) . . . 475
Kiss D (abst) . . . 732
Kissmeyer-Nielsen F: *See* Povlsen J V et al.
Kisters K (abst) . . . 746
Kistner A (abst) . . . 715
Klahr S (abst) . . . 302, 317, 659
Klaus G (abst) . . . 732
Klauser R (abst) . . . 754, 757
Kleim V (abst) . . . 671
Klein E (abst) . . . 725
Klein J B (abst) . . . 725
Kleinknecht C: *See* Laouari D et al.
Klimešová D (abst) . . . 399
Klin M (abst) . . . 470, 744
Klinger M (abst) . . . 467
Klinger M (letter) . . . 835
Klinkmann H: *See* Monti J P et al.
Kluchert S A: *See* Burger H et al.
Knapowski J (abst) . . . 470
Knight-Gibson C (abst) . . . 663
Knotková V (abst) . . . 393
Knudsen F (abst) . . . 830
Koc M (abst) . . . 704
Kočandrle V: *See* Marečková O et al.
Kočandrle V (abst) . . . 397
Koch K-M: *See* Nonnast-Daniel B et al.
Koch K-M (abst) . . . 648, 667, 671, 673, 706, 708, 713, 726
Koch K-M *See* Haubitz M et al.
Köcher P (abst) . . . 397
Koduma T (abst) . . . 668, 720
Koehler L (abst) . . . 685
Koene R A P: *See* Wetzels J F M et al.
Koene R A P (abst) . . . 296, 307–8
Koepchen H (abst) . . . 696
Koepsell H (abst) . . . 637
Koffman G (letter) . . . 320
Köhler H: *See* Marx M et al.; Weber M et al.
Köhler H (abst) . . . 679
Kok A (abst) . . . 302
Kokot F (abst) . . . 470–2, 744
Kolář P (abst) . . . 396
Kolský A (abst) . . . 394, 399
Kolsters G (letter) . . . 78
König P (abst) . . . 651, 680, 758
Konigs F: *See* Mann H et al.
Konrad M (abst) . . . 656
Konstadinidoa I (abst) . . . 650
Koolen M I (abst) . . . 298
Koomans H A (abst) . . . 302, 309, 314, 317–18
Koomen G C M (abst) . . . 299, 313, 649, 721–2, 898
Koopman M G (abst) . . . 649
Kootstra G: *See* Burger H et al.
Kootte A M M (abst) . . . 753
Kopec A (abst) . . . 743
Kopeć W (abst) . . . 467, 471
Kopeć W (letter) . . . 835
Kopecký O (abst) . . . 396
Köppe B K: *See* Ittel T H et al.
Kopple J D (abst) . . . 698
Kordač V (abst) . . . 714
Kordić D *See* Čala S et al.
Kordić D (abst) . . . 698
Korzets A (letter) . . . 1056
Košecká G (abst) . . . 397
Koshi K T: *See* Ninan V T et al.
Koshikawa S (abst) . . . 732
Kostakis A (abst) . . . 749
Koteva A (letter) . . . 475
Kotileas P (abst) . . . 714
Köttgen E (abst) . . . 718
Koutsikos D (abst) . . . 650
Kouw P M (abst) . . . 715
Kováč A (abst) . . . 397
Kovar J (abst) . . . 673
Kovarik J (abst) . . . 754, 755, 756–7
Kox W (abst) . . . 312
Kraenzlin M E (abst) . . . 732
Kramer A (abst) . . . 697
Krasniak A (abst) . . . 743
Kraus V (abst) . . . 396
Krause P (abst) . . . 752
Krause R (abst) . . . 696
Kravaritis A (abst) . . . 733
Krediet R T : *See* Buysen J G M et al.
Krediet R T (abst) . . . 299, 313, 718, 721–2, 894–5, 897–8
Krejsek J (abst) . . . 396
Kremer Hovinga T K, de Jong P E, van der Hem G K, de Zeeuw D: Relief of Renal Artery Stenosis: A Tool to Improve or Preserve Renal Function in Renovascular Disease? . . . 481
Krempf M (abst) . . . 746
Kristensen S R (abst) . . . 719
Krivoshiev S (letter) . . . 475
Křižek M (abst) . . . 396
Kron I (abst) . . . 392
Krupa-Wojciechowska B (abst) . . . 466
Kruse T (abst) . . . 830
Krzymański M (abst) . . . 467–8
Ksiażek A (abst) . . . 740
Kubasiewics-Ujma B (abst) . . . 469

Kučerová M (abst) . . . 394
Kuczera M (abst) . . . 471, 744
Kudlacek S (abst) . . . 756
Kugel M: *See* Bommer J et al.
Kühn B (abst) . . . 679
Kühn K (abst) . . . 671
Kuhn R (abst) . . . 679
Kuijper E J (abst) . . . 894
Kuneš J (abst) . . . 398
Kurai K (abst) . . . 707
Kurokawa K (abst) . . . 707
Kurtz A (abst) . . . 743
Kurz R W (abst) . . . 690, 713, 753
Kuwata S (abst) . . . 707
Kuźniar J (abst) . . . 471
Kuźniewski M (abst) . . . 470, 743
Kwan J T C (abst) . . . 650
Laaban J-P: *See* Meyrier A et al.
Laage Ch: *See* Ebel H et al.
Labeeuw M (abst) . . . 643
Laborie C: *See* Friedlander G et al.
Lace R (abst) . . . 655
Lachmanová L (abst) . . . 396
Lacková V (abst) . . . 393
Lacono G P (abst) . . . 707
Lacour B: *See* Hannedouche T et al.
Lacour B: *See* Laouari D et al.
Lacour B (abst) . . . 640
Ladefoged S D: *See* Andersen C B et al.
Ladefoged S D (abst) . . . 676, 829–32
Lagana C (abst) . . . 702
La Greca G: *See* Ronco C et al.
Lai K N (abst) . . . 296
Laidlaw S A (abst) . . . 698
Lajdová I (abst) . . . 666
Lal S M (abst) . . . 719
Lamas S: *See* Sevillano G et al.
Lambert M C (abst) . . . 896
Lambert R (abst) . . . 641
Lamberts L V: *See* D'Haese P C et al.
Lamberts L V (abst) . . . 311, 731
Lameire N (abst) . . . 896
Lamm M E (abst) . . . 640, 675
Lamperi D (abst) . . . 734
Lamy M E (abst) . . . 705
Lamy M E (letter) . . . 1057
Landais P: *See* Laouari D et al.
Landini S: *See* Scanferla F et al.
Landriani N: *See* Barbiano di Belgiojoso G et al.
Landriani N (abst) . . . 717
Lane D A: *See* Anastassiades E et al.
Lang C C (abst) . . . 688, 694
Lang R E (abst) . . . 691–2
Langdale-Brown B (abst) . . . 677
Lange H: *See* Ebel H et al.
Lange H (abst) . . . 740
Längle F (abst) . . . 703
Laouari D, Kleinknecht C, Burtin M, Hinglais N, Lacour B, Landais P, Broyer M: Adverse Effects of Sucrose-Rich Diets on Uraemic Rats . . . 923
LaPointe M S (abst) . . . 689
Lappin T R J: *See* Brown J H et al.
Laraia E: *See* Manno C et al.
Largiadèr F: *See* von Kiparski A et al.
Largiadèr F (abst) . . . 749
Larochelle P (abst) . . . 641
Larsen N A (abst) . . . 830
Larsen S: *See* Andersen C B et al.
Lasserre J J (abst) . . . 667
Laurent G (abst) . . . 726
Lauridsen I N (abst) . . . 830
Lauritsen H K: *See* Andersen C B et al.
Lauritsen H K (abst) . . . 832
Lauster F, Gerzer R, Weil J, Fülle H-J, Schiffl H: Assessment of Dry Body-Weight in Haemodialysis Patients by the Biochemical Marker cGMP . . . 356
Lauzurica R: *See* Serra A et al.
Lavaud S: *See* Bindi P et al.
Lavaud S (abst) . . . 700, 755
Layward L, Hattersley J M, Patel H R, Tanner M S, Feehally J: Gut Permeability in IgA Nephropathy . 569
Layward L (abst) . . . 309, 680
Leal M (abst) . . . 697
Leal M (letter) . . . 552
Lebon P (abst) . . . 707
Le Carpentier J E: *See* El Nahas A M et al.; Wight J P et al.
Le Carpentier J E (abst) . . . 316, 671
Lee M (abst) . . . 755
Lefkowith J (abst) . . . 317, 659
Legendre J M (abst) . . . 745
Legrand J C (abst) . . . 692
Le Hoang P (abst) . . . 745
Lell B (abst) . . . 693–4
Lemke H-D, Heidland A, Schaefer R M: Hypersensitivity Reactions During Haemodialysis: Role of Complement Fragments and Ethylene Oxide Antibodies . . . 264
Lemoine R (abst) . . . 650
Lenhardt E (abst) . . . 670
Lenzner B (abst) . . . 706
Leo A (abst) . . . 737
Leon M (abst) . . . 653
Lerma J (abst) . . . 679
Letienne Ph (abst) . . . 728
Leunissen K M L (abst) . . . 299, 708, 750, 899
Levi J (abst) . . . 710
Lewis H M: *See* Figueroa C D et al.
Lewis N P: *See* Macdougall I C et al.
Leyssac P P (abst) . . . 672, 829, 831
Lhotta K (abst) . . . 651, 680, 758
Li C C (abst) . . . 727
Licata C (abst) . . . 707
Lichodziejewska M (abst) . . . 466, 759–60
Liebich R (abst) . . . 670
Lieht N v d (abst) . . . 708
Lillevang S T: *See* Otte K E et al.
Lillevang S T (abst) . . . 680, 709
Lindblad A S (book review) . . . 403
Linderkamp O (abst) . . . 737
Lindert O (abst) . . . 708
Lindner G: *See* Soliani F et al.
Lindsjö M (abst) . . . 733
Lins L E (abst) . . . 655, 665
Lins R L (abst) . . . 667, 701
Lipkin G W, Kendall R G, Russon L J, Turney J H, Norfolk D R, Brownjohn A M: Erythropoietin Deficiency in Acute Renal Failure . . . 920
Lipkin G W (abst) . . . 310
Lips P T A M (letter) . . . 906
Lisiewicz J (abst) . . . 743
Liška J (abst) . . . 395–6

Lison A E: *See* Rolf N et al.
Liu Yin J A (abst) 736
Ljunghall S (abst) 733
Llins R (abst) 708
Lobos A V (abst) 697
Locatelli F (abst) 646, 667
Locatelli F, Ponti R, Pedrini L, Di Filippo S: Adequate Sodium Balance and Cardiovascular Stability . . . S141
Lock S (letter) 400
Lockwood C M (abst) 296, 309
Logue F C: *See* Van der Merwe W M et al.
Loibi U (abst) 719
Loibl U (abst) 690, 741, 743
Løkkegaard H (abst) 830
Lombardi A (abst) 670
Lomeña F (abst) 724, 755
London G M: *See* Sultan Y et al.
Longo L (abst) 655
Lonnemann G (abst) 667, 706
Loopez Gomez J M (abst) 646
Lopez J (abst) 723
Lopez T: *See* Casino F G et al.
Lopez-Costea M A (abst) 753
Lopez-Pedret J (abst) 664
Lopez-Revuelta K (abst) 721
Lorenz M (abst) 664
Lorenzi S (abst) 708
Lorenzo V: *See* Gonzalez-Posada J M et al.
Lorenzo V (abst) 731, 751
Lornoy W (abst) 667
Losada M: *See* Gonzalez-Posada J M et al.
Losekann A, Ureña P, Khiraoui F, Casadevall N, Zins B, Bererhi L, Zingraff J, Bourdon R, Drüeke T: Aluminium Intoxication in the Rat Induces Partial Resistance to the Effect of Recombinant Human Erythropoietin 258
Losonczy Gy, Walter J, Mucha I, Taraba I: Changes of Arterial Prostaglandin E_2 During Haemodialysis . . 937
Lou C (abst) 750
Lovett D H: *See* Bommer J et al.
Löw-Friedrich I (abst) 706
Lucas B (abst) 746
Lucatello A: *See* Fabbri A et al.
Lucchi L (abst) 722
Luciak M (abst) 468–9
Luciani L (abst) 700
Lucio J: *See* Sevillano G et al.
Ludvik B (abst) 693–4
Ludwig R (abst) 737
Luft F C (book review) 635
Lumsden L (abst) 684
Lundberg M: *See* Buur T et al.
Lundin P: *See* Mall G et al.
Lungaroni G: *See* Spallone V et al.
Lusenti T: *See* Soliani F et al.
Lusvarghi E (abst) 722
Lye W C: Paecilomyces Peritonitis in a Patient on Continuous Ambulatory Peritoneal Dialysis 1053
Lynn K L (abst) 316
Lysiak-Szydłowska W (abst) 468
Maarshchalkerweerd W W A v (abst) 687
McClelland P (abst) 311
MacDougall A I (abst) 718
Macdougall I C, Davies M E, Hutton R D, Cavill I, Lewis N P, Coles G A, Williams J D: The Treatment of Renal Anaemia in CAPD Patients with Recombinant Human Erythropoietin 950
Macdougall I C (abst) 759
Maceira B: *See* Gonzalez-Posada J M et al.
Maceira B (abst) 731
Maceira B S (abst) 751
McGeown M G: *See* Brown J H et al.
McGeown M G (abst) 640, 745
Macharáček O (abst) 395
Macia M (abst) 666,704
Maciejewski J (abst) 467
MacIver A G: *See* de Caestecker M P et al.; Figueroa C D et al.
Mackay I G: *See* Al-Haidary A D et al.
Mackenzie J C: *See* Al-Haidary A D et al.; Figueroa C D et al.
McLean A (letter) 904
MacLeod A M (abst) 295, 684, 756, 757
MacManus M (abst) 640
McMurray J J (abst) 694
McNally P G, Walls J, Feehally J: The Effect of Nifedipine on Renal Function in Normotensive Cyclosporin-A-Treated Renal Allograft Recipients 962
McNally P G (abst) 303, 660
McNamee P (abst) 664
Macnicol A M (abst) 653, 688
Macurová H (abst) 398
Madaliński K (abst) 467
Madhok R (abst) 639
Madia G: *See* Cagnoli L et al.
Madri J A (abst) 681
Madsen M: *See* Povlsen J V et al.
Maduell F, Fernandez J, Díez J: Alterations of the $Cl^-/NaCO_3-$ Anion Exchanger in Erythrocytes of Uraemic Patients 1018
Maeda K (abst) 668, 720
Maekawa M (abst) 725
Maffei S (abst) 665, 710
Maggiore Q: *See* Catalano C et al.
Maggiore Q (abst) 644, 710
Mahiout A (abst) 706, 718, 724
Maiello M R: *See* Spallone V et al.
Main J, Thomas T, Wilkinson R: Sodium Content and Transport of White and Red Blood Cells in Undialysed Uraemic and Continuous Ambulatory Peritoneal Dialysis Patients 369
Maiorca R: *See* Ravelli M et al.; Sandrini S et al.
Maiorca R (abst) 698, 737–8
Maistre G (abst) 692
Makdassi R (abst) 660
Makram S (abst) 711
Makriniotou J (abst) 733
Mal F (abst) 651
Malberti F (abst) 715
Maldague B (abst) 728
Maldini M: *See* Docci D et al.
Malegos J (abst) 733
Malghem J (abst) 727
Mall G: *See* Ritz E et al.
Mall G, Huther W, Schneider J, Lundin P, Ritz E: Diffuse Intermyocardiocytic Fibrosis in Uraemic Patients 39
Mall K (abst) 667
Mallamaci F (abst) 654–5, 690, 695
Mallick N P: The Significance and Management of Proteinuria S35
Mallick N P (abst) 300, 304

Mallol J (abst) . . . 705
Malovrh M (abst) . . . 643
Malý J: *See* Marečková O et al.
Mampaso F (abst) . . . 679
Mancini E: *See* Santoro A et al.
Mancini E (abst) . . . 707, 712
Mandelbaum A: *See* Ritz E et al.
Mandelbaum A: *See* Ruffmann K et al.
Mandolfo S (abst) . . . 707
Mandreoli M (abst) . . . 651, 680
Manfro R C (abst) . . . 758
Manitius A (abst) . . . 466, 469, 471, 742
Manitius J (abst) . . . 468, 471
Manker N (abst) . . . 741
Manker W (abst) . . . 686, 690, 719, 743
Mann H, Stiller S, Gladziwa U, Kõnigs F: Kinetic Modelling and Continuous On-Line Blood Volume Measurement During Dialysis Therapy . . . S144
Manno C, Proscia A R, Laraia E, Giangrande M, Di Carlo M, Salvatore C, Tasco A, Schena F P: Clinicopathological Features in Patients with Isolated C3 Mesangial Proliferative Glomerulonephritis . . . S78
Marai P (abst) . . . 667
Marcelli D (abst) . . . 667
Marcén R (abst) . . . 716
Marchais S J: *See* Sultan Y et al.
Marchesi D (letter) . . . 903
Marchini P (abst) . . . 708
Marcinkowski K (abst) . . . 470
Marcussen N (abst) . . . 828
Mareček Z: *See* Marečková O et al.
Mareček Z (abst) . . . 392
Marečková O, Skála I, Mareček Z, Malý J, Kočandrle V, Schück O, Bláha J, Prát V: Bile Composition in Patients with Chronic Renal Insufficiency . . . 423
Maren R (abst) . . . 714
Marenah C B: *See* Morgan L J et al.
Marengo M (abst) . . . 724
Maret J (abst) . . . 707
Marié A (abst) . . . 727, 736
Markovic-Lipkovski J, Müller C A, Risler T, Bohle A, Müller G A: Association of Glomerular and Interstitial Mononuclear Leukocytes with Different Forms of Glomerulonephritis . . . 10
Markovic-Lipkovski J (abst) . . . 681
Marques L P (abst) . . . 640
Marquez L P: *See* Hannedouche T et al.
Marsden J (abst) . . . 314
Marselis-Jonges E (abst) . . . 758
Marsh F P (abst) . . . 298, 650, 729
Marshall D H (abst) . . . 319
Martella D: *See* Vangelista A et al.
Martí I (abst) . . . 672
Martin J (abst) . . . 668, 741
Martin M (abst) . . . 685
Martin Malo A (abst) . . . 717
Martín R (abst) . . . 749
Martin X: *See* Cochat P et al.
Martin-Malo A: *See* Quesada J M et al.
Martin-Malo A (abst) . . . 705, 723, 750
Martina G (abst) . . . 724
Martines V (abst) . . . 708
Martínez A (abst) . . . 748–9
Martinez M (abst) . . . 731
Martinez M E: *See* Quesada J M et al.
Martinez M E (abst) . . . 721
Martins Prata M (letter) . . . 474
Martos R: *See* Sevillano G et al.
Marx M (abst) . . . 681
Marx M, Weber M, Köhler H: Urinary Secretory Immunoglobulin A in Acute Renal Allograft Rejection . . . 520
Marx M, Weber M, Merkel F, Meyer zum Büschenfelde K-H, Köhler H: Additive Effects of Calcium Antagonists on Cyclosporin A-Induced Inhibition of T-Cell Proliferation . . . 1038
Masalas K (abst) . . . 701
Maschio G: *See* Panzetta G et al.
Maschio G, Bedogna V, Valvo E, Alberti D: The Use of Converting-Enzyme Inhibitors in Glomerulonephritis . . . S33
Massara C (abst) . . . 710, 720
Mathias M T (abst) . . . 691
Matoušovic K (abst) . . . 398
Matthys E G: *See* Boelaert J R et al.
Matuszkiewicz-Rowińska J . . . 468
Mauro M M: *See* Rizzuto G et al.
Maury C P J (abst) . . . 724
Mavridis A (abst) . . . 701
Maxwell A P (abst) . . . 745
Maxwell A P (letter) . . . 554
Maxwell P (abst) . . . 640, 664
Mažuran R: *See* Čala S et al.
Mazzaferro S: *See* Spallone V et al.
Mazzali A: *See* Biasioli S et al.
Mazzoni A (abst) . . . 649
Mecca G (letter) . . . 903
Medcraft J (abst) . . . 681–2
Meer J v d (abst) . . . 687
Mehls O (abst) . . . 656–7, 706, 732, 754
Mehring N (abst) . . . 689
Meijer S: *See* Rademaker P et al.
Meijer-Paape M E (abst) . . . 297
Meinhold R (abst) . . . 732
Meis F (abst) . . . 690
Meisinger V (abst) . . . 741
Meisl F (abst) . . . 686, 719, 741
Melin J P (abst) . . . 755
Melon S (abst) . . . 749
Memmos D (abst) . . . 733
Menzinger G: *See* Spallone V et al.
Mercatello A (abst) . . . 657, 661
Meredith D: *See* Fervenza F C et al.
Merke J (abst) . . . 732
Merkel F: *See* Marx M et al.
Merta J (abst) . . . 395
Merta M (abst) . . . 394, 396, 714
Mertz A: *See* Vogt A et al.
Merville P (abst) . . . 664
Messa P (abst) . . . 658
Messina M (abst) . . . 754
Mestre M (abst) . . . 756
Metaxatos G (abst) . . . 733
Metsärinne K (abst) . . . 672
Meulen J v d (abst) . . . 651
Meuwissen S G M (abst) . . . 302, 318
Meyer zum Büschenfelde K-H: *See* Marx M et al.
Meyrier A, Becquemont L, Simon P, Laaban J-P: Protracted Anuria Due to Active Vasoconstriction in Primary or Secondary Malignant Hypertension . . . 174
Meyrier A (abst) . . . 651–2

Michael R (abst) . . . 713
Michalk D (abst) . . . 656
Michałkiewicz J (abst) . . . 467
Michel C (abst) . . . 692
Miescher P A (abst) . . . 650
Mignon F (abst) . . . 696
Mignot L (abst) . . . 659
Miguel Garcia A (abst) . . . 668, 741
Miguel Sosa A (abst) . . . 668, 741
Mihatsch M J (abst) . . . 650, 752
Milan M: *See* Ronco C et al.
Milani S (abst) . . . 717
Millar N D: *See* Al-Haidary A D et al.
Milner A D: *See* Donnelly P K et al.
Miltenburg A M M (abst) . . . 297
Mineshaima M (abst) . . . 745
Minetti I (abst) . . . 712
Minetti L (abst) . . . 642, 645, 737
Minetti L (book review) . . . 635
Mingardi G (letter) . . . 903
Mion C (abst) . . . 723
Miranda B (abst) . . . 721
Misiewicz I (abst) . . . 466
Mistry C D, O'Donoghue D J, Nelson S, Gokal R, Ballardie F W: Kinetic and Clinical Studies of β_2-Microglobulin in Continuous Ambulatory Peritoneal Dialysis: Influence of Renal and Enhanced Peritoneal Clearances Using Glucose Polymer . . . 513
Mistry C D (abst) . . . 299
Mistry N (abst) . . . 303
Mitchell R (abst) . . . 695
Mittman N (abst) . . . 698
Mkeisl F (abst) . . . 743
Modai D, Averbukh Z, Rauch E, Berman S, Cohn M, Weissgarten J: Transplacental Transport and Pharmacological Manipulations on Renotropic Activity in Post-Nephrectomised Rats . . . 579
Modol J (letter) . . . 158
Moehring H (abst) . . . 706
Mogensen M N (book review) . . . 477
Mohamed A S: *See* Yaqoob M et al.
Möhring K (abst) . . . 657
Mokfali P (abst) . . . 658
Molinelli G (abst) . . . 734
Molino A (abst) . . . 683
Moll R (abst) . . . 668, 741
Møller J T (abst) . . . 832
Mombelloni S: *See* Ravelli M et al.
Mombelloni S (abst) . . . 737–8
Moncalián F J (abst) . . . 720
Monhart V (abst) . . . 397
Monnens L A H (abst) . . . 896–7
Monnens L (abst) . . . 303
Montenegro M: *See* Schena F P et al.
Montero A (abst) . . . 652
Monti J P, Baz M, Klinkmann H, Elsen R, Berland Y, Crevat A: Adaptation of Uraemic Patients to Anaemia: A ^{31}P Nuclear Magnetic Resonance Study . . . 604
Monti J P (abst) . . . 689
Montinaro V (abst) . . . 677
Montoliu J: *See* Fernández E et al.
Montoliu J (abst) . . . 739
Montoliu J (letter) . . . 237
Montoyo C (abst) . . . 653
Monzani F (abst) . . . 669
Monzani G (abst) . . . 670
Moore H (abst) . . . 719
Moore R (abst) . . . 681–2
Moorhead J F: *See* Scoble J E et al.; Wheeler D C et al.
Moorhead J F (letter) . . . 904
Morachiello P: *See* Scanferla F et al.
Morales J M: *See* Rodicio J L et al.
Morales J M (abst) . . . 653, 749
Morcos S (abst) . . . 659
Morelli E: *See* Barsotti G et al.
Moreno E (abst) . . . 717, 750
Moreno F (abst) . . . 749
Morgan A G: *See* Morgan L J et al.
Morgan A G (abst) . . . 704, 747, 752
Morgan L J, Marenah C B, Morgan A G, Burden R P, John W G: Glycated Haemoglobin and Fructosamine in Non-Diabetic Subjects with Chronic Renal Failure . . . 868
Morin J F (abst) . . . 745
Moriniere Ph (abst) . . . 707, 710, 727, 736
Moriniere Ph (letter) . . . 553
Moroni G (abst) . . . 648
Morris P J: *See* Higgins R M et al.
Mörsky P (abst) . . . 734
Mortensen P B (abst) . . . 831
Moscatelli M (abst) . . . 699
Moskovtchenko J F (abst) . . . 657, 661
Mosquera J (abst) . . . 682–3
Moullier P (abst) . . . 678
Mourikis D (abst) . . . 650, 733
Moustafa F (abst) . . . 654, 684
Movilli E: *See* Ravelli M et al.
Movilli E (abst) . . . 737–8
Mračková E (abst) . . . 395–6
Mucha I: *See* Losonczy Gy et al.
Mühlbacher F (abst) . . . 703, 748, 753–4
Muhlfelder T: *See* Saggi S et al.
Muirhead N, Hodsman A B: Occult Infection and Resistance of Anaemia to rHuEpo Therapy in Renal Failure . . . 232
Mulder M F (abst) . . . 301
Müller C A: *See* Markovic-Lipkovski J et al.
Müller C A (abst) . . . 681
Muller C (abst) . . . 718
Müller G A: *See* Markovic-Lipkovski J et al.
Müller G A (abst) . . . 681
Muller-Ruchholtz W (abst) . . . 468
Müller-Wiefel D E (abst) . . . 657, 737
Mullins J J (abst) . . . 686
Munaut C (abst) . . . 303
Munck O (abst) . . . 829
Munclinger M (abst) . . . 704
Munn S (letter) . . . 904
Muñoz J (abst) . . . 724
Munoz R F (abst) . . . 714
Muno-Gomez J (abst) . . . 755
Murphy A (abst) . . . 664
Murray A (abst) . . . 315
Murúla D (abst) . . . 658
Mustonen J (abst) . . . 681, 734
Mytilineos J (abst) . . . 656
Nádvorníková H: *See* Schück O et al.
Nádvorníková H (abst) . . . 391–2, 397–8
Naish P (abst) . . . 315, 673
Nakagawa Y (abst) . . . 663
Nakashaima H (abst) . . . 745

Nakazawa H (abst) . . . 757
Nakopoulou L (abst) . . . 682
Naranjo P (abst) . . . 704
Naret C (abst) . . . 699
Nasini M G (abst) . . . 717, 726
Nässberger L (abst) . . . 660
Natov S: *See* Hannedouche T et al.
Natov S (abst) . . . 640
Nauck M: *See* Wanner C et al.
Neale T J (abst) . . . 309
Nedrud J (abst) . . . 675
Nefrologia H (abst) . . . 751
Négrier S (abst) . . . 657, 661
Negus R (abst) . . . 314
Neild G H (abst) . . . 300, 674
Nelson S: *See* Mistry C D et al.
Nelson W (abst) . . . 664
Němeček K (abst) . . . 393, 704
Němeček K (letter) . . . 238
Neu U (abst) . . . 695
Neumann K H (abst) . . . 671, 689
Neumayer H-H, Blossei N, Seherr-Thohs U, Wagner K: Amelioration of Postischaemic Acute Renal Failure in Conscious Dogs by Human Atrial Natriuretic Peptide . . . 32
Neumayr H (abst) . . . 680
Neves F (abst) . . . 721
Neves P L (letter) . . . 320
Newa T (abst) . . . 668
Newbold K M (letter) . . . 552
Newstead C G (letter) . . . 402
Newton K E (abst) . . . 306, 747
Ng L L (abst) . . . 667
Nicaise H (abst) . . . 700
Nicholls A J: *See* Thomas D M et al.
Nicholson M L: *See* Donnelly P K et al.
Nicholson M L (abst) . . . 756
Nielsen B (abst) . . . 832
Nielsen H K (abst) . . . 830
Nielsen S L (abst) . . . 831–2
Nielsen T H (abst) . . . 830
Niemierko J (abst) . . . 469
Niemir Z (abst) . . . 467
Nieuwenhuis P (abst) . . . 296
Nigreli S (abst) . . . 702
Nigrelli S (abst) . . . 710
Nikolopoulou N (abst) . . . 733
Nilolipoulos T (abst) . . . 749
Ninan V T, Koshi K T, Niyamthullah M M, Jacob C K, Gopalakrishnan G, Pandey A P, Shastry J C M: A Comparative Study of Methods of Estimating Renal Size in Normal Adults . . . 851
Ninomiya S (abst) . . . 709
Nishi T (abst) . . . 707
Nishisaka M (abst) . . . 725
Nitenberg A: *See* Amiel C et al.
Nitenberg A: *See* Friedlander G et al.
Niwa T (abst) . . . 720
Niyamthullah M M: *See* Ninan V T et al.
Nobuhiro Sugino (abst) . . . 741
Noël L H: *See* Hannedouche T et al.
Nolasco F (letter) . . . 552
Nolph K D (abst) . . . 719
Nolph K D (book review) . . . 403
Nonnast B (abst) . . . 726
Nonnast-Daniel B, Deschodt G, Brunkhorst R, Creutzig A, Bahlmann J, Shaldon S, Koch K-M: Long-Term Effects of Treatment with Recombinant Human Erythropoietin on Haemodynamics and Tissue Oxygenation in Patients with Renal Anaemia . . . 444
Nonnast-Daniel B (abst) . . . 708, 742
Noordzij T (abst) . . . 708
Noordzij T C (abst) . . . 750
Nooyen Y A (abst) . . . 316
Nordal K P: *See* Dahl E et al.
Norden A G W (abst) . . . 654
Norden G (abst) . . . 750
Nordio M (abst) . . . 708
Norfolk D R: *See* Lipkin G W et al.
Nortier J (letter) . . . 1055
Nosaka K (abst) . . . 707
Nossent J C (abst) . . . 310
Nouwen E J (abst) . . . 661
Novak J W (book review) . . . 403
Nowack R (abst) . . . 652
Nowak J (abst) . . . 469, 742
Nowak R (abst) . . . 737
Nundel M (abst) . . . 711
Nurmohamed M T (abst) . . . 708
Nuyts G D (abst) . . . 661
Nyberg G: *See* Friman S et al.
Nyberg G (abst) . . . 663, 750
Oba S (abst) . . . 745
O'Brien H (abst) . . . 658
Odani H (abst) . . . 728
Oddone A (abst) . . . 700
O'Donogue D J: *See* Mistry C D et al.
O'Donogue D J (abst) . . . 298, 304
Odum J (abst) . . . 673
Oe P L (abst) . . . 313, 895–6
Offerman J J G (letter) . . . 78
Offermann G *See* Keller F et al.
Offermann G (abst) . . . 752
Offner G (abst) . . . 656
Ofstad J (abst) . . . 690
Ogawa H (abst) . . . 728
Ogg C (abst) . . . 298, 721
Ogg C S (letter) . . . 78
Oko A (abst) . . . 467
Oksa H: *See* Ala-Houhala I et al.
Okutsu I (abst) . . . 709
Olah A J (abst) . . . 732
Olbricht C J (abst) . . . 673
Oldhafer K: *See* Vogt P et al.
Oleggini R *See* Ginevri F et al.
Ølgaard K (abst) . . . 829, 831
Olivan P (abst) . . . 704
Oliver D (abst) . . . 298
Oliver D O: *See* Athanasou N A et al.
Olmer M: *See* Berland Y et al.
Olmer M (book review) . . . 635
Olmos A (letter) . . . 902
Olsen N V (abst) . . . 831–2
Olthof C G (abst) . . . 715, 896
O'Meara Y (letter) . . . 320
Ong A C M (letter) (abst) . . . 905
Ono K: Oxalate Crystal Deposits in the Heart in Chronic Renal Failure: An Experimental Study . . . 493
Ono K (abst) . . . 709
Ono M (abst) . . . 728
Oosterhuis J W: *See* Rademaker P et al.

Oosting J (abst) . . . 718
Opatrný K (abst) . . . 397
Opatrný K Jr (abst) . . . 391, 669
Opelz G (abst) . . . 656
Oppenheimer F (abst) . . . 746, 757
Ordinas A (abst) . . . 664, 723
O'Reilly D StJ (abst) . . . 639
O'Reilly P H (abst) . . . 638
Ori Y (letter) . . . 1056
O'Riordan J (abst) . . . 729
Orofino L (abst) . . . 716
Orriols J (letter) . . . 158
Orsatti A (abst) . . . 738
Orsi C: *See* Cagnoli L et al.
Ort J (letter) . . . 238
Ortega R (abst) . . . 652
Ortiz A (abst) . . . 679
Ortuño J (abst) . . . 647, 714, 716
Ošanec J (abst) . . . 395
Østerby R (abst) . . . 750
Ota K (abst) . . . 663, 745, 757
Otsubo K (abst) . . . 709
Otsubo O (abst) . . . 709
Otte K E, Lillevang S T, Rasmussen A G, Christensen H K, Pedersen F B: Acetate or Bicarbonate for Haemodialysis: A Randomised, Double-Blind Controlled Trial . . . 931
Otte K E (abst) . . . 709, 830
Otto G: *See* Schürmann G et al.
Ozono Y (abst) . . . 303
Pacchiarotti A (abst) . . . 669
Pacitti A (abst) . . . 665, 720
Packard C J (abst) . . . 654
Paczek L (abst) . . . 673, 742
Paganini E P: *See* Abdulhadi M H et al.
Pagliari B (abst) . . . 730
Paineau J (abst) . . . 746
Palacios S (abst) . . . 729
Palla R: *See* Di Bello V et al.
Palla R (abst) . . . 669
Palmer A (abst) . . . 307, 314, 747
Palmieri P F: *See* Albertazzi A et al.
Palop L P (abst) . . . 702
Pandey A P: *See* Ninan V T et al.
Panichi V: *See* De Bello V et al.
Panichi V (abst) . . . 669
Panzetta G, Tessitore N, Faccini G, Maschio G: The Protein Catabolic Rate as a Measure of Protein Intake in Dialysis Patients: Usefulness and Limits . S125
Paoletti E (abst) . . . 734
Paolini F: *See* Santoro A et al.
Paolini F (abst) . . . 707, 712
Papadakis J (abst) . . . 682, 733
Papadimitriou M (abst) . . . 733
Pappas M (abst) . . . 701
Paradowski M (abst) . . . 469
Paraiso V (abst) . . . 696
Pardo-Mindán F J, Diez J, Esparza N, Robledo C: Renal Siderosis in Patients with Heart-Valve Prostheses: Clinical Implications . . . 847
Parisoli A: *See* Soliani F et al.
Parlongo S (abst) . . . 654–5, 695, 731
Parra G (abst) . . . 683
Parravicini C: *See* Barbiano di Belgiojoso G et al.
Parrini M: *See* Di Bello V et al.
Parsons V (abst) . . . 306, 314, 661, 747
Pasanen M: *See* Ala-Houhala I et al.
Pasquali S (abst) . . . 680
Pasquier R (abst) . . . 685
Passalacqua S: *See* Sturniolo A et al.
Passerini P: *See* Ponticelli C and Passerini P
Passerini P (abst) . . . 646
Pasternack A: *See* Ala-Houhala I et al.
Pasternack A (abst) . . . 734
Pataca I (abst) . . . 661
Patapis P (abst) . . . 749
Patek E (abst) . . . 690
Patel H R: *See* Layward L et al.
Patel H R (abst) . . . 309
Patel M K (letter) . . . 834
Paterson K R (abst) . . . 639
Paties C: *See* Bergonzi G et al.
Patrikarea A (abst) . . . 733
Patrono C, Pierucci A: The Use of Antiplatelet Agents in Glomerulonephritis: A Pharmacological Approach . . . S29
Pavlovič D (abst) . . . 705
Pawlicki J (abst) . . . 468–9
Pecchio F (abst) . . . 691
Peces R (abst) . . . 652, 689
Pedersen E (abst) . . . 676
Pedersen E G: *See* Sørensen S S et al.
Pedersen E B (abst) . . . 694, 830
Pedersen F B: *See* Otte K E et al.
Pedersen F B (abst) . . . 709
Pederson E (abst) . . . 830
Pederson E B: *See* Jespersen B et al.
Pedrini L: *See* Locatelli F et al.
Pedrini L (abst) . . . 716
Peer G (abst) . . . 697
Pehrsson S K (abst) . . . 665
Pelletier L (abst) . . . 685
Peona C (abst) . . . 665
Per F (abst) . . . 693, 709, 748
Perdomo M (abst) . . . 702
Perego A (abst) . . . 712
Perez A (abst) . . . 668, 741
Pérez Fontán M (abst) . . . 720
Perez Garcia R (abst) . . . 646
Pérez L: *See* Fernández E et al.
Perez Miranda M (abst) . . . 729
Perez R (abst) . . . 717, 750
Perfumo F: *See* Ghiggeri G M et al.
Perfumo F: *See* Ginevri F et al.
Perkins J D (abst) . . . 748
Perks J (abst) . . . 716
Perrino L (abst) . . . 712
Perrino M L (abst) . . . 737
Perry G J: *See* Frampton G et al.
Perry G J (abst) . . . 683
Persaud J W: *See* Wheeler D C et al.
Peten E, Cosyns J P, van Ypersele de Strihou C: Coronary Arteriography as a Cause of Disseminated Cholesterol Emboli . . . 155
Peters J (abst) . . . 686
Petersen F M (abst) . . . 719
Petersen J (abst) . . . 727
Petit J (abst) . . . 710
Petit M (abst) . . . 684
Petitclerc T (abst) . . . 692
Petrosino L: *See* Biasioli S et al.
Petrová V (abst) . . . 396

Petrtýl J (abst) . . . 392, 394–5
Petrů I (abst) . . . 393
Petrů K (abst) . . . 396
Philip T (abst) . . . 657, 661
Philips M E: *See* Spencer S J W
Phillips A (abst) . . . 759
Phocas I (abst) . . . 650
Piberhofer S (abst) . . . 637, 662
Picciotto G (abst) . . . 683
Piccoli G (abst) . . . 665, 675, 683, 691, 720, 724
Piccoli G B (abst) . . . 665, 720
Pichlmayr R: *See* Vogt P et al.
Piera C (abst) . . . 647, 724
Piera L (abst) . . . 687
Piera L (letter) . . . 902
Pierucci A: *See* Patrono C
Pietilä K (abst) . . . 734
Pignatelli P M (abst) . . . 653
Pinchera A (abst) . . . 669
Pinka J (abst) . . . 393
Pinkowshi J (abst) . . . 754
Piocoli G B (abst) . . . 710
Pires C (abst) . . . 703
Pirson Y (letter) . . . 1057
Pizarro J L (abst) . . . 729
Pizzarelli F (abst) . . . 710
Pizzoccola G: *See* Sandrini S et al.
Plaza C (abst) . . . 702
Pluvio C (abst) . . . 665, 671
Pluvio M (abst) . . . 665, 671
Pnz E (abst) . . . 755
Poch E (abst) . . . 687
Pocino M (abst) . . . 703
Podjarny E (abst) . . . 642, 662
Poelstra K (abst) . . . 305
Pogglitsch H (abst) . . . 711–12
Pohanka B (abst) . . . 755
Pohanka E (abst) . . . 750, 754, 756–8
Poignet J L (abst) . . . 699
Poisetti P G: *See* Bergonzi G et al.
Poisetti P G (abst) . . . 722
Policastro M (abst) . . . 670
Polito G: *See* Rizzuto G et al.
Pollok M (abst) . . . 742
Pomeranz A (abst) . . . 642, 662
Ponti R: *See* Locatelli F et al.
Ponticelli C: *See* Casati S et al.
Ponticelli C (abst) . . . 646, 738
Ponticelli C and Passerini P: The Natural History and Therapy of Idiopathic Membranous Nephropathy . S37
Ponticelli C (book review) . . . 635
Ponz E (abst) . . . 647, 724, 746, 751
Popovic J (letter) . . . 981
Popovtzer M M: *See* Anteby E Y et al.
Popovzer M M (abst) . . . 710
Porcellini G (abst) . . . 655
Porter C (abst) . . . 747, 752
Pos J M (abst) . . . 703
Posada J (abst) . . . 731
Posada J M G (abst) . . . 751
Pospíšil J (abst) . . . 394
Posthuma N (abst) . . . 640
Posthuma N (letter) . . . 906
Poston L (abst) . . . 641, 662
Postorino M: *See* Catalano C et al.
Postorino M (abst) . . . 644, 654–5
Potaux L (abst) . . . 663
Poulsen J H (abst) . . . 830
Pound S E (abst) . . . 653
Pourchez T (abst) . . . 710
Povlsen J V, Rasmussen A, Hansen H E, Fjeldborg O, Kissmeyer-Nielsen F, Madsen M: Acquired Haemolytic Anaemia Due to Isohaemagglutinins of Donor Origin Following ABO-Minor-Incompatible Kidney Transplantation . . . 148
Powell F J (abst) . . . 704
Power D (abst) . . . 756
Power D A (abst) . . . 684, 757
Pozet N (abst) . . . 661
Pozzi C (abst) . . . 646
Pracros J P (abst) . . . 726
Praga M (abst) . . . 653
Prager H (abst) . . . 694
Prát V: *See* Marečková O et al.
Prát V (abst) . . . 394, 398
Precht K: *See* Schmidtmann S et al.
Prescott M C (abst) . . . 300
Preuschof L: *See* Keller F et al.
Preuss H G (book review) . . . 404
Prichzy B (abst) . . . 685
Prien T (abst) . . . 746
Priest A St (abst) . . . 710
Prieto C (abst) . . . 749
Prins F A (abst) . . . 296
Probst W, Fischer J A, Binswanger U: Intravenous 1,25$(OH)_2$ Vitamin D3 Therapy in Haemodialysis Patients: Evaluation of Direct and Calcium-Mediated Short-Term Effects on Serum Parathyroid Hormone Concentration . . . 457
Probst W (abst) . . . 702, 711
Propper D J (abst) . . . 295, 756
Proscia A R: *See* Manno C et al.
Puddu G: *See* Stefoni S et al.
Pulido R (abst) . . . 696
Pullig O: *See* Weber M et al.
Puretić Z (abst) . . . 662
Purkiss J (abst) . . . 315, 673
Pusey C D: *See* Clutterbuck E J et al.
Pusey C D: *See* Isaacs J D et al.
Pusey C D (abst) . . . 297, 304–5, 676
Quarello F (abst) . . . 665, 691, 710, 720
Quattrocchio G (abst) . . . 683, 724
Queluz T T, Andres G: Pathogenesis of an Experimental Model of Goodpasture's Haemorrhagic Pneumonitis . . . S3
Quereda C (abst) . . . 647, 716
Querfeld U (abst) . . . 656
Quérin S (abst) . . . 641
Quesada J M, Martín-Malo A, Santiago J, Hervas F, Martinez M E, Castillo D, Barrio V, Aljama P: Effect of Calcitriol on Insulin Secretion in Uraemia . . . 1013
Quesniaux V (abst) . . . 758
Quin J D (abst) . . . 301, 639
Rabelink A J (abst) . . . 309
Rabenseiferová I (abst) . . . 391
Racek J (abst) . . . 397
Radeke H H (abst) . . . 752
Rademaker P, Meijer S, Oosterhuis J W, Vermey A, Zwierstra R, Hem G v d, Geerlings W: Successful Surgical Treatment of Parathyroid Carcinoma in Two Haemodialysis Patients . . . 545

Radermacher J (abst) . . . 641
Radmilovi A (abst) . . . 701
Radotra B D: *See* Gupta K L et al.
Raftery M J: *See* Serón D et al.
Ragni R (abst) . . . 707, 710
Rahman A R (abst) . . . 688
Rahn K-H (abst) . . . 689, 739
Raine A E G (abst) . . . 691
Rambausek M: *See* Ritz E et al.
Rambausek M (abst) . . . 706
Rambousek Vl (abst) . . . 399
Ramee M P (abst) . . . 643
Ramos A (abst) . . . 697
Ramos O L: *See* Sesso R et al.
Rampino T (abst) . . . 644
Ramsis R (abst) . . . 711
Ramsy R (abst) . . . 684
Ramzy M F (abst) . . . 711
Rao G (letter) . . . 633
Rashed A (abst) . . . 744
Rashed A (letter) (abst) . . . 834
Rasher W (abst) . . . 754
Rasmussen A: *See* Povlsen J V et al.
Rasmussen A G (abst) . . . 709
Rasmussen C (abst) . . . 828
Rasmussen K C (abst) . . . 676
Rath W (abst) . . . 695
Rathaus M (abst) . . . 642, 662
Rathaus M (letter) . . . 553
Rauch E: *See* Modai D et al.
Raum E (abst) . . . 652
Ravelli M, Scaroni P, Mombelloni S, Movilli E, Feller P, Apostoli P, De Maria G, Valotti C, Sciuto G, Maiorca R: Acute Visual Disorders in Patients on Regular Dialysis Given Desferrioxamine as a Test . 945
Reaveley D A (abst) . . . 312
Recker A (abst) . . . 734
Reddingius R E (abst) . . . 896
Redlak M (abst) . . . 470
Rees A J (abst) . . . 297, 676
Reetze P (abst) . . . 697
Regan C (abst) . . . 311
Reicel H (abst) . . . 734
Reichwald-Klugger E (abst) . . . 656
Reilly D St J (abst) . . . 301
Reis N D (abst) . . . 658
Reiss U (abst) . . . 657
Reitschlägerová V (abst) . . . 391, 398
Relander A (abst) . . . 693
Remédio F (abst) . . . 697
Renaud H (abst) . . . 660
Repp H: *See* Vogt P et al.
Requena M J (abst) . . . 705
Resch K (abst) . . . 685, 752
Rettig R (book review) . . . 635
Revell P (abst) . . . 729
Revert J (abst) . . . 672
Revert L (abst) . . . 647, 664, 687, 703, 723–4, 757
Revert L (letter) . . . 903
Reverter J (abst) . . . 723
Revillard J P (abst) . . . 726, 728
Reyden H J v d (abst) . . . 651
Reyna A (abst) . . . 724
Reynolds J (abst) . . . 304
Riancho J A: *See* De Francisco A L M et al.
Ribeiro F (abst) . . . 697
Ricart M J (abst) . . . 746
Richard M J (abst) . . . 669
Richards N (abst) . . . 681
Richards N T (abst) . . . 641, 662, 683
Richardson A J: *See* Higgins R M et al.
Richardson K (abst) . . . 683
Richter D (abst) . . . 718, 724
Riddervold F (abst) . . . 693
Riedel E (abst) . . . 711
Riedl M (abst) . . . 686
Riegel W (abst) . . . 663
Rifai A (abst) . . . 677
Rifkin I (abst) . . . 661, 747
Rigden S P A (letter) . . . 320
Righetto F: *See* Scanferla F et al.
Rigotti A: *See* Cagnoli L et al.
Rincón B (abst) . . . 696
Ringoir S (abst) . . . 701, 725, 736, 898
Rino C (abst) . . . 721
Risler T: *See* Markovic-Lipkovski J et al.
Risler T (abst) . . . 681
Rissoni G: *See* Bergstrom C et al.
Ritz E: *See* Bommer J et al.; Mall G et al.; Ruffmann K et al.
Ritz E (abst) . . . 652, 673, 688, 706, 732, 734–5, 737
Ritz E (letter) . . . 901
Ritz E, Hasslacher Ch: The Role of Hypertension in Diabetic Nephropathy . . . 623
Ritz E, Rambausek M, Mall G, Ruffmann K, Mandelbaum A: Cardiac Changes in Uraemia and Their Possible Relationship to Cardiovascular Instability on Dialysis . . . S93
Rivera C F (abst) . . . 720
Rivera F (abst) . . . 687
Rivera M (abst) . . . 647, 714
Rivolta E (abst) . . . 648
Rizos D (abst) . . . 650
Rizzoni G: *See* Broyer M et al.; Brunner F P et al.
Rizzoni G, Broyer M, Ehrich J H H, Selwood N H, Brunner F P, Brynger H, Dykes S R, Fassbinder W, Geerlings W, Tufveson G, Wing A J: The Use of Continuous Peritoneal Dialysis in Europe for the Treatment of Children with End-Stage Renal Failure: . . . 985
Rizzuto G, Jorno A, Mauro M M, Polito G, Scida G: Monitoring of Serum Potassium in Bicarbonate Dialysis . . . S122
Roberts C (abst) . . . 314
Robertson W R (abst) . . . 695
Robinson M I (abst) . . . 759
Robledo C: *See* Pardo-Mindán F J et al.
Robles A (abst) . . . 679
Robles R (abst) . . . 729
Robson R A (abst) . . . 316
Roccatello D (abst) . . . 675, 683, 724
Rodger R S C: *See* Van der Merwe W M et al.
Rodger R S C (abst) . . . 718
Rodicio J L, Morales J M, Ruilope L M: Calcium Antagonists and the Kidney . . . 81
Rodicio J L (abst) . . . 653, 749
Rodrigues M C (letter) . . . 474
Rodriguez J C (abst) . . . 702
Rodriguez Jornet A (letter) . . . 158
Rodríguez-Iturbe B: Renal Response to an Acute Protein Load in Man: Clinical Perspective . . . 1
Rodriguez-Iturbe B (abst) . . . 682–3

Rodriguez-Puyol D: *See* Sevillano G et al.
Rodriguez-Puyol M: *See* Sevillano G et al.
Rogerson M E (abst) 300
Roland R (abst) 392–3
Rolando L (abst) 642
Rolf N, Tenschert W, Lison A E: Results of a Long-Term Administration of Omega-3 Fatty Acids in Haemodialysis Patients with Dyslipoproteinaemia . 797
Rolla D (abst) 734
Rombolà G (abst) 642, 645, 712
Rombouts R F M (abst) 296
Romero R: *See* Serra A et al.
Ronco C, Feriani M, Chiaramonte S, Conz P, Brendolan A, Bragantini L, Milan M, Fabris A, Dell Aquila R, Dissegna D, Crepaldi C, Agazia B, Finocchi G, De Dominicas E, La Greca G: Impact of High Blood Flows on Vascular Stability S109
Ronco P: *See* Allergri L et al.
Roob I M (abst) 712
Rooney I (abst) 759
Roose R (abst) 667
Ropolo R (abst) 683
Rosales M (abst) 720
Roseau S (abst) 317
Rosen C B (abst) 748
Rosenkranz J (abst) 656
Rosenlöf K (abst) 672
Rossi M: *See* Santoro A et al
Rossi M (abst) 707, 712
Rossi R (abst) 664
Rossmann P (abst) 398
Rössner S (abst) 665
Rother U (abst) 648
Rotllan E (abst) 723
Rott T (abst) 643
Roujouleh H: *See* Hussein M M et al.
Rovelli E (abst) 700
Roy-Chaudhury P (abst) 684
Rozeman C A M (abst) 897
Rozing J (abst) 296
Rubinstein I (abst) 658
Ruder H (abst) 656
Ruffini M P: *See* Sturniolo A et al.
Ruffmann K: *See* Ritz E et al.
Ruffmann K, Mandelbaum A, Bommer J, Schmidli M, Ritz E: Doppler Echocardiographic Findings in Dialysis Patients 426
Ruilope L M: *See* Rodicio J L et al.
Ruiter D J (abst) 307
Ruiz J C (abst) 730
Ruiz M C (abst) 704
Ruschitzka F (abst) 695
Russo D: *See* Sabbatini M et al.
Russon L J: *See* Lipkin G W et al.
Russon L J (abst) 310
Rutkowski B (abst) 468–9, 742
Ryan J J (abst) 752
Ryffel B (abst) 758
Ryo Tabata (abst) 741
Sabaté I (abst) 756
Sabater J (abst) 716
Sabbatini M, De Nicola L, Uccello F, Russo D, Conte G, Dal Canton A, Andreucci V E: Absence of Acute Nephrotoxicity with Low Doses of Cyclosporin: Experimental Study in the Rat 69
Sad M (abst) 684
Saffman C: *See* Yaqoob M et al.
Saggi S, Calandri C, Muhlfelder T, Choi H, Kahn T, Kaji D: Renal Failure Due to Leukaemic Infiltration in Chronic Lymphocytic Leukaemia 1051
Saha H (abst) 734
Saito A (abst) 728
Sakhuja V: *See* Gupta K L et al.
Salaman J R: *See* Ferguson C J et al.
Saleh A Q M (abst) 669
Sałek J (asbst) 468
Salem R R: *See* Steger A C et al.
Salido E: *See* Gozalez-Posada J M et al.
Salido E (abst) 751
Salit M (abst) 717, 726
Salmonson T (abst) 742
Salnitro F (abst) 654–5, 690
Salomone M (abst) 665, 710, 720
Salvadeo S (abst) 648
Salvaggiol A (abst) 717
Salvatierra O Jr (abst) 750, 758
Salvatore C: *See* Manno C et al.
Samà F (abst) 730
Samková P (abst) 394
Samsa R (abst) 705
San A (abst) 660
Sanchez A (abst) 735
Sánchez L (abst) 652, 748
Sanchez-Cabezudo M J (abst) 721
Sanchez-Casado E (abst) 729
Sánchez-Madrid F (abst) 696
Sandrini M (abst) 737–8
Sandrini S, Callea F, Cristinelli L, Savoldi S, Setti G, Scaini P, Scolari F, Scalzini A, Pizzoccolo G, Maiorca R: Viral Hepatitis in HBsAg-Positive Renal Transplant Patients Treated with Cyclosporin and Steroids 525
Santangelo R (abst) 665, 670
Santiago J: *See* Quesada J M et al.
Santoro A, Mancini E, Spongano M, Rossi M, Paolini F, Zucchelli P: A Haemodynamic Study of Hypotension During Haemodialysis Using Electrical Bioimpedance Cardiography S147
Santoro A (abst) 707, 712, 716
Santoro G: *See* Di Bello V et al.
Santos I (abst) 729
Santos J R (abst) 697
Sanz C (abst) 723
Sanz De Castro S: *See* De Francisco A L M et al.
Sanz de Castro S (abst) 730
Sanz T (abst) 729
Saporiti E (abst) 708
Sarandakou A (abst) 650
Sardella D: *See* Spallone V et al.
Sarfati E (abst) 743
Saure B: *See* Ebel H et al.
Sautner T (abst) 754
Savazzi G: *See* Allergri L et al.
Savi E (abst) 722
Savoldi S: *See* Sandrini S et al.
Scaini P: *See* Sandrini S et al.
Scalzini A: *See* Sandrini S et al.
Scanferla F, Landini S, Fracasso A, Morachiello P, Righetto F, Toffoletto P P, Bazzato G: On-Line Bioelectric Impedance During Haemodialysis: Monitoring of Body Fluids and Cell Membrane Status S167

Scaroni P: *See* Ravelli M et al.
Scarpioni L: *See* Bergonzi G et al.
Scarpioni L (abst) . . . 722
Schaefer F (abst) . . . 695, 713
Schaefer J (abst) . . . 726
Schaefer K (abst) . . . 734
Schaefer R M: *See* Lemke H-D et al.
Schaefer R M (abst) . . . 673, 742
Schaeffer G: *See* Wanner C et al.
Schalekamp M A D H: *See* Vincent H H et al.
Schakekamp M A D H (abst) . . . 899
Schärer K: *See* Schürmann G et al.
Scharer K (abst) . . . 656–7, 695, 713, 737
Schaub U (abst) . . . 740
Scheer J (abst) . . . 734
Scheler F (abst) . . . 695
Schena F P: *See* Manno C et al.
Schena F P, Montenegro M, Scivittaro V: Meta-Analysis of Randomised Controlled Trials in Patients with Primary IgA Nephropathy (Berger's Disease) . . . S47
Schena F P (abst) . . . 640, 677
Scherberich J E (abst) . . . 653
Scherer S (abst) . . . 656
Schiffl H: *See* Lauster F et al.
Schiffl H (abst) . . . 689
Schindler R (abst) . . . 713
Schmid M (abst) . . . 673
Schmidli M: *See* Ruffmann K et al.
Schmidt P (letter) . . . 555
Schmidt R (letter) . . . 901
Schmidt U: *See* Seyfert U T et al.
Schmidt U (abst) . . . 670
Schmidtmann S, Baehr R v, Precht K: Free Radicals Induce Increased Lysis of Red Blood Cells After Haemodialysis . . . 600
Schmiedeke T: *See* Vogt A et al.
Schmit J L (abst) . . . 660
Schmitt F: *See* Hannedouche T et al.
Schmitt F (abst) . . . 640
Schmitt Y (abst) . . . 713
Schneble F (abst) . . . 656
Schneditz D (abst) . . . 711–12
Schneider H (abst) . . . 713
Schneider J: *See* Mall G et al.
Schneider R (abst) . . . 697
Schoel G (abst) . . . 695
Schoeppe W (abst) . . . 653
Schollmeyer P J: *See* Wanner C et al.
Schollmeyer P J (abst) . . . 663, 697
Scholten A P: *See* Burger H et al.
Schrader J (abst) . . . 695
Schrama Y C (abst) . . . 897
Schreiner G (abst) . . . 302, 317, 659, 682
Schreurs O (abst) . . . 306
Schröder C H (abst) . . . 896–7
Schück O: *See* Marečková O et al.
Schück O, Taplan V, Nádvorniková H: The Effect of Haemodialysis on Tubular Secretion of Creatinine in Residual Nephrons . . . 549
Schück O (abst) . . . 391, 397–8
Schück O (letter) . . . 634
Schuiling G A (abst) . . . 305
Schuller M (abst) . . . 693
Schulz A (abst) . . . 673
Schulz W (abst) . . . 679
Schulze M (abst) . . . 667, 706
Schulze M *See* Haubitz M et al.
Schurgers M L: *See* Boelaert J R et al.
Schürmann G, Schärer K, Wingen A–M, Otto G, Herfarth C: Early Liver Transplantation for Primary Hyperoxaluria Type 1 in an Infant with Chronic Renal Failure . . . 825
Schütterle G (abst) . . . 637, 662, 715
Schwartz A (abst) . . . 395
Schwarz A (abst) . . . 752
Schwer E H (abst) . . . 695
Schwöbel B: *See* Bommer J et al.
Scida G: *See* Rizzuto G et al.
Sciuto G: *See* Ravelli M et al.
Scivittaro V: *See* Schena F P et al.
Scoble J E (letter) . . . 904
Scoble J E, Freestone, A, Varghese Z, Fernando O N, Sweny P, Moorhead J F: Cyclosporin-Induced Renal Magnesium Leak in Renal Transplant Patients . . . 812
Scoble J E, Screaton G R, Havard C W H: Renal Magnesium Wasting in Bartter's Syndrome . . . 388
Scolari F: *See* Sandrini S et al.
Scorza D: *See* Genderini A et al.
Scorza D (abst) . . . 717
Scott R (abst) . . . 758
Screaton G R: *See* Scoble J E et al.
Sebert J L (abst) . . . 727, 736
Seelig R: *See* Bommer J et al.
Seemann J: *See* Keller F et al.
Sefrologia S (abst) . . . 729
Segelmark M, Butkowski R, Wieslander J: Antigen Restriction and IgG Subclasses Among Anti-GBM Autoantibodies . . . 991
Segoloni G P (abst) . . . 710, 720, 752, 754
Seherr-Thohs U: *See* Neumayer H-H et al.
Seidel A (abst) . . . 673, 735
Seidel C (abst) . . . 695
Selgas R (abst) . . . 721
Sells R A (abst) . . . 755
Selwood N H: *See* Bergstrom C et al.; Broyer M et al.; Brunner F P et al.; Rizzoni G et al.
Semethkowska-Jurkiewicz E (abst) . . . 466
Semmekrot B (abst) . . . 317
Sena L M (abst) . . . 724
Sennesael J (abst) . . . 743
Sepe V: *See* Capuano A et al.
Sepe V (abst) . . . 677–8
Seppänen E (abst) . . . 734
Seron D, Alexopoulos E, Raftery M J, Hartley B, Cameron J S: Number of Interstitial Capillary Cross-Sections Assessed by Monoclonal Antibodies: Relation to Interstitial Damage . . . 889
Serón D (abst) . . . 753, 756
Serra A, Encabo B, Romero R, Bonal J, Bonet J, Lauzurica R, Teixido J, Caralps A: Clinical Spectrum of Segmental Necrotising Glomerulitis: Observations in 16 patients . . . S88
Serra A (abst) . . . 665, 720
Sert Ş (abst) . . . 704
Sertl X (abst) . . . 713
Sesso R, Ancão M S, Draibe S A, Sigulem D, Ramos O L: Survival Analysis of 1563 Renal Transplants in Brazil: Report of the Brazilian Registry of Renal Transplantation . . . 956
Setti G: *See* Sandrini S et al.
Setti G (abst) . . . 649

Severn A (abst) . . . 661
Sevillano G, Rodríguez-Puyol M, Martos R, Duque I, Lamas S, Díez-Marqués M L, Lucio J, Rodríguez-Puyol D: Cellulose Acetate Membrane Improves Some Aspects of Red Blood Cell Function in Haemodialysis Patients . . . 497
Sewing K F (abst) . . . 752
Seyfert U T, Gumbel W, Berger H, Schmidt U, Albert F W: Interleukin-2 Determinations for Monitoring the Renal Allograft . . . 612
Shaldon S: *See* Nonnast-Daniel B et al.
Shaldon S (abst) . . . 706, 713, 725–6, 742
Shallcross T (abst) . . . 646
Shand B I (abst) . . . 316
Shanks D (abst) . . . 736
Sharma A M: *See* Wenzel-Seifert K et al.
Shasha S (abst) . . . 710
Shastry J C M: *See* Ninan V T et al.
Shenkman L (abst) . . . 642
Shepherd J (abst) . . . 654
Sheth K (abst) . . . 698
Shibata M (abst) . . . 668
Shilo L (abst) . . . 642
Shires M (abst) . . . 679, 685
Short A: *See* Gopal Rao G et al.
Short A K (letter) . . . 633
Short C D (abst) . . . 304
Siakotos M (abst) . . . 733, 749
Siamopoulos K C (abst) . . . 670, 701
Siciliano A (abst) . . . 670
Siciński A (abst) . . . 468
Sicuso C (abst) . . . 702, 731
Sieberth H G: *See* Braendle E et al.; Ittel T H et al.
Sieberth H G (abst) . . . 732
Sigulem D: *See* Sesso R et al.
Simon P: *See* Meyrier A et al.
Simon P (abst) . . . 643
Simoni G, Gurreri G, Friedman D: Five Years' Experience with Hickman Catheters as Temporary Access for Haemodialysis . . . 59
Simonini P (abst) . . . 646
Simonsen S (abst) . . . 693
Simpson A R: *See* Donnelly P K et al.
Simpson J G (abst) . . . 684
Singh P P: *See* Gupta K L et al.
Sinico R A: *See* D'Amico G and Sinico R A
Sinico R A (abst) . . . 681–2, 684
Sipilä R, Hortling L, Hovi T: Good Seroresponse to Enhanced-Potency Inactivated Poliovirus Vaccine in Patients on Chronic Dialysis . . . 352
Siraieddine K (abst) . . . 669
Sirkis Y (letter) . . . 1056
Sisca S (abst) . . . 710
Sjöholm A (abst) . . . 660
Skaarup P (abst) . . . 829
Skála I: *See* Marečková O et al.
Skielboe M (abst) . . . 830
Slaaf D W (abst) . . . 299
Slavčiek J (abst) . . . 662
Slováček R (abst) . . . 395–6
Słowik E (abst) . . . 467
Słowik E (letter) . . . 835
Sluiter H E: *See* Dofferhoff A S M et al.
Sluiter W J (abst) . . . 308
Smet L (abst) . . . 894
Smetana S (abst) . . . 649
Smetiško A (abst) . . . 662
Smith C (abst) . . . 760
Smith I W: *See* Bunney M H et al.
Smith M J B (abst) . . . 315
Smoleński O (abst) . . . 469
Smulevici I (abst) . . . 644
So A (abst) . . . 297
Sobh M (abst) . . . 654, 684
Sochor L (abst) . . . 396
Sødal G (abst) . . . 748
Sodi A (abst) . . . 670
Soergel M (abst) . . . 656
Solé M (abst) . . . 757
Solé M (letter) . . . 237
Soler Amigo J (letter) . . . 158
Soliani F, Davoli V, Franco V, Lindner G, Lusenti T, Parisoli A, Brini M, Borgatti P P: Intradialytic Changes of the Oxyhaemoglobin Dissociation Curve During Acetate and Bicarbonate Haemodialysis . . S119
Solini A (abst) . . . 665
Solski J (abst) . . . 740
Sonnenberg A (abst) . . . 306
Sonntag R (abst) . . . 663
Sørensen P J: *See* Sørensen S S et al.
Sørensen S S, Glud T K, Sørensen P J, Amdisen A, Pedersen E B: Change in Renal Tubular Sodium and Water Handling During Progression of Polycystic Kidney Disease: Relationship to Atrial Natriuretic Peptide . . . 247
Sorribes A (abst) . . . 739
Sotirchos G (abst) . . . 749
Sotorník I (abst) . . . 392
Soulillou J P (abst) . . . 746–7
Souqiyyeh M Z (abst) . . . 669
Sousa J (letter) . . . 552
Spallone V, Mazzaferro S, Tomei E, Maiello M R, Lungaroni G, Sardella D, Diacinti D, Menzinger G, Coen G: Autonomic Neuropathy and Secondary Hyperparathyroidism in Uraemia . . . S128
Speelman P (abst) . . . 894
Spencer E S (abst) . . . 830
Spencer S J W, Philips M E: Transitional-Cell Carcinoma in Acquired Cystic Disease of the Kidney in a Patient on CAPD . . . 464
Sperschneider H (abst) . . . 713, 734
Spieker C (abst) . . . 746
Spindler E (abst) . . . 726
Spitz L (book review) . . . 404
Splendiani G: *See* Sturniolo A et al.
Spongan M (abst) . . . 712
Spongano H (abst) . . . 707
Spongano M: *See* Santoro A et al.
Spongano M (abst) . . . 716
Spustová V (abst) . . . 391, 397, 666, 669
Squiccimarro G (abst) . . . 752
Srp A (abst) . . . 394
Stabell U (abst) . . . 679
Stachowski J (abst) . . . 467, 684
Stahl M (abst) . . . 830
Stamatiadis D (abst) . . . 749
Stanziale P (abst) . . . 678
Starklint H (abst) . . . 680
Staszewski S (abst) . . . 653
Stauder R (abst) . . . 758
Steadman R (abst) . . . 466, 759–60
Štec J (abst) . . . 393

Steenweg L (abst) . . . 718
Stefanadis C (abst) . . . 714
Stefanidis C J (abst) . . . 682
Stefoni S, Coli L, Zacă F, Bombardini T, Puddu G, Feliciangeli G, Cianciolo G, Facchini M G: Modulated Dialysis: A New Strategy for the Treatment of Intradialytic Intolerance . . . S154
Steger A C, Timoney A S A, Griffen S, Salem R R, Williams G: The Influence of Immunosuppression on Peptic Ulceration Following Renal Transplantation and the Role of Endoscopy . . . 289
Stein G (abst) . . . 673, 679, 713, 734–5
Steinbach K (abst) . . . 686
Steinbrüchel D A (abst) . . . 680
Steiner G (abst) . . . 757
Steininger R (abst) . . . 748, 753–4
Stejskal J (abst) . . . 399
Stellwaag M: *See* Ebel H et al.
Stelwagen T (abst) . . . 315
Stenver D (abst) . . . 832
Sterioff S (abst) . . . 748
Stevens M (abst) . . . 674
Stevens P (abst) . . . 708
Stewart K N (abst) . . . 684, 757
Stibor V (abst) . . . 394
Stiedl B (abst) . . . 656
Stiller S: *See* Mann H et al.
Stockenhuber F (abst) . . . 690, 713, 723, 741, 743, 753
Stockenhuber T (abst) . . . 719
Stöckl F: *See* Vogt A et al.
Stölzl K (abst) . . . 643
Straková M (letter) . . . 238
Strandgaard S (abst) . . . 672, 829
Stratos C (abst) . . . 714
Strauch M (abst) . . . 667
Strongman R S (abst) . . . 685
Struijk D G (abst) . . . 299, 313, 718, 721–2, 894–5, 898
Struthers A D (abst) . . . 688, 694
Struyvenberg A (abst) . . . 648
Stubbs J (abst) . . . 641
Stuby U (abst) . . . 643
Sturani A: *See* Fabbri A et al.
Sturniolo A, Costanzi S, Barbera G, Ruffini M P, Passalacqua S, Fulignati P, Splendiani G: Computerised Monitoring of Sodium and Fluid During Haemodialysis . . . S162
Suarez C (abst) . . . 652
Suassuna J (abst) . . . 721
Suga H (abst) . . . 663
Sugano M (abst) . . . 668
Sugimura S (abst) . . . 725
Sugisaki Y: *See* Vogt A et al.
Sułowicz W (abst) . . . 470, 743
Sultan Y, London G M, Goldfarb B, Toulon P, Marchais S J: Activation of Platelets, Coagulation and Fibrinolysis in Patients on Long-Term Haemodialysis: Influence of Cuprophan and Polyacrylonitrile Membranes . . . 362
Sumethkul V (abst) . . . 674
Sunder-Plassmann G (abst) . . . 685
Surachno S (abst) . . . 307
Surian M (abst) . . . 700, 715
Susanna F (abst) . . . 714
Sutcliffe N P: *See* Fox J G et al.
Svarstad E (abst) . . . 690
Swaak A J G (abst) . . . 310
Sweany A E (abst) . . . 641
Sweny P: *See* Scoble J E et al.; Wheeler D C et al.
Sweny P (letter) . . . 904
Szabo A (abst) . . . 735
Szczepańska-Konkel M (abst) . . . 470
Szewczyk Z (abst) . . . 467, 674
Szewczyk Z (letter) . . . 835
Szopa J (abst) . . . 467, 674
Táborský P (abst) . . . 392
Tagariello G (abst) . . . 714
Takahashi K: *See* Warrens A N et al.
Takahashi K (abst) . . . 676, 757
Takatori Y (abst) . . . 709
Takayama K (abst) . . . 732
Takehashi K (abst) . . . 745
Talartschik J (abst) . . . 695
Tampieri G: *See* Fabbri A et al.
Tan D (abst) . . . 698
Tanabe K (abst) . . . 745, 757
Tanner M S: *See* Layward L et al.
Tanner M S (abst) . . . 309
Taplan V: *See* Schück O et al.
Taraba I: *See* Losonczy Gy et al.
Tasco A: *See* Manno C et al.
Tasmussen A G: *See* Otte K E et al.
Tattersall J E (abst) . . . 319, 691
Taube D (abst) . . . 306–7, 314
Taugner R (book review) . . . 403
Tawfik A (abst) . . . 654
Tax W J (abst) . . . 308
Tax W J M (abst) . . . 307
Tcatchev K (abst) . . . 705
Teatini V (abst) . . . 712
Tebbe U (abst) . . . 695
Tegzess A M (abst) . . . 308, 753
Tegzess A M (letter) . . . 906
Teixidó J: *See* Serra A et al.
Teizeira Sousa F (letter) . . . 474
ten Berge R J M (abst) . . . 307
ten Cate J (abst) . . . 708
ten Cate J W (abst) . . . 708
ten Dam M A G J (abst) . . . 302, 318
ten Kate R W (abst) . . . 302
ten Kate T W (abst) . . . 318
Tenschert W: *See* Rolf N et al.
Tentori F L (abst) . . . 667
Teplan V (abst) . . . 391, 397–8
Teppo A-M (abst) . . . 724
ter Wee P M (abst) . . . 753, 895
Teraoka S (abst) . . . 663, 757
Terlecki J (abst) . . . 742
Terrat J C (abst) . . . 726
Teruel J L (abst) . . . 714
Tesař V (abst) . . . 392, 394–5
Tesio F (abst) . . . 645, 739
Tessitore N: *See* Panzetta G et al.
Testa A: *See* Esnault V et al.
Testa H J (abst) . . . 300
Theilmann L (abst) . . . 706
Thieler H (abst) . . . 670
Thijs L G (abst) . . . 301
Thomas C E (letter) . . . 400
Thomas D M, Nicholls A J, Feest T G: Ulcerative Colitis and Glomerulonephritis: Is There an Association? . . . 628
Thomas H (abst) . . . 667

Thomas J H: *See* Wang Y et al.
Thomas T: *See* Abdulhadi M H et al.; Main J et al.
Thomas T H (abst) 644
Thomasy M (abst) 393
Thomsen A (abst) 830
Thomsen H S (abst) 833
Thomson A (abst) 756
Thomson D (abst) 315
Thorbjørn Jensen L (abst) 828
Tidow G (abst) 708
Timoney A S A: *See* Steger A C et al.
Timpka T: *See* Buur T et al.
Tindale W (abst) 311
Tizado J (abst) 644, 658
Tjalma W (abst) 731
Tjandra Y I (abst) 897–8
Toborek M (abst) 470
Todorov N (abst) 705
Toffoletto P P: *See* Scanferla F et al.
Tognet E (abst) 657, 661
Toma H (abst) 757
Tomei E: *See* Spallone V et al.
Tomková D (abst) 397
Tomson C R V: Echocardiographic Assessment of Systolic Function in Dialysis Patients 325
Tönshoff B (abst) 754
Tönshoff C (abst) 754
Toothill C (abst) 306, 747
Topley N (abst) 466, 685, 759–60
Tornero F (abst) 704, 735
Torras A (abst) 647
Torrente J (abst) 666, 704
Torres A: *See* Gonzalez-Posada J M et al.
Torres A (abst) 731, 751
Torvik D (abst) 693
Tóth M (abst) 691–2
Toulon P: *See* Sultan Y et al.
Toupance O: *See* Bindi P et al.
Toupance O (abst) 755
Tournade H (abst) 685
Toutouzas P (abst) 714
Tovar J L (abst) 687
Tovbin D (abst) 662
Traeger J (book review) 635
Traindl O (abst) 754–5
Tran D D (abst) 310
Traneus A, Heimbürger O, Granqvist S: Diverticular Disease of the Colon: A Risk Factor for Peritonitis in Continuous Peritoneal Dialysis 141
Travaglini M (abst) 658
Traver J (abst) 696
Tricot F (abst) 669
Triolo G (abst) 720, 752
Triolog G (abst) 754
Trznadel K (abst) 468–9
Tsianas N (abst) 733
Tsianos E (abst) 701
Tucker B, Brown A L, d'Ardenne A J, Cattell W R: Reversible Renal Failure Due to Renal Infiltration and Associated Tubulointerstitial Disease in Chronic Lymphocytic Leukaemia 616
Tufveson G: *See* Alarabi A A et al.; Bergstrom C et al.; Broyer M et al.; Rizzone G et al.
Tulloch A (abst) 315
Turci F: *See* Docci D et al.
Turney J H: *See* Lipkin G W et al.
Turney J H (abst) 310, 319
Tzaphlidou M (abst) 670
Ubeda I (abst) 735
Ubhi C S, Woodhouse L, Giles G R: Interaction of Intravenous Methylprednisolone with Oral Cyclosporin 376
Uccello F: *See* Sabbatini M et al.
Uehara Y (abst) 668, 720
Uhlschmid G: *See* von Kiparski A et al.
Ulrichs K (abst) 468
Ureña P: *See* Losekann A et al.
Ureña P (abst) 743
Uzar J (abst) 471
v Osnabrugge-Bondon C H H M (abst) 304
v Velthuysen M L F (abst) 304
Vago L: *See* Barbiano di Belgiojoso G et al.
Valderrabano F (abst) 646
Valdés F (abst) 720
Valenti G (abst) 664
Valentijn R M (abst) 898
Vallon J J: *See* Cochat P et al.
Valor R (abst) 666
Valotti C: *See* Ravelli M et al.
Valvo E: *See* Maschio G et al.
van Acker B A C (abst) 649
van Breda Vriesman P J C (abst) 306, 647
van Brummelen P (abst) 316
Van de Vyver F L: *See* D'Haese P C et al.
Van de Vyver F L (abst) 735
Van de Vyver F L, Visser W J, D'Haese P C, De Broe M E: Iron Overload and Bone Disease in Chronic Dialysis Patients 781
van de Winkel J G J (abst) 307
van den Bemd B J C M (abst) 313, 718
van den Born J (abst) 295, 303
van den Bos G C (abst) 301
Van Den Broek L J C M: *See* Hogendoorn P C W et al.
van den Heuvel L (abst) 303
van den Heuvel L P W J (abst) 295
van der Hem G K: *See* Kremer Hovinga T K et al.
van der Hem G K (abst) 298, 301, 894
van der Maas A P C (abst) 897
Van der Merwe W M, Rodger R S C, Grant A C, Logue F C, Cowan R A, Beastall G H, Junor B J R, Briggs J D: Low Calcium Dialysate and High-Dose Oral Calcitriol in the Treatment of Secondary Hyperparathyroidism in Haemodialysis Patients . . 874
van der Meulen J (abst) 310, 313, 895
van der Meulen J (letter) 78
van der Ploeg J C M (abst) 296
van der Woude F J (abst) 297, 758
van Diepen F N J (abst) 307
van Dorp W T (abst) 758
van Dorp W T (letter) 903
van Duyl W A: *See* Vincent H H et al.
van Duyl W A (abst) 898–9
van Eendenburg J D H (abst) 306
van Es L A (abst) 297, 758
van Esser J (abst) 899
van Hooff J P (abst) 299, 750, 899
van Ittersum M C: *See* Vincent H H et al.
van Kamp G J (abst) 302, 318
van Kraats A A (abst) 301
van Lambalgen A A (abst) 301
Van Landschoot N (abst) 725, 898
Van Landuyt H W: *See* Boelaert J R et al.

van Leer E H G (abst) . . . 296
van Leusen R (abst) . . . 718, 895
van Liebergen F J H M (abst) . . . 718, 895
van Meijel J J M (abst) . . . 896
van Olden R W (abst) . . . 896
van Son J P H F (abst) . . . 296
van Son W J (letter) . . . 906
van Wieringen P A M (abst) . . . 758
van Ypersele de Strihou C (letter) . . . 1057
van Ypersele de Strihou C: *See* Ghysen J et al.; Peten E et al.
van Ypersele de Strihou C (abst) . . . 705, 727–8
Vandeberg B (abst) . . . 727
Vandemiepen P (abst) . . . 743
Vandenbogaerde J (abst) . . . 754
VanderStiggel G (abst) . . . 754
Vaneerdeweg W (abst) . . . 731
Vaněk I (abst) . . . 398
Vanel T (abst) . . . 726
Vangelista A, Frascà G M, Martella D, Bonomini V: Glomerulonephritis in Renal Transplantation . . . S42
Vanholder R (abst) . . . 701, 725, 736, 754, 898
Varghese Z: *See* Scoble J E et al.; Wheeler D C et al.
Varghese Z (letter) . . . 904
Varlaj V (abst) . . . 705
Varvařovská J (abst) . . . 395–6
Vassallo G: *See* Bergonzi G et al.
Vassent G (abst) . . . 317
Vatne K (abst) . . . 748
Vaudwell V (abst) . . . 728
Vazquez J J (abst) . . . 652
vd Reijden H J (abst) . . . 313
Veen E A V d (abst) . . . 687
Veerkamp J H (abst) . . . 295, 303
Vega N (abst) . . . 702
Veitch P S: *See* Donnelly P K et al.
Veitch P S (abst) . . . 756
Velosa J A (abst) . . . 748
Venier G B (abst) . . . 708
Veninga A (abst) . . . 296, 306
Venning M (abst) . . . 681
Venning M C (letter) . . . 555
Verbeelen D (abst) . . . 743
Verbrugh H A (abst) . . . 313
Vercellone A (abst) . . . 752, 754
Verhoef J (abst) . . . 313
Vermey A: *See* Rademaker P et al.
Verpooten G A (abst) . . . 311
Verpooten G V (abst) . . . 661
Verroust P: *See* Allergri L et al.
Veselá E (abst) . . . 396–7
Veyt D (abst) . . . 896
Vichers S (abst) . . . 641
Vidal M T (letter) . . . 902
Vidláková M (abst) . . . 391
Viganò E: *See* Graziani G et al.
Viglietta G: *See* Cagnoli L et al.
Vigna L (abst) . . . 738
Vilardell J (abst) . . . 746
Villafruela J J (abst) . . . 716
Villamor N (abst) . . . 723
Villaro J (abst) . . . 668
Vincendeau Ph (abst) . . . 663
Vincent C (abst) . . . 726, 728
Vincent H H, Akçahuseyin E, Vos, M C, van Ittersum F J, van Duyl W A, Schalekamp M A D H: Determinants of Blood Flow and Ultrafiltration in Continuous Arteriovenous Haemodiafiltration . . . 1031
Vincent H H (abst) . . . 898–9
Viron B (abst) . . . 696
Višnjar-Perovič A (abst) . . . 643
Visscher C A (abst) . . . 305
Visser W J: *See* D'Haese P C et al.; Van de Vyver F L et al.
Visser W J (abst) . . . 735
Visvardis G (abst) . . . 733
Vites N P (abst) . . . 300
Vítko Š (abst) . . . 394, 714
Vivas N (abst) . . . 658
Vlachos L (abst) . . . 650
Vlček J (letter) . . . 634
Vlek L F M (abst) . . . 306
Vocino V (abst) . . . 666
Vogt A, Schmiedeke T, Stöckl F, Sugisaki Y, Mertz A, Batsford S: The Role of Cationic Proteins in the Pathogenesis of Immune Complex Glomerulonephritis . . . S6
Vogt P, Frei U, Repp H, Bunzendahl H, Oldhafer K, Pichlmayr R: Malignant Tumours in Renal Transplant Recipients Receiving Cyclosporin: Survey of 598 First-Kidney Transplantations . . . 282
Volkmann R (abst) . . . 740
von dem Borne A E G Kr (abst) . . . 298
von Herrath D (abst) . . . 734
von Kiparski A, Frei D, Uhlschmid G, Largiadèr F, Binswanger U: Post-Transplant Diabetes Mellitus in Renal Allograft Recipients: A Matched-Pair Control Study . . . 220
von Sperling V (abst) . . . 303
Vos M C: *See* Vincent H H et al.
Vos M C (abst) . . . 898–9
Vos P F (abst) . . . 302
Vosnides G (abst) . . . 749
Vossbein M A (abst) . . . 691
Votruba M (abst) . . . 396
Voudiclari S (abst) . . . 714
Vránová Z (abst) . . . 398
Vroom T M (abst) . . . 310
Vychytil A (abst) . . . 755, 757
Vyzantiadis A (abst) . . . 733
Waaga A M (abst) . . . 468
Wada S (abst) . . . 725
Wadström J: *See* Alarabi A A et al.
Wagner K: *See* Neumayer H-H et al.
Wagner L (abst) . . . 685
Wahlberg J: *See* Alarabi A A et al.
Wald H: *See* Anteby E Y et al.
Waldek S (abst) . . . 317
Waldherr R (abst) . . . 656
Waldherr R (letter) . . . 901
Walker M (abst) . . . 299
Walker R G: *See* Frampton G et al.
Walls J: *See* McNally P G et al.
Walls J (abst) . . . 303, 660
Walstad R A: *See* Dahl K et al.
Walter J: *See* Losonczy Gy et al.
Walters H (abst) . . . 314, 747
Wamser P (abst) . . . 754
Wang H (abst) . . . 676
Wang Y, Al-Nawab M D, Evans B, Das A K, Thomas J H, Davies D R: Glomerular Epithelial-Cell Endocytosis of Horseradish Peroxidase-Polylysine

Conjugate in Immune-Complex Glomerulonephritis 771
Wanner C, Wieland H, Nauck M, Schaeffer G, Schollmeyer P, Hörl W H: Effective Hypolipidaemic Therapy with Beclobrate in Haemodialysis Patients: Interference with L-Carnitine 588
Ward M (abst) 298
Wardyn K (abst) 468
Ware R (abst) 661
Waring R (abst) 639
Warneke G (abst) 695
Warrens A N, Cassidy M J D, Takahashi K, Ghatei M A, Bloom S R: Endothelin in Renal Failure 418
Warwick G L (abst) 654
Waterloos M (abst) 725, 898
Waters H M (abst) 736
Watschinger B (abst) 754, 755
Watson M L: *See* Al-Haidary A D et al.
Watson M L (abst) 653, 688
Watzinger U (abst) 703
Wawrzychi S (abst) 740
Wchoeppe W (abst) 706
Webb J A W (book review) 477
Weber B (abst) 757
Weber M: *See* Marx M et al.
Weber M, Pullig O, Köhler H: Distribution of Goodpasture Antigens Within Various Human Basement Membranes 87
Weber M H (abst) 695
Weening J J (abst) 296, 306, 316
Weil J: *See* Lauster F et al.
Weinreich T: *See* Bommer J et al.
Weisensee D (abst) 706
Weissgarten J: *See* Modai D et al.
Welsh K (abst) 307
Wenger R (abst) 758
Wens R (abst) 894
Wenzel-Seifert K, Sharma A M, Keller F: Repeated Dialysis Anaphylaxia 821
Westberg G (abst) 660
Westeel P F (abst) 660, 727, 736
Westenend P J (abst) 316
Westwick J (abst) 300
Wetzels J F M, Hoitsma A J, Koene R A P: Decreases of Proteinuria During Alternate-Day Prednisone Therapy in Nephrotic Syndrome 914
Wetzels J F M (abst) 640
Wheeler D C, Persaud J W, Fernando R, Sweny P, Varghese Z, Moorhead J F: Effects of Low-Density Lipoproteins on Mesangial Cell Growth and Viability In Vitro 185
Wicek A (abst) 744
Widecka K (abst) 692, 696
Widerøe T-E: *See* Dahl K et al.
Widstam-Attorps U (abst) 657
Wieland H: *See* Wanner C et al.
Wielgosz A (abst) 469
Wieslander J: *See* Segelmark M et al.
Wigger J (abst) 746
Wight H P, Bassett A H, Le Carpentier J E, El Nahas A M: Effect of Treatment with Enalapril, Verapamil and Indomethacin on Compensatory Renal Growth in the Rat 777
Wijnen J (abst) 708
Wikstad I (abst) 655
Wikström B: *See* Alarabi A A et al.
Wikström B (abst) 742
Wilkinson R: *See* Main J et al.
Wilkinson R (abst) 298, 644
Will E J: *See* Davenport A et al
Will E J (abst) 306, 312, 646, 658, 700, 739, 747
William-Olsson T (abst) 663
Williams D G (abst) 303
Williams G: *See* Steger A C et al.
Williams J D: *See* Ferguson C J et al.; Macdougall I C et al.
Williams J D (abst) 466, 759–60
Williams L C (abst) 309
Williams P S (abst) 311, 674
Wilmink J M (abst) 307
Wilson C B (abst) 678
Winberg J (abst) 655
Wing A J: *See* Bergtstrom C et al.; Broyer M et al.; Brunner F P et al.; Rizzoni G et al.
Wingen A H M (abst) 657
Wingen A-M: *See* Schürmann G et al.
Winkler L (abst) 651
Wirtz J J J M (abst) 299, 899
Wizemann V (abst) 715
Woerly G (abst) 758
Wolf C (abst) 707
Wolf J P (abst) 696
Wolman Y (abst) 697
Woloszcsuk W (abst) 757
Wong T (abst) 700, 755
Woo J (abst) 756
Woodhouse L: *See* Ubhi C S et al.
Wrazidlo W (abst) 656
Wrenger E (abst) 671
Wright A F (abst) 653, 688
Wright C: *See* Cochat P et al.
Wright M (abst) 725
Wróblewska M (abst) 468
Wrong O M (abst) 654
Wuhl E (abst) 713
Wurnig P (book review) 404
Wynnckfel A (abst) 755
Wystrychowski A (abst) 470
Xenos K (abst) 733
Yagisawa T (abst) 757
Yamada N (abst) 668
Yamagami S (abst) 725
Yamaguchi Y (abst) 663
Yamazaki Y (abst) 745
Yanagisawa H (abst) 302, 659
Yaqoob M, Saffman C, Mohamed A S, Finn R: Acute Urate Nephropathy Due to Partial Hypoxanthine-Guanine Phosphoribosyl Transferase Deficiency . . 383
Yaqoob M (abst) 744
Yazawa T (abst) 668, 720
Yung S (abst) 759
Žabka J (abst) 392, 394–5
Zacă F: *See* Stefoni S et al.
Zacharová M (abst) 397
Zachée P (abst) 701
Zahradník J (abst) 392, 396
Zambello A: *See* Biasioli S et al.
Zangrandi A: *See* Bergonzi G et al.
Zástava V (abst) 398
Zavázal V (abst) 395–6
Zazgornik J (abst) 643
Ždárský E (abst) 394
Zdrojkowska E (abst) 468

Zech P (abst) 643
Zeier M (abst) 688, 737
Zeier M (letter) 901
Zeis P M (abst) 682
Zeluska W (abst) 740
Zemel D (abst) 722
Zevin D (letter) 1056
Zichová M (abst) 397
Zidek W (abst) 689, 739
Ziegler T (abst) 737
Zijlstra J J: *See* Burger H et al.
Zingraff J: *See* Losekann A et al.
Zingraff J (abst) 707, 743
Zinman C (abst) 658
Zins B: *See* Losekann A et al.
Zlabinger G J (abst) 756–7
Zoccali C (abst) 654–5, 690, 695, 702
Zolota V (abst) 682
Zubimendi A: *See* De Francisco A L M et al.
Zuccalà A, Zucchelli P: Use and Misuse of the Renal Functional Reserve Concept in Clinical Nephrology 410
Zucchelli A: *See* Cagnoli L et al.
Zucchelli A (abst) 651
Zucchelli P: *See* Santoro A et al.; Zuccalà A.
Zucchelli P (abst) 651, 674, 680, 707, 712, 716
Züchner C (abst) 695
Zwiers A (abst) 318
Zwierstra R: *See* Rademaker P et al.

Subject Index to Volume 5

Ablation Nepropathy, in the rat (abst) 398
ABO-Incompatible renal transplantation 148, 745
ACE Inhibition 837
  and atrial natriuretic factor (abst) 693
  antiproteinuric effect of (abst) 315
  in CRF (abst) 672, 674
  in diabetic nephropathy (abst) 672
  in essential hypertension (abst) 686
  in glomerular disease S81
Acetate
  in haemodialysis 931
  in haemodialysis (abst) 702, 709
  in ventricular performance (abst) 705
Acid-Base Balance
  effect of lactate-based fluids 342
  in dialysis 397
  in haemodialysis (abst) 396
  in haemofiltration (abst) 396
Acquired Cystic Kidney Disease
  anaemia in (abst) 702
  erythropoietin in (abst) 702
  in chronic renal insufficiency (abst) 656
  in paediatric patients (abst) 656
  transitional-cell carcinoma in 464
Acromegaly
  hypertension in (abst) 688
  relationship between GH and cellular sodium transport in (abst) 688
  sodium transport in (abst) 688
Acute Compartmental Syndrome
  mannitol in (abst) 658
  muscle tamponade in (abst) 658
Acute Gouty Arthritis, in chronic renal failure (abst) . 645
Acute Interstitial Nephritis
  clinical and morphological study 94
  in adolescents (abst) 399
Acute Obstructive Nephropathy, ultrasonography in (abst) 649
Acute Renal Dysfunction, puromycin in (abst) 659
Acute Renal Failure
  aetiology and prognosis of (abst) 660
  alpha-Interferon in (abst) 661
  atraumatic blood pump (abst) 319
  atrial natriuretic peptide in (abst) 470
  carnitine palmitoyl transferase deficiency in (abst) . 649
  CAVHD in (abst) 661
  dobutamine in (abst) 301
  dopexamine in (abst) 301
  energy expendidture in (abst) 311
  erythropoietin deficiency in 920
  erythropoietin in (abst) 310
  follow up (abst) 319
  glycerol-induced 118
  in chronic lymphocytic leukaemia 616
  in hepatocyte gluconeogenesis (abst) 663
  in ketogenesis (abst) 663
  in ureagenesis (abst) 663
  interleukin 2 in (abst) 661
  intracranial pressure in 192
  mortality in (abst) 310
  muscle calcifications in 461
  nitrogen balance in (abst) 311
  non-traumatic rhabdomyolysis in (abst) 649
  norepinephrine in (abst) 657
  pancreatitis in 542
  postischaemic 32
  prostaglandin I_2 in (abst) 317
  puromycin in 659
  renal cortical necrosis in 542
  rhabdomyolysis in 461
  ultrasonography in (abst) 649
Acute Urate Nephropathy, due to partial hypoxanthine-guanine phosphoribosyl transferase deficiency 383
Adriamycin
  and low protein diet (abst) 664
  in nephrotic syndrome (abst) 673
  in pregnancy (abst) 662
  in proteinuria (abst) 679
Adriamycin Nephrosis
  low-protein diet in S63
  xanthine-metabolising enzymes in S63
Age Effects
  in Haemodialysis 1023
  in Kidney Donors (abst) 746
Age-Matching, in renal transplantation 808
AIDS-Associated Nephrophathy S84
Albumin
  charge distribution pattern in nephrotic syndrome (abst) 639
  in essential hypertension (abst) 686
  in glomerulonephritis 997
  in glomerulonephritis (abst) 694
  in renoparenchymal hypertension (abst) 686
Albumin-Bound Furan-Carboxylic Acid (abst) 720
Albumin-Bound Indoxyl Sulfate (abst) 668
Albuminuria
  dietary effects in (abst) 315
  essential hypertension (abst) 643
  in essential hypertension (abst) 686
Alcohol Intoxication and IgA Nephropathy (abst) . . 675
Aldosterone
  in analbuminaemic rat (abst) 314
  in nephrolithiasis (abst) 471

metabolism in isolated perfused rat liver and kidney (abst) . . . 831
metabolism in the rat (abst) . . . 828
Allograft Dysfunction, anti-HLA antibodies in (abst) . 307
Allograft Function
calcium-channel blockers in . . . 816
nifedipine in . . . 816
Allograft Rejection
histological diagnosis of (abst) . . . 307
HLA-DR expression in (abst) . . . 751
immunoglobulin A in . . . 520
methylprednisolone in . . . 320
monoclonal antibodies in (abst) . . . 307
X-irradiation in (abst) . . . 306
Allografts, fine-needle aspiration biopsy in . . . 226, 903
$Alpha_1$ Proteinase Inhibitor, in proteolysis of antithrombin III (abst) . . . 702
Alpha-Interferon, in acute renal failure (abst) . . . 661
Alpha-Ketoanalogues, in haemodialysis (abst) . . . 711
Alport's Syndrome
antithyroid antibodies in (abst) . . . 645
a symptomatic autoimmune thyroiditis in (abst) . . . 645
inheritance of . . . 900
thyroid dysfunction in (abst) . . . 645
x-linked form (abst) . . . 830
Aluminium
accumulation in bone (abst) . . . 735
effect of recombinant human erythropoietin response (abst) . . . 738
in bacterial sepsis (abst) . . . 306, 747
in bone disease, DFO infusion test in (abst) . . . 729
in chronic renal failure . . . 449
in haemodialysis . . . 441, 942
in haemodialysis (abst) . . . 729, 741
in mononuclear phagocytic system (abst) . . . 685
in osteomalacic bone disease (abst) . . . 729
intestinal absorption of . . . 860
intoxication in the rat . . . 258
localisation in bone tissue (abst) . . . 392
monitoring in dialysis patients . . . 45
overload in uraemia . . . 945
Aluminium Hydroxide, in dialysis (abst) . . . 830
Aluminium-Related Bone Disease (abst) . . . 732
Aluminoxamine, biliary elimination of (abst) . . . 731
Amiloride, in lithium excretion (abst) . . . 318
Amino Acid Sequence, of beta-2-microglobulin (abst) 728
Amino Acids
hyperfiltration induced by, glucagon secretion in . . 110
in chronic renal failure (abst) . . . 392, 665
in creatinine clearance (abst) . . . 831
in glomerular filtration rate increase (abst) . . . 831
in haemodialysis (abst) . . . 711
infusion in insulin-dependent diabetics (abst) . . . 640
membrane transport in erythrocytes . . . 594
renal haemodynamic effects of (abst) . . . 638
renal vasodilatation induced by (abst) . . . 639
Amoxycillin, in nephrotic syndrome . . . 1055
Amylin, in haemodialysis (abst) . . . 694
Amyloid Deposits, in haemodialysis (abst) . . . 727
Amyloidosis
dialysis (abst) . . . 728
dialysis-associated . . . 901
haemodialysis-associated . . . 237
in familial Mediterranean fever (abst) . . . 651
in spondyloarthropathy . . . 199
renal replacement in (abst) . . . 664
Anaemia
acquired haemolytic . . . 148
adaptation of uraemic patients to . . . 604
erythropoietin in (abst) . . . 742
in acquired cystic kidney disease (abst) . . . 702
in CAPD . . . 950
in chronic renal failure . . . 232, 1055
in dialysis (abst) . . . 702
recombinant human erythropoietin in . . . 232, 950, S102
recombinant human erythropoietin in (abst) . . . 737
tissue oxygenation in . . . 444
Analbuminaemia, in the rat (abst) . . . 314
Analgesic Nephropathy, diagnostic criteria of (abst) . 667
Anaphylactoid Reactions, in haemodialysis . . . 821
Angiotensin II
in hypertension (abst) . . . 687
in lithium clearance (abst) . . . 302
in polycystic kidney disease . . . 247
Angiotensin-Converting-Enzyme Inhibitors. *See* ACE Inhibition
Anion Exchanger, $Cl^-/NaCO_3^-$ . . . 1018
Antibody Binding in chronic serum sickness in isolated erythrocyte perfused rat kidney (abst) . . . 678
Anticardiolipin Antibodies, in dementia, renal insufficiency and unique renal immunopathological lesions (abst) . . . 647
Anti-CD4-Receptor in mercuric chloride induced glomerulonephritis (abst) . . . 680
Anti-GBM Antibodies in Goodpasture's Syndrome . . 991
Antigen Binding in chronic serum sickness in isolated erythrocyte perfused rat kidney (abst) . . . 678
Antiglomerular Basement Membrane Disease, associated with thin membrane nephropathy . . . 909
Antihypertensive Therapy, in chronic renal failure (abst) 648
Anti-Idiotypic Antibodies, in donor-specific transfusion (abst) . . . 758
Antineutrophil Cytoplasmic Antibody
in microscopic polyarteritis (abst) . . . 296
in vasculitis (abst) . . . 309
in vasculitic syndromes (abst) . . . 684
in Wegener's granulomatosis (WG) (abst) . . . 296
Antiphospholipid Antibodies, in lupus or lupus-like nephritis (abst) . . . 678
Antiplatelet Agents in Glomerulonephritis . . . S29
Antithrombin III, proteolysis by neutrophil elastase (abst) . . . 702
Antithyroid Antibodies, in Alport's syndrome (abst) . 645
Anuria, in malignant hypertension . . . 174
Apolipoprotein B Metabolism, in nephrotic proteinuria (abst) . . . 654
Apolipoproteins
in continuous ambulatory peritoneal dialysis (abst) . . . 698
in haemodialysis (abst) . . . 698
Arteriovenous Fistulae
detection of (abst) . . . 747
effect of percutaneous transluminal angioplasty . . . 608
in haemodialysis (abst) . . . 708
jugular vein bypass to preserve . . . 977
vein grafts as (abst) . . . 703
Aspirin, effect on ADPase activity (abst) . . . 305
AST-120 Oral Sorbent (abst) . . . 668
Asymptomatic Microscopic Haematuria, in living related kidney donation (abst) . . . 654
Atherosclerotic Renal Artery Stenosis, percutaneous transluminal angioplasty in (abst) . . . 686

Atrial Natriuretic Peptide
and ACE inhibitors (abst) . . . 693
and exchangeable body sodium (abst) . . . 691
and fractional urinary sodium excretion (abst) . . . 692
and renal sympathetic nervous system (abst) . . . 694
and renin-angiotensin-aldosterone (abst) . . . 694
and serum calcium level (abst) . . . 691
and sodium intake (abst) . . . 692
cellular localisation of . . . 25
diuretic and natriuretic responses (abst) . . . 317
effect on GFR and ERPF (abst) . . . 301
in acute renal failure (abst) . . . 470
in autosomic dominant polycystic kidney disease (abst) . . . 691
in CRF (abst) . . . 692
in dry body-weight assessment . . . 356
in essential hypertension (abst) . . . 695
in glomerulonephritis . . . 997
in glomerulonephritis (abst) . . . 694
in haemodialysis (abst) . . . 691, 693, 696
in haemodialysis patients (abst) . . . 691
in hyperthyroidism (abst) . . . 696
in hypothyroidism (abst) . . . 692
in natriuresis (abst) . . . 470
in polycystic kidney disease . . . 247, 395
in postischaemic acute renal failure . . . 32
in renal transplantation (abst) . . . 695
in ultrafiltration (abst) . . . 691, 693
Aurothiopropanolsulfonate Sodium Salts in Autoimmune Disease (abst) . . . 685
Autoimmune Disease
aurothiopropanolsulfonate sodium salts in (abst) . . . 685
cyclosporin A in (abst) . . . 658
hypertension in (abst) . . . 658
nephrotoxicity in (abst) . . . 658
Autoimmune Nephritis, gold salt-induced (abst) . . . 685
Autoimmune Reactivity, $HgCl_2$-induced (abst) . . . 296
Autonomic Nervous System, dysfunction in uraemia . . . S98, S128
Autosomal Dominant Polycystic Kidney Disease
atrial natriuretic factor in (abst) . . . 691
atrial pressure in (abst) . . . 691
DNA diagnosis of (abst) . . . 394
hypertension in (abst) . . . 688
lithium clearance in (abst) . . . 394
Azathioprine
effect on erythropoietin (abst) . . . 736
effect on skin disorders . . . 379
in renal transplantation (abst) . . . 398
Bacteraemia, in haemodialysis . . . 130
Bacterial Sepsis
aluminium in (abst) . . . 306, 747
in renal transplantation (abst) . . . 747
Bacteriuria, in diabetes mellitus (abst) . . . 466
Bartter's Syndrome
lithium clearance in . . . 904
Na reabsorption in (abst) . . . 645
pathogenesis of (abst) . . . 645
renal magnesium wasting . . . 388
Basement Membranes, Goodpasture antigens . . . 87
Beclobrate, in haemodialysis . . . 588
Berger's Disease, randomised controlled trials in . . . S47
Beta-blockade, in diabetic nephropathy (abst) . . . 672
β_2-Microglobulin
amino acid sequence of (abst) . . . 728
amyloidosis in haemodialysis (abst) . . . 727
deposition of . . . 554
in CAPD . . . 513
in dialysis related amyloidosis (abst) . . . 726-7
in haemodialysis (abst) . . . 726, 728
in periotonitis (abst) . . . 726
in spondyloarthropathy . . . 199
β_2-Microglobulin Amyloid, in haemodialysis . . . 878
β Thromboglobulin
in haemodialysis . . . 362
in uraemia (abst) . . . 668
Bicarbonate
in CAPD (abst) . . . 719
in haemodialysis . . . 931
in haemodialysis (abst) . . . 709
in ventricular performance (abst) . . . 705
Bicarbonate Dialysis, versus CAPD (abst) . . . 720
Bilateral Ureteral Obstruction
prostaglandin E in (abst) . . . 659
thromboxane in (abst) . . . 302, 659
Bile Composition in Chronic Renal Failure . . . 423
Bio-Compatibility, membrane attack complex as marker of (abst) . . . 723
Bioelectrial Impedance Analysis (abst) . . . 713
Bioimpedance Cardiography, in haemodialysis . . . S147
Blood Flow
impact on vascular stability . . . S109
in CAVH or CAVHD . . . 1031
in haemodiafiltration (abst) . . . 898
Blood Groups, P1 antigen in urinary tract infection (abst) . . . 760
Blood Lipids, effect of heparin (abst) . . . 713
Blood Pressure (see also Hypertension)
in 5/6 nephrectomy (abst) . . . 667
in CAPD (abst) . . . 894
in CRF (abst) . . . 672
in diabetic nephropathy . . . 337
in end-stage renal disease (abst) . . . 689
in glomerulonephritis . . . 337
in haemodiafiltration (abst) . . . 716
in haemodialysis (abst) . . . 696
Blood Reticulocytes, in haemodialysis (abst) . . . 743
Blood Rheology, in glomerulopathies (abst) . . . 316
Blood Serum Concentrations
in haemodialysis (abst) . . . 469
in uraemia (abst) . . . 469
Blood Volume
continuous on-line recording (abst) . . . 707
in glomerulonephritis . . . 997
in glomerulonephritis (abst) . . . 694
in haemodialysis (abst) . . . 711
measurement in dialysis . . . S144
Bone Disease
aluminium-related (abst) . . . 732
diagnosis of (abst) . . . 736
in dialysis . . . 781
in haemodialysis (abst) . . . 735
parathyroid hormone in (abst) . . . 736
Bone Marrow Stromal Cells, in hemodialysis (abst) . . . 469
Bone Metabolism, in renal stone formers (abst) . . . 733
Bone Tissue, aluminium in (abst) . . . 392
Bradycardia, in haemodialysis (abst) . . . 712
Brazilian Registry . . . 956
Brushite, in calcium oxalate lithiasis . . . 179
Bullous Dermatosis, in CRF (abst) . . . 714
C5a receptor modulation of endotoxin (abst) . . . 667
C-Reactive Protein, in haemodialysis . . . 500

Calcified Thrombus of Inferior Vena Cava S71
Calcitriol
effect on insulin secretion 1013
in chronic renal failure (abst) 664
hyperparathyroidism in 874
in haemodialysis (abst) 729, 734
in ultrafiltration (abst) 736
in uraemia 1013
parathyroid response to (abst) 734
Calcium
in CAPD (abst) 717
in renal stone formers (abst) 733
intestinal absorption of 860
Calcium Acetate
as phosphate binder (abst) 733
in haemodialysis (abst) 729, 734
in hyperphosphataemia 630
Calcium Carbonate
as phosphate binder (abst) 733
in CAPD (abst) 314
in chronic renal failure (abst) 664
in dialysis (abst) 830
in haemodialysis (abst) 729
in hyperparathyroidism (abst) 734
ranitidine effect on absorption (abst) 731
Calcium Channel Blockers
and cyclosporin A nephrotoxicity (abst) 745
cardiovascular effects of 81
in allograft function 816
in CRF (abst) 674
in essential hypertension (abst) 686
in T-cell proliferation 1038
renal effects of 81
Calcium Citrate, in hyperparathyroidism (abst) 734
Calcium Load
in renal transplantation 531
metabolic and pressor effects (abst) 655
Calcium Oxalate Lithiasis, brushite in 179
Calcium transport in synaptosomes of uraemic animals (abst) 666
Calorimetry, energy expenditure evaluation (abst) . . 708
CAPD (see also CCPD)
1,25 (OH)2D3 in (abst) 717, 735
25 (OH)2D3 in (abst) 721
anaemia in 950
apolipoproteins in (abst) 698
beta$_2$-microglobulin in 513
bicarbonate in (abst) 719
blood pressure in (abst) 894
Ca^{++} in (abst) 717
calcium carbonate in (abst) 314
cefuroxime in 275
compared with haemodialysis (abst) 718
diabetic nephropathy in (abst) 718
encephalopathy in (abst) 897
endothelin in 418
endothelin in (abst) 692
erythopoiesis in (abst) 720
erythrocytes in 369
erythropoietin in (abst) 896
fungal peritonitis in 555
glucose polymer dialysate in (abst) 299
immunomodulators in (abst) 719
in diabetic nephropathy (abst) 895
in end-stage renal failure 985
in USA (book review) 403
intellectual impairment (abst) 716
interleukin-1 in (abst) 313
KT/V urea in (abst) 896
lactate in (abst) 719
leucocytes in 369
magnesium carbonate in (abst) 314
monitoring (abst) 298
mycoplasma peritonitis in 633
paecilomyces peritonitis in 1053
peripheral nervous system in (abst) 897
peritoneal capillary endothelial cells in (abst) 721
peritoneal eosinophilia in 903
peritoneal fluid kinetics in (abst) 299
peritoneal macrophages in (abst) 718, 726
peritoneal mesothelial cells in (abst) 721
peritoneal permeability in (abst) 722
peritonitis in 141, 235, 275
peritonitis in (abst) 313, 718, 720, 894, 897–8
phosphate binders in (abst) 314
plasma refilling rate in (abst) 717
protein intake in (abst) 716
protein permeability in (abst) 313
sodium content in 369
speech abnormalities (abst) 716
versus bicarbonate dialysis (abst) 720
washout kinetics of intraperitoneal IgG 78
Captopril 99mTc-DTPA Renography, in renovascular hypertension (abst) 687
Captopril
in CRF (abst) 674
in exercise-induced renal vascular resistance (abst) . 690
in glomerular disease S81
in glomerulosclerosis (abst) 316, 671
in proteinuria (abst) 671
in proteinuria associated with obesity (abst) 653
renal haemodynamic response (abst) 673
Carbamylated Haemoglobin, time-averaged urea derived index of chronic uraemia (abst) 650
Cardiac Arrhythmias, in haemodialysis S165
Cardiac Function, effect of recombinant human erythropoietin (abst) 738
Cardiac Side Effects, in renal transplantation (abst) . . 746
Cardiovascular Impairment, in haemodialysis 1023
Cardiovascular Stability
and sodium balance S141
in dialysis S93
in haemodiafiltration (abst) 716
in haemodialysis S137
Cardiovascular Stress, in haemodialysis S133
Carnitine
in haemodialysis 588
in haemodialysis (abst) 468
Carnitine Palmitoyl Transferase Deficiency, in acute renal failure (abst) 649
Catheters, peritoneal dialysis (abst) 895
Cationic Antigens, in immune complex glomerulonephritis S6
CAVHD. *See* Haemodiafiltration
CCPD, peritonitis in (abst) 313
Ceftriazone, in nephrolithiasis 974
Cefuroxime, in CAPD 275
Cell Membrane Status, in haemodialysis S167
Cellobiose-Mannitol Test 569
Cellulosic Membranes, leukotriene B4 in (abst) 724
Cerebral Dysfunction, in haemodialysis (abst) 312
Children

end-stage renal failure . . . 985
renal disease in (book review) . . . 556
Chloroquine, effect on intestinal absorption of aluminum and calcium . . . 860
Chlorthalidone-induced Hypokalaemia (abst) . . . 648
Cholesterol in Nephrotic Syndrome (abst) . . . 673
Chronic Lymphocytic Leukaemia
acute renal failure in . . . 616
tubulointerstitial disease in . . . 616
Chronic Proliferative Glomerulonephritis
antiaggregation and antithrombotic therapy in (abst) 393
eicosanoids in (abst) . . . 393
Chronic Renal Failure
ACE-inhibitors in (abst) . . . 674
acute gouty arthritis in (abst) . . . 645
aetiology and prognosis of (abst) . . . 660
aluminium in . . . 449
amino acids in (abst) . . . 392, 665
anaemia in . . . 232, 1055
antihypertensive therapy in (abst) . . . 648
atrial natriuretic peptide (abst) . . . 692
bile composition in . . . 423
blood pressure in (abst) . . . 672
(book review) . . . 635
bullous dermatosis in (abst) . . . 714
calcitriol in (abst) . . . 664
calcium carbonate in (abst) . . . 664
calcium-channel blockers in (abst) . . . 674
Captopril in (abst) . . . 674
copper in (abst) . . . 392
diabetic, lipoprotein metabolism in (abst) . . . 663
dietary protein/phosphate restriction in (abst) . . . 674
enalapril in (abst) . . . 672, 829
endothelin in . . . 418
essential amino acids versus ketoanalogues (abst) . . 667
fructosamine in . . . 868
glucose in (abst) . . . 665
glycated haemoglobin in . . . 868
growth hormone in (abst) . . . 671
hypercholesterolaemia in (abst) . . . 470
hyperlipidaemia in (abst) . . . 670
hyperporphyrinaemia in (abst) . . . 714
in infants . . . 825
in paediatric patients (abst) . . . 656–7
insulin in (abst) . . . 665
leucine in (abst) . . . 665
lithium clearance in (abst) . . . 665
lovastatin in (abst) . . . 641
luteotropic hormone in (abst) . . . 695
Na-K adenosine triphosphatase activity in (abst) . . 663
Nifedipine in (abst) . . . 674
$1.25(OH)_2D_3$ in (abst) . . . 732
oxalate crystal deposits in . . . 493
parathyroid hormone in (abst) . . . 730
potassium in (abst) . . . 471
pruritus in (abst) . . . 701
psychological and physiological aspects (book review) 907
reduced protein intake in (abst) . . . 670
sodium in (abst) . . . 471
TCR Vβ T cells in (abst) . . . 685
thyroid-stimulating hormone in (abst) . . . 669
tubular function in (abst) . . . 665, 670
uraemic neuropathy in (abst) . . . 646
valvular regurgitations in (abst) . . . 711
vitamin D in (abst) . . . 732
zinc in (abst) . . . 392
Chronic Renal Insufficiency, acquired cystic kidney disease in (abst) . . . 656
Chronic Serum Sickness
antibody binding in isolated erythrocyte perfused rat kidney (abst) . . . 678
antigen binding in isolated erythrocyte perfused rat kidney (abst) . . . 678
in rats, rheumatoid factor in glomerular bound antigen (abst) . . . 678
Chronic Uraemia, time averaged index of (abst) . . . 650
Churg-Strauss Syndrome, renal involvement in . . . 161
Chyluria, immunological disturbances in (abst) . . . 471
Cimetidine, in creatinine clearance (abst) . . . 832
Ciprofloxacin
in CAPD peritonitis (abst) . . . 894
in peritonitis in CAPD (abst) . . . 720
Cisplatin, in renal function (abst) . . . 659
$Cl^-/NaCO_3^-$ Anion Exchanger in uraemia . . . 1018
Coagulation, in heparin-free haemodialysis . . . 802
Collagen Defect of Skin (abst) . . . 670
Colonic Diverticula, influence on peritonitis . . . 141
Colour Doppler Ultrasound (abst) . . . 708
Combined isolated perfused rat liver and kidney (CIPLK) (abst) . . . 831
Compensatory Renal Growth
growth hormone in . . . 123
insulin-like growth factor-I in . . . 123
Complement
in haemodialysis (abst) . . . 704
in hypersensitivity in haemodialysis . . . 264
Complement Activation, dialysate in (abst) . . . 722
Computer-Modulated Haemodialysis . . . S162–5
Congestive Heart Failure, haemofiltration or -dialysis in (abst) . . . 895
Contaminated Dialysate, neutrophil activation in (abst) . 725
Continuous Ambulatory Peritoneal Dialysis *See* CAPD
Continuous Arteriovenous Haemodialysis (CAVHD) (abst) . . . 312
Continuous Arteriovenous Haemodiafiltration (CAVHD). *See* Haemodiafiltration
Continuous Arteriovenous Haemofiltration (CAVH) *See* Haemofiltration
Contrast Media
iopamidol (abst) . . . 662
renal effects of (abst) . . . 650
water soluble (abst) . . . 659
Converting-Enzyme Inhibitors in glomerulonephritis . S33
Copper
in chronic renal failure (abst) . . . 392
in glomerulonephritis (abst) . . . 393
Coronary Arteriography, in disseminated cholesterol emboli . . . 155
Corticosteroids, in glomerulonephritis . . . S23
Cortisol, in nephrolithiasis (abst) . . . 471
Craniocervical Amyloidosis . . . 554
Creatinine
and glomerular filtration rate relationship (abst) . . 829
as filtration marker (abst) . . . 831
in catabolic patients (abst) . . . 831
in glomerular filtration rate evaluation (abst) . . . 832
in haemodialysis . . . 549
Crescent Formation during pregnancy . . . 619
Crush Syndrome (abst) . . . 658
Cuprophan Haemodialysis, tumour necrosis factor in (abst) . . . 700
Cuprophan Membranes, influence on platelet

activation, coagulation and fibrinolysis 362
CY 222, in thrombosis prevention (abst) 707
Cyclic-GMP
in essential hypertension (abst) 695
in renal transplantation (abst) 695
marker in dry body-weight assessment 356
Cyclophosphamide Pulse Therapy, in Wegener's granulomatosis (abst) 648
Cyclosporin
and HLA phenotype (abst) 756
and renal vascular resistance (abst) 662
effect on skin disorders 379
in autoimmune glomerulonephritis (abst) 304
in automimmune diseases (abst) 658
in diabetes mellitus 168, 220
in gout (abst) 750
in hepatitis B virus 525
in hypomagnesaemia 812
in idiopathic uveitis (abst) 745
in intravenous methylprednisolone pulse therapy . . 905
in isolated perfused kidney (abst) 689
in kidney transplantation (abst) 751
in membranous lupus nephritis (abst) 650
in nephrosis (abst) 652
in nephrotic syndrome 321
in nephrotic syndrome (abst) 644
in pretransplantation kidney conditioning in the rat (abst) 398
in renal Allograft 612
in renal allograft recipients 962
in renal transplantation 84, 282, 531
in renal transplantation (abst) 308, 398, 755–7
in T-cell proliferation 1038
interaction with methylprednisolone 376
nephrotoxicity 69
nephrotoxicity amelioration (abst) 303
nephrotoxicity reduction (abst) 745
prevention of sensitisation by (abst) 757
Cyclosporin-associated Arteriolopathy (CAA), prostaglandins in (abst) 663
Cyclosporin Metabolite Combinations in Mesangial Cells (abst) 752
Cyclosporin Nephrotoxicity
nifedipine in (abst) 660
pathology of (abst) 755
Cyst Volume, reduction of (abst) 647
Cysteine, in haemodialysis (abst) 698
Cystic Kidney (book review) 907
Cystinuria, sodium intake in (abst) 652
Cytokines, release from mononuclear cells (abst) . . . 706
Cytomegalovirus
immunohistochemistry in 1045
in ICAM-I expression (abst) 758
in MHC class I expression (abst) 758
in renal transplantation (abst) 749
in-situ hybridisation in 1045
Cytosolic Calcium in Smooth Muscle Cells (abst) . . . 689
DDAVP, in lithium excretion (abst) 318
Death Risk in Dialysis (abst) 710
Decaris, in idiopathic nephrotic syndrome (abst) . . . 396
Dementia, anticardiolipin antibodies in (abst) 647
Dent's Disease (abst) 654
Deoxyribonuclease in uraemic lymphocytes (abst) . . 674
Desferrioxamine
biliary elimination of (abst) 731
in dialysis 945
in dialysis (abst) 311
in erythrocyte membrane peroxidation (abst) 668
in erythropoietin-resistant aluminium-related anaemia (abst) 744
in iron overload (abst) 739
in visual disorders 945
Dextran, in haemodialysis 54
DFO Infusion Test, in aluminium bone disease (abst) . 729
Diabetes Mellitus
and renal replacement therapy (abst) 644
bacteriuria in (abst) 466
cyclosporin A in 168, 220
fructosamines in (abst) 666
glycaemic status in (abst) 666
hyperfiltration in (abst) 652
hypertension in 623
in paediatric patients (abst) 657
in renal allograft recipients 220
in renal replacement therapy 788
kidney and hypertension in (book review) 477
microalbuminuria in S66
prednisone in 220
type II (abst) 652
Diabetic Nephropathy
ACE-inhibitors in (abst) 672
beta-blockade in (abst) 672
blood pressure in 337
CAPD in (abst) 895
enalapril in (abst) 674
glomerular charge selectivity in (abst) 639
glomerular filtration rate in 337
hypertension in 623
in continuous ambulatory peritoneal dialysis (abst) . 718
leucocyte intracellular pH in (abst) 667
lipoprotein metabolism in (abst) 663
Na/H antiporter in (abst) 667
protein clearance in 337
protein intake in (abst) 750
protein restriction in (abst) 672
proteinuria in 623
sodium excretion in 337
sodium-lithium countertransport in (abst) 644
Diabetic Recipients, rejection activity in (abst) 748
Dialysate
contamination (abst) 725
in complement activation (abst) 722
Dialysis (see also Haemodialysis)
acid-base balance 397
age effects on strategy 1023
aluminium hydroxide in (abst) 830
aluminium monitoring in 45
amyloidosis in 901
anaemia in (abst) 702
blood volume measurement S144
bone disease in 781
calcium carbonate in (abst) 830
cardiovascular instability in S93
catheter choice (abst) 895
death risk in (abst) 710
desferrioxamine in 945
diabetes mellitus in 788
doppler echocardiography in 426
echocardiography in 325
endothelin in (abst) 690
eosinophil cationic protein in (abst) 722
erythrocyte indices 77

gentamicin in (abst) . . . 470
hepatitis C virus in (abst) . . . 714
HLA antigens in (abst) . . . 295
hypertension in (abst) . . . 701
hypotension in (abst) . . . 708
immune response in (abst) . . . 396
in ethylene glycol intoxication (abst) . . . 396
intracellular pH in (abst) . . . 712
iron overload in . . . 504, 781
lead poisoning in (abst) . . . 670
left ventricular contractility in . . . S115
lymphocytotoxic antibodies in (abst) . . . 295
modulated, in intradialytic intolerance . . . S154
myocardial ischaemia in (abst) . . . 704
neoplasia in (abst) . . . 710
neutropenia in (abst) . . . 469
osteodystrophy in . . . 449
poliovirus vaccine in . . . 352
potassium monitoring in . . . S122
protein catabolic rate in . . . S125
protein intake in . . . S125
quality of life analysis in (abst) . . . 897
systolic function in . . . 325
thrombocytopenia in (abst) . . . 469
tuberculosis in . . . 584
urea kinetic model (abst) . . . 710, 894
venous compliance in (abst) . . . 708
ventricular function in (abst) . . . 705
Dialysis Membrane Biocompatibility (abst) . . . 759
Dialysis Related Amyloidosis
diagnostic imaging of (abst) . . . 724
factors influencing . . . 728
β_2-microglobulin in (abst) . . . 726–7
thickened joint capsules and tendons in (abst) . . . 727
Diatrizoate, in urine profiles (abst) . . . 833
Diet
in albumin excretion (abst) . . . 315
low-protein, in Adriamycin nephrosis . . . S63
phosphate restriction (abst) . . . 674
protein intake (abst) . . . 671
protein restricted (abst) . . . 671, 673–4
salt and hypertension (book review) . . . 635
sucrose-rich . . . 923
vegan supplemented, in nephrotic syndrome . . . S75
Dietary Fish-Oil, in renal transplantation (abst) . . . 308
Dietary Sodium Content, in hypokalaemia (abst) . . . 648
Dietary Supplement, in mesangial IgA glomerulonephritis . . . 241
Digoxin-like Factor (DLF), after IV administration (abst) . . . 642
1,25-Dihydroxyvitamin D_3 in haemodialysis (abst) . . 698
24–25 Dihydroxyvitamin D_3, in haemodialysis (abst) . 710
Diltiazem
in pretransplantation kidney conditioning in the rat (abst) . . . 398
in preventing delayed graft function (abst) . . . 398
Diphosphoglycerate, in haemodialysis . . . S119
Disseminated Cholesterol Emboli, after coronary arteriography . . . 155
Distal Renal Tubular Acidosis (DRTA) in Liver Disease (abst) . . . 392
Diverticulitis, influence on peritonitis . . . 141
DMSA Scintigraphy, in extracorporeal shock-wave lithotripsy (abst) . . . 832
Dobutamine, in acute renal failure (abst) . . . 301
Donor Age
and graft survival (abst) . . . 754
in paediatric kidney transplantation (abst) . . . 308
Donor Kidney Interstitial Fibrosis (abst) . . . 753
Donor-specific Transfusion
anti-idiotypic antibodies in (abst) . . . 758
protection against sensitisation after (abst) . . . 750
Dopamine
in glomerular filtration rate increase (abst) . . . 831
in oliguric acute renal failure (abst) . . . 660
Dopexamine, in acute renal failure (abst) . . . 301
Doppler Echocardiography
in CFR (abst) . . . 711
in dialysis . . . 426
uraemic cardiomyopathy (abst) . . . 711
Dry Body-Weight Assessment, haemodialysis in . . . 356
Dyslipoproteinaemia, in haemodialysis . . . 797
Echocardiography
fractional shortening/end-systolic stress (FS/ESS) correlation by . . . S115
in dialysis . . . 325
in haemodialysis (abst) . . . 700
Echography, inferior vena cava . . . 238
EDTA, in Pb nephropathy (abst) . . . 642
EDTA Registry . . . 432, 559, 985
Effective Renal Plasma Flow (ERPF), in nephrotic syndrome (abst) . . . 649
Eicosanoids, in chronic proliferative glomerulonephritis (abst) . . . 393
Elastase and Hydralazine Glomerulonephritis (abst) . 660
Enalapril
in chronic renal failure (abst) . . . 829
in compensatory renal growth . . . 777
in CRF (abst) . . . 672
in diabetic nephropathy (abst) . . . 674
in hypertension (abst) . . . 315, 693, 744
in sub-total renal ablation (abst) . . . 673
in subtotal nephrectomy (abst) . . . 470
Encephalopathy, in preterminal chronic renal insufficiency, chronic haemodialysis and CAPD (abst) 897
End-Stage Renal Disease
blood pressure in (abst) . . . 689
erythropoietin in (abst) . . . 832
platelet cytosolic free calcium concentration in (abst) 689
recombinant human erythropoietin in (abst) . . . 899
Endoscopy, in peptic ulceration . . . 289
Endothelial Cell Autoantigens, in glomerulonephritis (abst) . . . 683
Endothelin
in CAPD . . . 418
in CAPD (abst) . . . 692
in chronic renal failure . . . 418
in dialysis (abst) . . . 690
in different diseases (abst) . . . 695
in haemodialysis (abst) . . . 692–3, 695
in normal persons (abst) . . . 695
in renal graft recipients (abst) . . . 690
in renal transplantation (abst) . . . 755
in systemic vasculitis (abst) . . . 676
in uraemia (abst) . . . 695
Endothelium-derived Relaxing Factor, in renal vascular resistance (abst) . . . 641
Endotoxin
and C5a Receptors (abst) . . . 667
in haemodialysis (abst) . . . 725
sensitivity in pregnancy (abst) . . . 305
Energy Expenditure

in acute renal failure (abst) . . . 311
in dialysis patients (abst) . . . 708
Energy Metabolism, in erythrocytes (abst) . . . 741
Energy Turnover, effect of erythropoietin (abst) . . . 740
Eosinophil Cationic Protein, in dialysis (abst) . . . 722
Erosive Arthropathy, in haemodialysis (abst) . . . 727
Erythropoiesis, in CAPD (abst) . . . 720
Erythrocyte Complement Receptors Type 1, in glomerulonephritis . . . 834
Erythrocyte Indices in dialysis . . . 77
Erythrocyte Membrane Peroxidation, desferroxiamine in (abst) . . . 668
Erythrocytes
deformability in haemodialysis (abst) . . . 737
effect of erythropoietin lipid layer (abst) . . . 742
energy metabolism in (abst) . . . 741
free radicals induce increased lysis of . . . 600
in CAPD . . . 369
in glomerulonephritis (abst) . . . 679
in haemodialysis . . . 497
membrane transport of aminoacids in . . . 594
Erythrocytosis, in renal transplantation . . . 969
Erythropoietin (see also Recombinant Human Erythropoietin)
and energy metabolism in erythrocytes (abst) . . . 741
and hepatitis B vaccination (abst) . . . 743
and oxygen-affinity of haemoglobin (abst) . . . 740
azathioprine effect on (abst) . . . 736
(book review) . . . 403
deficiency in acute renal failure . . . 920
effect of erythrocytes lipid layer (abst) . . . 742
effect on oxygen capacity and energy turnover (abst) 740
in acquired cystic kidney disease (abst) . . . 702
in acute renal failure (abst) . . . 310
in anaemia (abst) . . . 742
in CAPD (abst) . . . 896
in end-stage renal disease (abst) . . . 832
in erythrocyte deformability (abst) . . . 737
in haemodialysis . . . 474
in haemodialysis (abst) . . . 739, 741, 743, 831
in hypertension (abst) . . . 740, 742
in renal artery stenosis (abst) . . . 744
in renal venous blood (abst) . . . 744
intraperitoneal administration in children (abst) . . 896
synthesis and hypoxia (abst) . . . 744
vasopressive effect on renal proximal resistance vessels (abst) . . . 739
Erythropoietin-Resistant Aluminium-Related Anaemia, desferrioxamine in (abst) . . . 744
Erythropoietin Synthesis, andoxia (abst) . . . 744
Escherichia coli
in renal transplantation (abst) . . . 759
urinary tract infection (abst) . . . 466
Essential Amino Acids
in CRF (abst) . . . 667
in oliguric acute renal failure (abst) . . . 660
protein load in comparison to . . . 572
Essential Hypertension
ACE inhibitors (abst) . . . 686
albumin in (abst) . . . 686
albuminuria (abst) . . . 643, 686
atrial natriuretic peptide in (abst) . . . 695
calcium channel blockers (abst) . . . 686
cyclic-GMP in (abst) . . . 695
salt sensitivity in (abst) . . . 690
UV irradiation in . . . 906
Ethics, living-donor transplantation . . . 407
Ethylene Glycol Intoxication, dialysis in (abst) . . . 396
Ethylene Oxide, in hypersensitivity in haemodialysis . 264
Exercise-induced renal vascular resistance, captopril in (abst) . . . 690
Exercise Programmes in Predialytic Patients (abst) . . 665
Extracorporeal Shock-Wave Lithotripsy, DMSA scintigraphy in (abst) . . . 832
Familial Mediterranean Fever, amyloidosis in (abst) . 651
ω-3 Fatty Acid Fish Oil (FO), in renal transplantation (abst) . . . 745
Ferrioxamine, biliary elimination of (abst) . . . 731
Fertility, rHuEpo in . . . 834
Fibrin, in haemodialysis . . . 362
Fibrinogen Degradation Products, in haemodialysis . . 362
Fibrinolysis, in haemodialysis . . . 362
Fibrinopeptide A
in haemodialysis . . . 362
in uraemia (abst) . . . 668
Fibronectin
in glomerulonephritis (abst) . . . 682
in mesangial cells (abst) . . . 682
Fimbriae, in *E. coli* urinary tract infections (abst) . . . 466
Fine-Needle Aspiration Biopsy, in allografts . . . 226, 903
Fine-Needle Aspiration Cytology, HLA-DR expression in (abst) . . . 757
Fish-Oil Dietary Supplement, in mesangial IgA glomerulonephritis . . . 241
FK506 in renal transplantation (abst) . . . 756
Fluconazole, in fungal peritonitis . . . 555
Fluid Balance
in haemodialysis . . . S158
in haemodialysis (abst) . . . 896
in haemofiltration . . . S158
in haemofiltration (abst) . . . 896
Fluid Monitoring, in haemodialysis . . . S162–7
Fluoride, in aluminium-related bone disease (abst) . . 732
Focal Segmental Glomerular Sclerosis (FSGS) (abst) . . . 677
plasma exchange in (abst) . . . 747
recurrence in (abst) . . . 747
Fractional Shortening/End-Systolic Stress (FS/ESS), correlation by echocardiography . . . S115
Free Radicals, increased lysis of red blood cells . . . 600
Fructosamine
in chronic renal failure . . . 868
in diabetes (abst) . . . 666
Frusemide
in glomerulonephritis . . . 997
in glomerulonephritis (abst) . . . 694
in haemodialysis (abst) . . . 896
in oliguric acute renal failure (abst) . . . 660
Fulminant Hepatorenal Failure
haemofiltration in (abst) . . . 658
membrane Bio-compatibility in (abst) . . . 658
Fungal Peritonitis
fluconazole in . . . 555
in CAPD . . . 555
Furan-Carboxylic Acid, albumin-bound (abst) . . . 720
Galenic, effect on recombinant erythropoietin bioavailability (abst) . . . 743
Gentamicin, in dialysis (abst) . . . 470
Gliadin, lectinic binding (abst) . . . 675
Glomerular ADPase
effect of aspirin on (abst) . . . 305
sensitivity for endotoxin (abst) . . . 305

Glomerular Anionic Sites, cationic colloidal gold detection of (abst) . . . 679
Glomerular Basement Membrane in proteinuria (abst) 679
Glomerular Bound Antigen, rheumatoid factor in chronic serum sickness rats (abst) . . . 678
Glomerular Charge Selectivity, in diabetic nephropathy (abst) . . . 639
Glomerular Derived Migration Inhibition Factor Activity, and monoclonal antibodies (abst) . . . 683
Glomerular Dipeptidyl Peptidase Type IV, autoantibody-induced redistribution (abst) . . . 296
Glomerular Disease
angiotensin-converting-enzyme inhibitors in . . . S81
captopril in . . . S81
glomerular charge selectivity (abst) . . . 301
Glomerular Epithelial-Cell Endocytosis of Horseradish Peroxidase-Polylysine Conjugate . . . 771
Glomerular Filtration Rate
acute protein load . . . 1
after meat meal (abst) . . . 640
and creatinine relationship (abst) . . . 829
creatine clearance in (abst) . . . 832
effect of acute protein load . . . 572
effect of endothelium-dependent vasodilators (abst) 300
effects of calcium antagonists . . . 82
glucagon secretion . . . 110
in diabetic nephropathy . . . 337
in glomerulonephritis . . . 337
in Nephrotic syndrome (abst) . . . 649
iohexol clearance in (abst) . . . 638
protein loading effect on (abst) . . . 397
X-ray fluorescence analysis (abst) . . . 638
Glomerular Mononuclear Leukocytes, in glomerulonephritis . . . 10
Glomerular Podocytes, intercellular adhesion in (abst) 677
Glomerular Proteolytic Activity, in nephrotic syndrome (abst) . . . 673
Glomerular Sclerosis, in graft-versus-host disease (abst) . . . 303
Glomerular Thromboxane, in IgA nephropathy (abst) 640
Glomerulonephritis
albumin in . . . 997
albumin in (abst) . . . 694
and ulcerative colitis . . . 628
anti-GBM antibodies in . . . 991
antiplatelet agents in . . . S29
atrial natriuretic peptide in . . . 997
atrial natriuretic peptide in (abst) . . . 694
blood pressure in . . . 337
blood volume in . . . 997
blood volume in (abst) . . . 694
converting-enzyme inhibitors in . . . S33
copper in (abst) . . . 393
corticosteroids in . . . S23
diffuse endocapillary . . . 152
endothelial cell autoantigens in (abst) . . . 683
erythrocyte complement receptors type 1 in . . . 834
erythrocytes in (abst) . . . 679
experimental autoimmune (abst) . . . 304
fibronectin in (abst) . . . 682
follow-up (abst) . . . 309
frusemide in . . . 997
furosemide in (abst) . . . 694
glomerular and interstitial mononuclear leukocytes associated with . . . 10
glomerular filtration rate in . . . 337
hepatitis B virus antigens in (abst) . . . 467
$HgCl_2$-induced (abst) . . . 680
ICAM–1 in (abst) . . . 680–1
immune complex . . . 771, S6
immune complexes in (abst) . . . 467
immunologically mediated (abst) . . . 304
in renal transplantation . . . S42
in rheumatoid arthritis . . . 385
interleukin 2 (IL2) in . . . 551
laminin in (abst) . . . 682
mesangial IgA . . . 241
peripheral blood erythrócytes in (abst) . . . 467
protein clearance in . . . 337
sodium excretion in . . . 337
specific treatments . . . S16
steroids in . . . S23
zinc in (abst) . . . 393
Glomerulopathies
blood rheology in (abst) . . . 316
non-diabetic . . . 837
Glomerulosclerosis
captopril in (abst) . . . 316, 671
growth hormone in (abst) . . . 316
in chronic serum sickness . . . 100
in HIV-II . . . 320
in host-versus-graft reaction (abst) . . . 677
in sub-total renal ablation (abst) . . . 673
ketanserin in (abst) . . . 316
protein restricted diet in (abst) . . . 671
Glucagon Secretion, in aminoacid-induced hyperfiltration . . . 110
Glucose, in chronic renal failure (abst) . . . 665
Glucose Polymer Dialysate, in CAPD (abst) . . . 299
Glucose Polymers, in peritoneal clearance . . . 513
Glycaemic Status in diabetes (abst) . . . 666
Glycated Haemoglobin, in chronic renal failure . . . 868
Glycerol, in acute renal failure . . . 118
Glycoprotein, in Heymann's nephritis . . . S60
GMP140 Platelet Protein (abst) . . . 723
Gold Salt-induced Autoimmune Nephritis (abst) . . . 685
Goodpasture Antigens, distribution within human basement membranes . . . 87
Goodpasture's Syndrome
antigen restriction and IgG subclasses among anti-GBM autoantibodies . . . 991
haemorrhagic pneumonitis in . . . S3
HLA restrictions (abst) . . . 297
specificity of autoantibodies in (abst) . . . 305
Gout, cyclosporin in (abst) . . . 750
Graft Rejection
in paediatric kidney transplantation (abst) . . . 308
monoclonal antibodies in (abst) . . . 308, 468
Graft-Versus-Host Disease
glomerular dipeptidyl peptidase Type IV in (abst) . 296
glomerular sclerosis in (abst) . . . 303
in mice autoantibodies (abst) . . . 296
Growth Hormone
in compensatory renal growth . . . 123, 552
in CRF (abst) . . . 671
in glomerulosclerosis (abst) . . . 316
in haemodialysis (abst) . . . 738
Growth Hormone Releasing Hormone, in haemodialysis (abst) . . . 738
Gut Permeability in IgA nephropathy . . . 569
Haematuria
and renal cysts (abst) . . . 644

asymptomatic microscopic in living related kidney donation (abst) . . . 654
phase-contrast microscopy (abst) . . . 393
urinary red blood cell volume analysis in . . . S69
Haemodiafiltration
blood flow (abst) . . . 898
blood flow in . . . 1031
blood pressure in (abst) . . . 716
cardiovascular stability in (abst) . . . 716
dialysate in (abst) . . . 722
filter design (abst) . . . 898
in acute renal failure (abst) . . . 661
in respiratory failure (abst) . . . 661
phosphate removal in (abst) . . . 730
sodium balance in . . . S141
sodium modelling in (abst) . . . 716
solute transport in (abst) . . . 899
ultrafiltration in . . . 1031
Haemodialysis
2–3 diphosphoglycerate in . . . S119
1,25$(OH)_2$ Vitamin D3 in . . . 457
acetate accumulation in (abst) . . . 702
acetate in (abst) . . . 709
acetate vs. bicarbonate . . . 931
acid-base balance in (abst) . . . 396
acute intravascular haemolysis associated with indwelling catheter . . . 1055
age effects in . . . 1023
alpha-ketoanalogues in (abst) . . . 711
aluminium in . . . 441, 942
aluminium in (abst) . . . 729, 741
amino acids in (abst) . . . 711
amylin in (abst) . . . 694
amyloid deposits in (abst) . . . 727
anaphylactoid reactions in . . . 821
apolipoproteins in (abst) . . . 698
arteriovenous fistula in (abst) . . . 708
atraumatic blood pump (abst) . . . 319
atrial natriuretic peptide in (abst) . . . 691, 693, 696
bacteraemia in . . . 130
beclobrate in . . . 588
β_2-microglobulin amyloid in . . . 878
β_2-microglobulin amyloidosis in (abst) . . . 727
β_2-microglobulin in (abst) . . . 726, 728
bicarbonate in (abst) . . . 709
bioimpedance cardiography in . . . S147
blood pressure in (abst) . . . 696
blood reticulocytes in (abst) . . . 743
blood serum concentrations in (abst) . . . 469
blood volume in (abst) . . . 711
bone disease in (abst) . . . 735
bone marrow stromal cells in (abst) . . . 469
bradycardia in (abst) . . . 712
C-reactive protein in . . . 500
calcitriol in (abst) . . . 729, 734
calcium acetate in (abst) . . . 729, 734
calcium carbonate in (abst) . . . 729
cardiac arrhythmias in . . . S165
cardiovascular impairment in . . . 1023
cardiovascular stability in . . . S137
cardiovascular stress in . . . S133
carnitine in . . . 588
carnitine in (abst) . . . 468
cell membrane status in . . . S167
cerebral dysfunction in (abst) . . . 312
clinical evaluation . . . 347
collagen defect of skin (abst) . . . 670
compared with continuous ambulatory peritoneal dialysis (abst) . . . 718
complement in (abst) . . . 704
computer-modulated . . . S162–5
creatinine in . . . 549
cuprophan (abst) . . . 700
cysteine in (abst) . . . 698
dextran in . . . 54
24–25 dihydroxy vit D_3 in (abst) . . . 710
1,25-dihydroxyvitamin D3 in (abst) . . . 698
dry weight estimation . . . 238
dyslipoproteinaemia in . . . 797
effect on natural killer cells . . . 437
encephalopathy in (abst) . . . 897
endothelin in (abst) . . . 692–3, 695
endotoxin in (abst) . . . 725
erosive arthropathy in (abst) . . . 727
erythrocyte deformability in (abst) . . . 737
erythrocytes in . . . 497
erythropoietin in . . . 474
erythropoietin in (abst) . . . 739, 741, 743, 831
fluid balance in . . . S158
fluid balance in (abst) . . . 715, 896
fluid monitoring in . . . S162–7
free radicals induce increased lysis of red blood cells after . . . 600
frusemide in (abst) . . . 896
growth hormone in (abst) . . . 738
growth hormone releasing hormone in (abst) . . . 738
haemoglobin in (abst) . . . 743
haemorrhage in . . . 802
haemorrhagic risk in (abst) . . . 707
HCV antibodies in (abst) . . . 706
Hemasite device in . . . 508
heparin in . . . 135
heparin in (abst) . . . 470, 708, 713, 830
heparin-free . . . 802
hepatitis B in (abst) . . . 397
hepatitis C virus in (abst) . . . 699, 701, 705, 707, 714, 751
Hickman catheters in . . . 59
1 hydroxy vit D_3 in (abst) . . . 710
hyperkalaemia in . . . 400
hyperparathyroidism in . . . 874
hypersensitivity in . . . 264
hypotension in . . . S147
hypotension in (abst) . . . 712
hypoxaemia in (abst) . . . 704, 723
IL-2 receptor expression in (abst) . . . 679
impact of high blood flows on vascular stability . . . S109
in dry body-weight assessment . . . 356
in echocardiography (abst) . . . 700
in end-stage congestive heart failure (abst) . . . 895
in iron overload (abst) . . . 739
in mushroom poisoning (abst) . . . 662
iron overload in . . . 130
iron overload in (abst) . . . 735
lead accumulation in (abst) . . . 700
left ventricular function in (abst) . . . 714
leukotriene B4 in (abst) . . . 724
lipid bilayer in (abst) . . . 469
lipid peroxidation in (abst) . . . 468–9
liver disease in (abst) . . . 751
malnutrition in (abst) . . . 699
membrane transport of aminoacids in erythrocytes . . . 594
monitoring (abst) . . . 298

non-A non-B hepatitis in . . . 902
non-A non-B hepatitis in (abst) . . . 697
normotensive effect of association of high atrial natriuretic factor and high intracellular Na in (abst) 689
nutritional status in (abst) . . . 699
Ouabain-like factor in (abst) . . . 691
oxygen free radical intermediates/scavenger system in (abst) . . . 697
oxyhaemoglobin dissociation in . . . S119
PAF production in (abst) . . . 723
parathyroid carcinoma in . . . 545
parathyroid hormone in . . . 457
paroxysmal atrial fibrillation in . . . 474
peripheral nervous system in (abst) . . . 897
phosphate binder in (abst) . . . 729
platelet activation in (abst) . . . 723
platelet-lipoxygenase activity in (abst) . . . 723
polymorphonuclear glycolysis in (abst) . . . 725, 898
polysulphone high-flux dialysers . . . 942
polyunsaturated fatty acids in . . . 797
pregnancy in (abst) . . . 669
prostacyclin in (abst) . . . 470
prostaglandin E_2 in . . . 937
pulsed wave doppler in (abst) . . . 700
recombinant HBs vaccine in (abst) . . . 709
recombinant human erythropoietin in . . . 441, S102
recombinant human erythropoietin in (abst) 299, 739, 742
renal osteodystrophy in (abst) . . . 710, 732
sero-conversion in (abst) . . . 709
serum amyloid in (abst) . . . 724
shoulder joint pain and stiffness in (abst) . . . 709
sodium balance in . . . S141
sodium monitoring in . . . S162
spondyloarthropathy in . . . 199
subclavian vein thrombosis in . . . 977
superoxide anion generation in (abst) . . . 468–9
thrombosis in (abst) . . . 707
tubing-derived particles in macrophages . . . 208
tumour necrosis factor in (abst) . . . 312, 724
twice-weekly 5-h hospital (abst) . . . 895
uraemic myocardiopathy in (abst) . . . 706
urea kinetic modelling in . . . 347
vascular accesses in (abst) . . . 710
whole body filtration coefficient in (abst) . . . 712
zinc deficiency in (abst) . . . 705

Haemodynamics
effect of lithium in . . . 1007
effects of recombinant human erythropoietin in . . . 444

Haemofiltration
acid-base balance in (abst) . . . 396
blood flow in . . . 1031
calcium mass transfer (abst) . . . 715
elimination of low molecular weight proteins (abst) . 715
fluid balance in . . . S158
fluid balance in (abst) . . . 715, 896
Hemasite device in . . . 508
in end-stage congestive heart failure (abst) . . . 895
in fulminant hepatorenal failure (abst) . . . 658
intracranial pressure in . . . 192
left ventricular contractility in . . . S115
plasma calcium fraction dynamics (abst) . . . 715
prediluton high efficiency bicarbonate (abst) . . . 715
ultrafiltration in . . . 1031

Haemoglobin
in haemodialysis (abst) . . . 743
oxygen affinity of (abst) . . . 740

Haemolytic Uraemic Syndrome
associated with metastatic carcinoma . . . 886
X-irradiation in (abst) . . . 306

Haemoperfusion, sorption efficiency to uraemic toxins (abst) . . . 397

Haemorrhage
in haemodialysis . . . 802
risk in haemodialysis (abst) . . . 707

Head-Out Water Immersion, in renal transplantation . 535

Heart-Valve Prostheses, siderosis in . . . 847

Heliobacter pylori
in renal failure (abst) . . . 646
in renal transplantation (abst) . . . 646

Hemasite Device, in vascular access problems . . . 508

Heparan Sulphate Proteoglycan
(abst) . . . 303
glomerular and GBM (abst) . . . 295

Heparin
in haemodialysis . . . 135
in haemodialysis (abst) . . . 470, 708, 713, 830
in proteolysis of antithrombin III (abst) . . . 702
in thrombosis prevention (abst) . . . 707
low molecular weight (abst) . . . 708, 713
unfractionated (abst) . . . 708

Heparin-Free Haemodialysis . . . 802

Hepatic Encephalopathy, intracranial pressure in . . . 192

Hepatitis B Serologic Markers (abst) . . . 701

Hepatitis B Vaccination, and erythropoietin (abst) . . 743

Hepatitis B Virus
in haemodialysis (abst) . . . 397
in HBsAG-positive renal transplant patients . . . 525

Hepatitis B Virus Antigens, in glomerulonephritis (abst) 467

Hepatitis C Virus
and non-A non-B hepatitis (abst) . . . 701, 705
correlation with non-A and non-B hepatitis (abst) . 703
in dialysis (abst) . . . 714
in haemodialysis (abst) . . . 699, 701, 705, 707, 714, 751
in kidney transplantation (abst) . . . 752
in liver disease (abst) . . . 751
in renal transplantation (abst) . . . 748–9, 751
prevalence and significance in kidney graft recipients 1056

Hepatitis C Virus Antibodies
in haemodialysis (abst) . . . 706
in renal transplantation (abst) . . . 706

Hepatocyte Gluconeogenesis in Acute Renal Failure (abst) . . . 663

Hepatorenal Failure, lactate-based fluids in . . . 342

Heroin, in renal amyloidosis . . . 158

Heymann Nephritis
glycoprotein in . . . S60
nitrite in (abst) . . . 676

Hickmn Catheters in Haemodialysis . . . 59

Highly Sensitised Patients, graft survival in (abst) . . . 750

Hip's Synovial Thickness (abst) . . . 726

HIV Antigens, in HIV-associated nephropathy . . . 489

HIV-Associated Nephropathy . . . S84

HIV-II, glomerulosclerosis in (abst) . . . 320

HIV-Infection, renal involvement (abst) . . . 653

HIV-Transmission in Kidney Transplantation (abst) . 752

HLA Antigens, in dialysis (abst) . . . 295

HLA Compatibility, in renal transplantation (abst) . . 398

HLA Phenotype, and cyclosporin A (abst) . . . 756

HLA-DP Gene Polymorphism, in IgA nephropathy (abst) . . . 681

HLA-DQ Gene Polymorphism, in IgA nephropathy (abst) . . . 681–2

HLA-DR Expression
in allograft rejection (abst) . . . 751
in fine needle aspiration cytology (abst) . . . 757
in tubular cells . . . 903
Horseradish Peroxidase, conjugate with poly-L-lysine . 771
Host-versus-Graft Reaction
glomerulosclerosis in (abst) . . . 677
nephritogenic antibodies in (abst) . . . 677
Human Membranous Nephropathy, urinary MAC and C3dg in (abst) . . . 304
Humoral Factor in Nephrectomy . . . 579
Hyaluronic Acid, synthesis (abst) . . . 759
Hydralazine, in systemic lupus erythematosus (SLE) (abst) . . . 660
Hydralazine Glomerulonephritis
and elastase (abst) . . . 660
and myeloperoxidase (abst) . . . 660
1 Hydroxy Vit D_3, in haemodialysis (abst) . . . 710
Hyperaminoacidaemia in primary glomerulopathies (abst) . . . 671
Hypercalciuria
in essential hypertension (abst) . . . 654
in renal stone formers (abst) . . . 642
in urolithiasis (abst) . . . 654
Hypercholesterolaemia, in chronic renal failure (abst) 470
Hyperfiltration, in diabetes mellitus (abst) . . . 652
Hyperkalaemia
in haemodialysis . . . 400
in myocardial ischaemia . . . 237
Hyperlipidaemia, in nephrotic syndrome (abst) . . . 654
Hyperoxaluria, combined transplantation (abst) . . . 832
Hyperparathyroidism
calcitrol in . . . 874
calcium carbonate in (abst) . . . 734
calcium citrate in (abst) . . . 734
diagnosis of (abst) . . . 730
IL-2 in (abst) . . . 679
in haemodialysis . . . 874
in parathyroid carcinoma . . . 545
in uraemia . . . S128
parathyroid graft function in (abst) . . . 733
Hyperphosphataemia, calcium acetate in . . . 630
uraemic . . . 553
Hyperporphyrinaemia, in CRF (abst) . . . 714
Hypersensitivity, in haemodialysis . . . 264
Hypertension
and dietary sodium (book review) . . . 635
and renal cysts (abst) . . . 644
angiotensin-II in (abst) . . . 687
anuria in . . . 174
enalapril in (abst) . . . 315, 693, 744
erythropoietin in (abst) . . . 740, 742
IgA nephropathy (abst) . . . 643
in acromegaly (abst) . . . 688
in adult polycystic kidney disease (abst) . . . 688
in auto-immune diseases (abst) . . . 658
in autosomal dominant polycystic kidney disease (abst) . . . 688
in diabetes mellitus type I and II . . . 623
in diabetic microalbuminuria . . . S66
in diabetic nephropathy . . . 623
in dialysis (abst) . . . 701
in polycystic kidney disease (abst) . . . 394
insulin in (abst) . . . 687
malignant, prognostic factors . . . 563
malignant phase of . . . 174
morphological characterisation of rats harbouring mouse Ren-2 gene (abst) . . . 686
nifedipine in (abst) . . . 744
noradrenaline in (abst) . . . 687
sodium intake in (abst) . . . 692
Tamm-Horsfall protein in (abst) . . . 471
see also Antihypertensive therapy
Hypertensive Encephalopathy . . . 553
Hyperthyroidism
atrial natriuretic peptide in (abst) . . . 696
sodium balance in (abst) . . . 696
Hypokalaemia
chlorthalidone-induced (abst) . . . 648
dietary sodium content in (abst) . . . 648
Hypomagnesaemia
cyclosporin in . . . 812
in renal transplantation . . . 812
Hypophosphataemia, in renal transplantation . . . 62
Hypotension
in dialysis (abst) . . . 708
in haemodialysis . . . S147
in haemodialysis (abst) . . . 712
Hypothyroidism
atrial natriuretic peptide in (abst) . . . 692
sodium excretion in (abst) . . . 692
water excretion in (abst) . . . 692
Hypoxaemia
and EPO synthesis (abst) . . . 744
haemodialysis-associated . . . S119
in haemodialysis (abst) . . . 704, 723
sodium acetate in (abst) . . . 704
Hypoxanthine-Guanine Phosphoribosyl Transferase (HPRT) Deficiency . . . 383
Idiopathic Hypercalcuria, sodium handling in (abst) . 652
Idiopathic Interstitial Nephritis, in ulcerative colitis . . 901
Idiopathic Membranous Nephropathy
impaired hepatic sulphoxidation in (abst) . . . 639
natural history and therapy of . . . S37
Idiopathic Nephrotic Syndrome
Decaris in (abst) . . . 396
prevention of relapses of (abst) . . . 395
RFLP DRβ typing in (abst) . . . 656
Idiopathic Uveitis, cyclosporin in (abst) . . . 745
IgA
in antiglomerular basement membrane disease . . . 909
in IgA nephropathy (abst) . . . 680, 683
mesangial glomerulonephritis . . . 241
IgA Nephropathy
and alcohol intoxication (abst) . . . 675
glomerular thromboxane in (abst) . . . 640
gut permeability in . . . 569
gut permeability in (abst) . . . 309
HLA-DP gene polymorphism in (abst) . . . 681
HLA-DQ gene polymorphism in (abst) . . . 681–2
hypertension (abst) . . . 643
IgA affinity to ssDNA or endothelial cells in . . . 841
IgA deposition in glomerular capillary walls in . . . 841
IgA in (abst) . . . 680, 683
IgG in (abst) . . . 680, 683
immune response in (abst) . . . 303
mesangial cells in (abst) . . . 677
polyclonal B cell activation in (abst) . . . 298
prostaglandins in (abst) . . . 677
randomised controlled trials in . . . S47
Sendai virus in (abst) . . . 675
tetanus toxoid in (abst) . . . 303

IgG
in IgA nephropathy (abst) 680, 683
washout kinetics of intraperitoneal 78
IgG Subclasses in Goodpasture's Syndrome 991
IgM, in antiglomerular basement membrane disease . 909
Immune Complexes
in glomerulonephritis 771, S6
in glomerulonephritis (abst) 467
Immune Response
in dialysis (abst) 396
in IgA nephropathy (abst) 303
Immunofluorescence, Polaroid camera and prints . . . 473
Immunofluorescence of Urine Sediment (abst) 646
Immunoglobulin A, in allograft rejection 520
Immunoglobulins, production by B-lymphocytes (abst) 742
Immunohistochemistry, in cytomegalovirus infection . 1045
Immunomodulators, in continuous ambulatory peritoneal dialysis (abst) 719
Immunosuppression
and MHC class II haplotype (abst) 296
in hypophosphataemia 62
in peptic ulceration 289
in renal transplantation (abst) 398
Indomethacin
antiproteinuric effect (abst) 297
effect on renal function (abst) 638
in compensatory renal growth 777
in lithium excretion (abst) 318
-sensitive vasoconstrictor from renal arcuate arteries (abst) 641
Indoxyl Sulfate, albumin-bound (abst) 668
Infants, chronic renal failure in 825
Inferior Vena Cava
calcified thrombus of S71
echography 238
Infrarenal Aortic Cross Clamping, nifedipine in (abst) 658
In-Situ Hybridisation, in cytomegalovirus infection . . 1045
Insulin
in chronic renal failure (abst) 665
in hypertension (abst) 687
Insulin-dependent Diabetes
amino acid infusion in (abst) 640
sodium-lithium countertransport in (abst) 644
Insulin-Like Growth Factor-1, in compensatory renal growth 123, 552
Insulin Secretion, effect of calcium 1013
Intercellular Adhesion, in glomerular podocytes (abst) 677
Intercellular Adhesion Molecule, mesangial expression of (abst) 678
Intercellular Adhesion Molecule-1 (ICAM-1) (abst) . 676
in glomerulonephritis (abst) 680
in necrotising glomerulonephritis (abst) 677
in renal allografts (abst) 758
tubular expression of (abst) 681
Intercellular Adhesion Molecule-1 (ICAM-1) Expression
cytomegalovirus in (abst) 758
Interferon, side effects of (abst) 657
Interferon-α (IFN-α), in Goodpasture's haemorrhagic pneumonitis S3
Interleukin-1 (IL-1)
in CAPD (abst) 313
secretion by macrophages 208
Interleukin-1β (IL-1β)
in mesangial cells (abst) 685
mRNA in haemodialysis (abst) 713
Interleukin-2 (IL-2)
in acute renal failure (abst) 661
in glomerulonephritis 551
in Goodpasture's haemorrhagic pneumonitis S3
in hyperparathyroidism (abst) 679
in nephrotic syndrome (abst) 680
in renal allograft rejection (abst) 747
in renal insufficiency (abst) 713
in renal transplantation (abst) 752
monitoring of renal allograft 612
side effects of (abst) 657
Interleukin-3 (IL-3), as critical haematpoietic growth factor (abst) 737
Interleukin-6 (IL-6)
in Mesangial Glomerulonephritis (abst) 683
in rejection (abst) 307
in renal graft rejection (abst) 753
Intermyocardiocytic Fibrosis in Uraemia 39
Interstitial Capillary Cross-Sections, assessment by monoclonal antibodies 889
Interstitial Fibrosis, donor kidney (abst) 753
Interstitial Mononuclear Leukocytes
expression of MHC class II antigens on 14
in glomerulonephritis 10
Interstitial Nephritis, in nephrotic syndrome 1055
Interstitial Nephropathy, progression of (abst) 828
Intestinal Alkaline Phosphatase, in proximal tubular cells (abst) 661
Intracellular pH
in dialysis (abst) 712
in smooth muscle cells (abst) 689
Intracranial Pressure, in haemofiltration 192
Intradialytic Solute Extraction, uraemic markers for (abst) 701
Intraperitoneal Volume (IPV), measurement of (abst) 299
Iohexol, in urine profiles (abst) 833
Iohexol Clearance
in glomerular filtration rate (abst) 638
single injection techniques (abst) 638
Iopamidol, contrast medium (abst) 662
Iron Overload
in dialysis 504, 781
in haemodialysis 130
in haemodialysis (abst) 735
Isohaemagglutinins, acquired haemolytic anaemia due to 148
Isolated Erythrocyte-Perfused Rat Kidney
antibody binding in chronic serum sickness (abst) . . 678
antigen binding in chronic serum sickness (abst) . . 678
Isozymogens, measurement of fractional excretion (abst) 318
Jugular Vein Bypass, to preserve arteriovenous fistula 977
Juxtaglomerular Apparatus (book review) 403
Ketanserin in glomerulosclerosis (abst) 316
Ketoanalogues in CRF (abst) 667
Ketogenesis in Acute Renal Failure (abst) 663
Ketone Bodies, effect on hepatocyte gluconeogenesis and ureagenesis (abst) 663
Kidney, spontaneous decapsulation 75
Kidney Allograft Biopsies (abst) 753
Kidney Donors
age effect in (abst) 746
renal reserve filtration capacity in (abst) 753
KT/V, direct calculation of (abst) 703
KT/V Urea, in CAPD (abst) 896
Lactate, in continuous ambulatory peritoneal dialysis (abst) 719
Lactate-Based Fluids, in hepatorenal failure 342
Lactobacilli, vancomycin-resistant 235

LAL-Negative Small Bacterial Products (abst) 706
Laminin in Glomerulonephritis (abst) 682
Late Dialysis Arthropathy (abst) 726
Lead Accumulation in Haemodialysis (abst) 700
Lead-associated Nephropathy, EDTA in (abst) 642
Lead Burden, in acute gouty arthritis (abst) 645
Lead Poisoning in Dialysis (abst) 670
Left Ventricular Contractility
in dialysis S115
in haemofiltration S115
Left Ventricular Function, in haemodialysis (abst) . . 714
Legionella Pneumoniae, ofloxacin in (abst) 755
Leucine, in chronic renal failure (abst) 665
Leucocyte Intracellular pH in diabetic nephropathy (abst) 667
Leukaemia, chronic lymphocytic 616, 1051
Leukocyte Adhesion Molecules (CD11, CD18) and neutrophil plasma membrane (abst) 696
Leukocytes, in CAPD 369
Leukotriene B4, in haemodialysis (abst) 724
Lipid Bilayer, in haemodialysis (abst) 469
Lipid metabolism following combined pancreas and renal transplantation (abst) 746
Lipid Peroxidation
in haemodialysis (abst) 468–9
polyunsaturated fatty acids in (abst) 669
Lipoprotein
in CRF (abst) 670
in mesangial cell growth 185
metabolism in diabetic chronic renal failure (abst) . 663
Lisinopril, antiproteinuric effect (abst) 297
Lisinopril Converting Enzyme Inhibitor (abst) 664
Lithium Carbonate, in peritoneal ultrafiltration (abst) 719
Lithium Clearance
angiotensin II in (abst) 302
in autosomal dominant polycystic kidney disease (ADPKD) (abst) 394
in Bartter's Syndrome 904
in chronic renal failure (abst) 665
in estimation of end-proximal tubular fluid delivery (abst) 317
in renal haemodynamics 1007
in renal sodium handling 1007
Lithium Excretion, amiloride in (abst) 318
Lithium Nephrotoxicity 904
Liver Cysts, in polycystic kidney disease 882
Liver Disease
distal renal tubular acidosis (DRTA) in (abst) . . . 392
hepatitis C virus in (abst) 751
in haemodialysis (abst) 751
Liver Transplantation in primary hyperoxaluria Type 1 825
Living-donor transplantation 407
Lovastatin, in chronic renal failure (abst) 641
in nephrotic syndrome (abst) 673
Low Molecular Weight Solutes, peritoneal transport (abst) 721
Low Protein Diet and Adriamycin (abst) 664
Lupus, antiphospholipid antibodies in (abst) 678
Lupus Nephritis
antiphospholipid antibodies in (abst) 678
outcome prediction (abst) 310
steroids in (abst) 468
treatment and monitoring S58
Luteotropic Hormone, in chronic renal failure (abst) . 695
Lymphocyte β_2-Adrenoceptors in pheochromocytoma (abst) 687
Lymphocytes
and deoxyribonuclease activity (abst) 674
in membranous nephropathy (abst) 651
in nephrotic syndrome (abst) 651
renal-allograft-infiltrated (abst) 297
Lymphocytic Infiltrates, in allograft rejection (abst) . . 829
Lymphocytotoxic Antibodies, in dialysis (abst) 295
Macrophage (MO) Culture Supernatants (abst) 682
Macrophages, dialysis-tubing-derived particles in . . . 208
Magnesium, wasting in Bartter's syndrome 388
Magnesium Carbonate, in CAPD (abst) 314
Magnetic Resonance Spectroscopy, in uraemic myopathy (abst) 392
Malignancy
in renal transplantation 282
metastatic carcinoma associated with haemolytic uraemic syndrome 886
parathyroid bone disease in renal failure (abst) . . . 311
transitional-cell carcinoma in acquired cystic disease of the kidney 464
Malignant Hypertension
anuria in 174
prognostic factors 563
Malnutrition
and protein catabolic rate (abst) 707
in haemodialysis (abst) 699
Mannitol, in acute compartmental syndrome (abst) . . 658
Mast Cells, skin (abst) 701
Membrane Attack Complex, as marker of bio-compatibility (abst) 723
Membrane Bio-compatibility, in fulminant hepatorenal failure (abst) 658
Membrane Transport, of aminoacids in erythrocytes . 594
Membranes
cellulose acetate 497
cellulosic 432
effect of tumour necrosis factor 270
highly permeable haemodialysis (abst) 697
pyrogen-permeability of (abst) 706
Membranoproliferative Glomerulonephritis, immunological parameters in (abst) 467
Membranous Lupus Nephritis
cyclosporin A in (abst) 650
renal vein thrombosis in S71
steroids in (abst) 650
Membranous Nephropathy, peripheral blood lymphocytes in (abst) 467
Mercuric Chloride-Induced Autoimmune Reactivity (abst) 296
Mercuric Chloride-Induced Glomerulonephritis, anti-CD4-receptor in (abst) 680
Mercuric Chloride-Induced Nephropathy, monoclonal autoantibodies in (abst) 306
Mesangial Cells
cyclosporin metabolite combinations in (abst) 752
cytokine stimulated (abst) 685
fibronectin in (abst) 682
Il-1β in (abst) 685
in IgA nephropathy (abst) 677
in lectinic binding of gliadin (abst) 675
lipoprotein in 185
monoclonal antibodies in (abst) 684
PDGF-receptor alpha and beta-subunits in (abst) . . 681
Mesangial Glomerulonephritis, IL-6 in (abst) 683
Mesangial IgA Disease in Pregnancy 619
Mesangial Proliferative Glomerulonephritis, isolated C3 S78

Mesangial Trafficking in sub-total renal ablation (abst) 673
Mesangiocapillary Glomerulonephritis
peripheral blood lymphocytes in (abst) 467
Types I and III, treatment of (abst) 393
Methylprednisolone
in allograft rejection 320
in renal transplantation (abst) 756–7
interaction with cyclosporin 376, 905
MHC Class I Expression, cytomegalovirus in (abst) . . 758
MHC Class II Haplotype, and immunosuppresion (abst) 296
Microalbuminuria, in diabetes mellitus S66
Microproteins, in HIV-infection (abst) 653
Microscopic Polyarteritis, antineutrophil cytoplasmic
autoantibodies in (abst) 296
Migration Inhibition Factor (MIF) Activity (abst) . . . 683
Misonidazole Binding, renal cellular hypoxia in (abst) 640
Modulated Dialysis in intradialytic intolerance S154
Monoclonal Antibodies
against HLA-DR antigen (abst) 751
against human intestinal alkaline phosphatase (abst) 661
and glomerular derived migration inhibition factor
activity (abst) 683
anti-CD4-receptor (abst) 680
assessment of interstitial capillary cross-sections . . 889
enzyme-immuno-assay (abst) 725
in allograft rejection (abst) 307
in glomerular and GBM heparan sulphate
proteoglycan (abst) 295
in graft rejection (abst) 308, 468
in mesangial cells (abst) 684
Monoclonal Autoantibodies, in $HgCl_2$-induced
nephropathy (abst) 306
Monoclonal Renal Gammopathies, renal disease due to
(abst) 646
Mononuclear Cells, cytokine relase from (abst) 706
Mononuclear Leukocytes, and tumour necrosis factor
in (abst) 718
Mononuclear Phagocytic System, aluminium in (abst) . 685
Mortality, in acute renal failure (abst) 310
Multiple Myeloma, renal replacement in (abst) 664
Muscle Calcifications, in acute renal failure 461
Muscle Tamponade, in acute compartmental syndrome
(abst) 658
Mushroom Poisoning (abst) 662
Mycoplasma Peritonitis, in CAPD 633
Myeloperoxidase
and hydralazine glomerulonephritis (abst) 660
autoantibodies to (abst) 298
Myocardial ischaemia
hyperkalaemia in 237
in dialysis (abst) 704
Na^+ Transport, in synaptosomes of Uraemic animals
(abst) 666
Na/H Antiporter in Diabetic Nephropathy (abst) . . . 667
Na-K Adenosine Triphosphatase Activity, in chronic
renal failure (abst) 663
Naproxen, in nephrotic syndrome 1055
Natriuresis, atrial natriuretic factor in (abst) 470
Natural Killer (NK) Cells, effect of uraemia and
haemodialysis on 437
Necrotising Glomerulonephritis, intercellular adhesion
molecule-1 in (abst) 678
Neonates, renal failure in (abst) 395
Neoplasia, in dialysis (abst) 710
Neopterin, in rejection (abst) 307
Nephrectomy
5/6 model (abst) 667
humoral factor in 579
in the rat 118
renotropin in 579
Nephritogenic Antibodies, in host-versus-graft reaction
(abst) 677
Nephroangiosclerosis in uraemia (abst) 665
Nephrolithiasis
aldosterone in (abst) 471
ceftriazone in 974
cortisol in (abst) 471
thyroxine in (abst) 471
Nephrology
current (book review) 477
current therapy (book review) 476
International Yearbook (book review) 476
Nephrosis, cyclosporin A in (abst) 652
Nephrotic Syndrome
Adriamycin 2 in (abst) 673
albumin charge distribution pattern in (abst) 639
amoxycillin 1055
cholesterol in (abst) 673
cyclosporin A in (abst) 644
cyclosporin in 321
effective renal plasma flow (ERPF) in (abst) 649
enhanced pressor activity in (abst) 309
glomerular filtration rate in (abst) 649
glomerular proteolytic acitivity in (abst) 673
hyperlipidaemia in (abst) 654
hypovolaemia versus intra-renal mechanism in (abst) 646
IL–2 in (abst) 680
interstitial nephritis in 1055
lovastatin in (abst) 673
naproxen in 1055
PAN in (abst) 659
prednisone in 914
probucol in (abst) 673
puromycin in (abst) 317
secondary heroin-associated renal amyloidosis . . . 158
sodium reabsorption in (abst) 646
symvastatin in (abst) 673
tubular dysfunction in (abst) 653
vegan supplemented diet in S75
vitamin D therapy in (abst) 648
water reabsorption in (abst) 646
Nephrotoxic Nephritis
nitrite in (abst) 676
PGE1 in (abst) 676
Nephrotoxicity
cyclosporin in 69
in auto-immune diseases (abst) 658
Neutropenia, in dialysis (abst) 469
Neutrophil Activation, in contaminated dialysate (abst) . 725
Neutrophil Elastase, proteolysis of antithrombin III by
(abst) 702
Neutrophil Plasma Membrane
and leukocyte adhesion molecules (CD11, CD18)
(abst) 696
and phosphotyrosine phosphatase leukocyte common
antigen (CD45) (abst) 696
Nifedipine
effect on renal function in normotensive cyclosporin-
A-treated renal allograft recipients 962
in allograft function 816
in CRF (abst) 674
in cyclosporin A nephrotoxicity (abst) 303, 660

in cyclosprin A nephrotoxicity reduction (abst) . . . 745
in hypertension (abst) 744
in infrarenal aortic cross clamping (abst) 658
Nitrite
in Heymann nephritis (abst) 676
in nephrotoxic nephritis (abst) 676
Nitro-L-Arginine Methyl Ester, effect on renal function (abst) 638
Nitrogen Balance, in acute renal failure (abst) 311
Non-A Non-B Hepatitis
and hepatitis C virus (abst) 701, 705
correlation with hepatitis C virus antibodies (abst) . 703
in haemodialysis 902
in haemodialysis (abst) 697
prevalence of (abst) 703
Non-Hodgkin's Lymphoma, in rheumatoid arthritis . . 385
Non-obstructive Reflux Nephropathy, follow-up (abst) 649
Non-traumatic Rhabdomyolysis, in acute renal failure (abst) 649
Noradrenaline in hypertension (abst) 687
Norepinephrine
in acute renal insufficiency (abst) 657
renal effects of circulating and neuronally released (abst) 688
Nuclear Magnetic Resonance, uraemia adaptation to anaemia 604
Nuclear Magnetic Resonance Spectroscopy 62
Nutritional Status in haemodialysis (abst) 699
Obesity, in proteinuria (abst) 653
Ofloxacin, in *Legionella pneumoniae* (abst) 755
$1,25(OH)_2D$, in continuous ambulatory peritoneal dialysis (abst) 735
$1,25(OH)_2D_3$
and parathyroid hormone (abst) 734
and phosphate balance (abst) 734
in CAPD (abst) 717, 721
in chronic renal failure (abst) 732
in haemodialysis 457
in haemodialysis (abst) 734
in hyperparathyroidism 874
in psoriasis 293
in renal transplantation 531
$24,25(OH)_2D_3$, in aluminium-related bone disease (abst) 732
OKT3
and cytokine release (abst) 757
in renal transplantation (abst) 756
Oliguric Acute Renal Failure
dopamine in (abst) 660
essential amino acids in (abst) 660
furosemide in (abst) 660
Organ Donors (abst) 748
Organ Procurement System (abst) 748
Organic Anions
in renal insufficiency (abst) 391
transport system in renal failure (abst) 669
Osteocalcin
in predialysis (abst) 731
in renal bone disease (abst) 713
Osteodystrophy, in dialysis 449
Osteomalacic Bone Disease, aluminium in (abst) . . . 729
Ouabain-like Factor in haemodialysis (abst) 691
Oxalate Crystal Deposits, in chronic renal failure . . . 493
Oxalosis, renal transplantation in 332
Oxygen, affinity of haemoglobin (abst) 740
Oxygen Capacity, effect of erythropoietin (abst) . . . 740
Oxyhaemoglobin Dissociation in haemodialysis S119
Paecilomyces Peritonitis, in CAPD 1053
Paediatric Kidney Transplantation, graft rejection in (abst) 308
PAF
in haemodialysis (abst) 723
in proteinuria (abst) 679
PAN in nephrotic syndrome (abst) 659
Pancreas Graft in renal transplantation (abst) 748
Pancreas Transplantation, lipid metabolism in (abst) . 746
Pancreatitis, in acute renal failure 542
Parasitic Infection in schistosomal nephropathy (abst) 684
Parathyroid Bone Disease, in renal failure (abst) . . . 311
Parathyroid Carcinoma
hyperparathyroidism in 545
in haemodialysis 545
Parathyroid Glands, ultrasound of (abst) 733
Parathyroid Graft Function, in hyperparathyroidism (abst) 733
Parathyroid Hormone
and cellular immune responsiveness (abst) 679
and $1,25(OH)_2D_3$ (abst) 734
in bone disease (abst) 736
in chronic renal failure (abst) 730
in haemodialysis 457
in predialysis (abst) 731
tubular and peritubular handling (abst) 829
Parathyroidectomy, early and late effects of (abst) . . 743
Parenteral Nutrition, in creatinine clearance (abst) . . 831
Paroxysmal Atrial Fibrillation, in haemodialysis 474
Pepsinogen A Excretion, effect of protein load (abst) . 302
Pepsinogens, measurement of fractional excretion (abst) 318
Peptic Ulceration
endoscopy in 289
immunosuppression in 289
in renal transplantation 289
Peptides, in HIV-infection (abst) 653
Percutaneous Transluminal Angioplasty (abst) 748
effect on fistulas and shunts 608
in atherosclerotic renal artery stenosis (abst) 686
Percutaneous Transluminal Renal Angioplasty (PTRA) in renovascular disease 481
Peripheral Blood Erythrocytes, in glomerulonephritis (abst) 467
Peripheral Blood Lymphocytes
in membranous nephropathy (abst) 467
in mesangiocapillary glomerulonephritis (abst) . . . 467
Peripheral blood neutrophils, enzyme activity in (abst) 743
Peripheral Nervous System, in preterminal chronic renal insufficiency, chronic haemodialysis and CAPD (abst) 897
Peritoneal Capillary Endothelial Cells, in CAPD (abst) 721
Peritoneal Cavity, proteoglycans in (abst) 759
Peritoneal Clearance, glucose polymers in 513
Peritoneal Dialysis, tumour necrosis factor in (abst) . 718
Peritoneal Eosinophilia, in CAPD 903
Peritoneal Fluid Kinetics, in CAPD (abst) 299
Peritoneal Macrophages, in CAPD (abst) 718, 726
Peritoneal Mesothelial Cells, in CAPD (abst) 721
Peritoneal Permeability
in CAPD (abst) 722
low molecular weight solutes (abst) 721
to low-molecular-weight solutes (abst) 898
Peritoneal Ultrafiltration, lithium carbonate in (abst) . 719
Peritonitis
β_2-microloglobulin in (abst) 726
in CAPD 141, 235, 275

in CAPD (abst) 313, 718, 720, 894, 897–8
in CCPD (abst) 313
Phenols, plasma concentration and renal excretion (abst) 391
Pheochromocytoma, lymphocyte beta$_2$-adrenoceptors in (abst) 687
Phosphate Balance, and 1,25$(OH)_2D_3$ (abst) 734
Phosphate Binder
calcium acetate as (abst) 733
calcium carbonate as (abst) 733
in CAPD (abst) 314
in haemodialysis (abst) 729
Phosphate Removal, in haemodiafiltration (abst) . . . 730
Phosphate Restriction, dietary (abst) 674
Phosphotyrosine Phosphatase Leukocyte Common Antigen (CD45), and neutrophil plasma membrane (abst) 696
Physical Exercise, in renal transplantation 633
Plasma Cell Dyscrasias (book review) 635
Plasma Refilling Rate in CAPD (abst) 717
Plasmaphoresis, in mushroom poisoning (abst) 662
Platelet Abnormalities in uraemia (abst) 664
Platelet Activation
in haemodialysis 362
in haemodialysis (abst) 723
Platelet Cytosolic Free Calcium Concentration in end-stage renal disease (abst) 689
Platelet Derived Growth Factor-receptor alpha and beta-Subunits in mesangial cells (abst) 681
Platelet Factor 4(PF4), in haemodialysis 362
Platelet-lipoxygenase activity, in haemodialysis (abst) . 723
Poliovirus Vaccine, in dialysis 352
Polyacrylonitrile Membranes, influence on platelet activation, coagulation and fibrinolysis 362
Polycystic Kidney Disease
adult polycystic disease (abst) 688
atrial natriuretic factor in (abst) 395
change in renal tubular sodium and water handling in 247
genetic heterogeneity in (abst) 653
hypertension in (abst) 394
liver cysts in 882
mapping techniques in (abst) 653
prognosis of (abst) 647
reduction of cyst volume by percutaneous cystic puncture in (abst) 647
Poly-L-Lysine, conjugate of horseradish peroxidase with 771
Polymorphonuclear Glycolysis, in haemodialysis (abst) 725, 898
Polymorphonuclear Granulocyte Dysfunction, recombinant human erythropoietin in 504
Polytetrafluroethylene Grafts (abst) 700
Polyunsaturated Fatty Acids
in haemodialysis 797
in lipid peroxidation (abst) 669
Potassium
in chronic renal failure (abst) 471
monitoring in bicarbonate dialysis S122
Predialysis
osteocalcin in (abst) 731
parathyroid hormone in (abst) 731
vitamin D in (abst) 731
Prednisolone, in hypophosphataemia 62
Prednisone
in diabetes mellitus 220
in glomerulonephritis S23
in nephrotic syndrome 914
in renal transplantation (abst) 398
Pregnancy
Adriamycin induced renal disease (abst) 662
cresent formation during 619
haemodialysis (abst) 669
mesangial IgA disease in 619
renal transplantation (abst) 745
sensitivity for endotoxin (abst) 305
Preterminal Chronic Renal Insufficiency
encephalopathy in (abst) 897
polyneuropathy in (abst) 897
Primary Anticardiolipin Syndrome (abst) 647
Primary Hyperoxaluria, liver transplantation in 825
Probucol in nephrotic syndrome (abst) 673
Procollagen Aminoterminal Propeptide, type III (abst) 828
Progressive Hereditary Nephritis. *See* Alport's Syndrome
Prostacyclin, in haemodialysis (abst) 470
Prostaglandin E, bilateral ureteral obstruction (abst) . 659
Prostaglandin E1 in nephrotoxic nephritis (abst) . . . 676
Prostaglandin E_2
in haemodialysis 937
in polycystic kidney disease 247
Prostaglandin I_2, in acute renal failure (abst) 317
Prostaglandins
in cyclosporin-associated arteriolopathy (CAA) (abst) 663
in cytokine stimulated mesangial cells (abst) 685
in IgA nephropathy (abst) 677
Protein
dietary intake (abst) 671
dietary restriction
(abst) 673–4
in diabetic nephropathy (abst) 672
in glomerulosclerosis (abst) 671
in proteinuria (abst) 671
permeability in CAPD (abst) 313
Protein Catabolic Rate
and malnutrition (abst) 707
in dialysis S125
Protein Clearance
in diabetic nephropathy 337
in glomerulonephritis 337
Protein Intake
and urea excretion 552
in CAPD (abst) 717
in diabetic nephropathy (abst) 750
in dialysis S125
Protein Load
effect on glomerular filtration rate (abst) 397
effect on urinary protein excretion (abst) 302
haemodynamic response to 2
in comparison to essential amino acids 572
mechanisms of stimulation of GFR by 4
renal response to 1
Proteinuria
Adriamycin in (abst) 679
and renal cysts (abst) 644
captopril in (abst) 671
clinical implications S10
glomerular basement membrane in (abst) 679
in diabetic nephropathy 623
in military service (abst) 395
in PAF (abst) 679
in prednisone therapy 914
in TNF (abst) 679
management of S35
obesity-related (abst) 653

pathophysiology S10
protein restricted diet in (abst) 671
Proteoglycans, in peritoneal cavity (abst) 759
Proximal Tubular Cells, intestinal alkaline phosphatase in (abst) 661
Proximal Tubular Epithelial Cells (PTEC) (abst) . . . 297
Pruritus, in ESRD (abst) 701
Pseudouridine
accumulation in renal insufficiency (abst) 666
in kidney disease (abst) 391
Psoriasis, 1,25$(OH)_2$ vitamin D3 in 293
Pulsed Wave Doppler, in haemodialysis (abst) 700
Puromycin
in acute renal dysfunction (abst) 659
in nephrotic syndrome (abst) 317
Pyrogen-Permeability of membranes (abst) 706
Quality of Life Analysis, in dialysis (abst) 897
Radiographic Contrast Agents, renal toxicity of 84
Ranitidine
in calcium-carbonate absorption (abst) 731
in renal transplantation 980
Recombinant HBs Vaccine, in haemodialysis (abst) . . 709
Recombinant Human Erythropoietin (see also Erythropoietin)
administration of (abst) 830
against red cell oxidation (abst) 741
and enzyme activities in peripheral blood neutrophils (abst) 743
and erythroid precursors (abst) 737
and growth hormone response to growth hormone releasing hormone (abst) 738
and sympathetic nervous system (abst) 740
effect of aluminium on (abst) 738
effect of galenic (abst) 743
effect on cardiac function (abst) 738
effects on haemodynamics 444
erythrocyte indices 77
immunoglobulin production by B-lymphocytes (abst) 742
in aluminium intoxication in the rat 258
in anaemia 232, 950, S102
in anaemia (abst) 737
in end-stage renal disease (abst) 899
in haemodialysis 441, S102
in haemodialysis (abst) 299, 739, 742
in iron overload (abst) 739
in polymorphonuclear granulocyte dysfunction . . . 504
in renal transplantation (abst) 754
in women on dialysis 834
increase in haematocrit (Hct) induced by (abst) . . . 739
metabolism in the rabbit 855
optimal application form (abst) 737
sexual function with 204
subcutaneous therapy (abst) 759
Recombinant Human Growth Hormone, in renal transplantation (abst) 754
Recombinant Tissue Plasminogen Activator
in subclavian vein thrombosis 400
in thrombolysis of clotted central venous catheters (abst) 709
Red Blood Cells. *See* Erythrocytes
Red Cell Lithium 904
Red Cell Survival, effect of rhuEPO (abst) 741
Reflux Nephropathy
in uraemia (abst) 655
prognosis of (abst) 655
Refractory Secondary Hyperparathyroidism, vitamin D in (abst) 732
Rehabilitation of dialysis treated uraemic patients (abst) 705
Rejection
activity in diabetic recipients (abst) 748
interleukin 6(IL-6) in (abst) 307
neopterin in (abst) 307
Renal Allograft-Infiltrated Lymphocytes (abst) 297
Renal Allograft Rejection
interleukin 2 in (abst) 747
tumour necrosis factor in (abst) 747
Renal Allografts
biopsy (abst) 753
ICAM-1 in (abst) 758
IL-2 monitoring 612
Renal Amyloidosis
aetiology of (abst) 643
heroin-associated 158
Renal Arcuate Arteries, indomethacin sensitive vasoconstrictor from (abst) 641
Renal Artery Stenosis
diagnosis of (abst) 314
in renovascular disease 481
in transplanted kidneys (abst) 754
percutaneous transluminal angioplasty in (abst) . . . 686
Renal Biopsy
classical versus Biopty cut (abst) 643
transjugular (abst) 651
Renal Bone Disease, osteocalcin in (abst) 713
Renal Cell Carcinoma, in solitary kidney (abst) 651
Renal Cell Turnover, in allograft rejection (abst) . . . 829
Renal Cellular Hypoxia, in misonidazole binding (abst) 640
Renal Cortical Necrosis, in acute renal failure 542
Renal Cysts
and haematuria (abst) 644
and hypertension (abst) 644
and proteinuria (abst) 644
in tuberous sclerosis (abst) 394
Renal Disease
due to monoclonal renal gammopathies (abst) . . . 646
in children (book review) 556
management of (book review) 404
Renal Failure
end-stage 985
Heliobacter pylori in (abst) 646
in chronic lymphocytic leukaemia 1051
in neonates (abst) 395
in sucklings (abst) 395
organic anion transport system in (abst) 669
parathyroid bone disease in (abst) 311
sodium-lithium countertransport in (abst) 644
Renal Function
after tumour enucleation (abst) 651
cisplatin in (abst) 659
in paediatric patients (abst) 657
Renal Functional Reserve 410, 763
Renal Graft Recipients, endothelin in (abst) 690
Renal Graft Rejection, interleukin-6 in (abst) 753
Renal Granulomatous Sarcoidosis 18
Renal Growth, compensatory 552, 777
Renal Imaging, clinical (book review) 477
Renal Immunopathological Lesions, anticardiolipin antibodies in (abst) 647
Renal Insufficiency
anticardiolipin antibodies in (abst) 647
interleukin-2 in (abst) 713
pseudouridine accumulation in (abst) 666

Renal Na^+-D-Glucose Cotransporter (abst) 637
Renal Osteodystrophy
diagnosis of (abst) 733
in haemodialysis (abst) 710, 732
Renal Plasma Flow, effect of acute protein load 572
effects of calcium antagonists 82
Renal Replacement
in amyloidosis (abst) 664
in diabetes (abst) 644
in multiple myeloma (abst) 664
vascular disease in (abst) 300
Renal Reserve Filtration Capacity in kidney donors (abst) 753
Renal Selectivity Properties in diabetic microalbuminuria S66
Renal Size, methods of estimating 851
Renal Stone Disease, Tamm-Horsfall protein in (abst) 472
Renal Stone Formers
bone metabolism in (abst) 733
calcium in (abst) 733
hypercalciuria in (abst) 642
ion transport in (abst) 642
Renal Sympathetic Nervous System, and atrial natriuretic factor (abst) 694
Renal Toxicity, of radiographic contrast agents 84
Renal Transplantation
$1,25(OH)_2D3$ in 531
ABO-incompatible 148, 745
age-matching in 808
atrial natriuretic peptide in (abst) 695
Brazilian Registry 956
calcium load in 531
cardiac side effects in (abst) 746
cyclic-GMP in (abst) 695
cyclosporin in 84, 282, 531
cyclosporin in (abst) 308, 751, 755–7
cytomegalovirus in (abst) 749
diabetes mellitus in 788
dietary fish-oil in (abst) 308
endothelin in (abst) 755
erythrocytosis in 969
Escherichia coli in (abst) 759
FK506 in (abst) 756
from live related donors (abst) 749
glomerulonephritis in S42
HCV antibodies in (abst) 706
head-out water immersion 535
Heliobacter pylori in (abst) 646
hepatitis C virus in (abst) 748–9, 751–2
highly sensitised patients (abst) 750
HIV-transmission in (abst) 752
hypomagnesaemia in 812
hypophosphataemia in 62
in bacterial sepsis (abst) 747
in over 60 age group (abst) 755
in primary oxalosis 332
interleukin-2 in (abst) 752
lipid metabolism in (abst) 746
living-donor 407
malignancy in 282
methylprednisolone in (abst) 756–7
OKT3 in (abst) 756
omega-3 fatty acid-fish oil (FO) in (abst) 745
pancreas graft in (abst) 748
patient survival and causes of death after (abst) . . . 749
peptic ulceration in 289
physical exercise in 633
pregnancy in (abst) 745
ranitidine in 980
recombinant human erythropoietin in (abst) 754
recombinant human growth hormone in (abst) . . . 754
steroids in (abst) 756
urinary tract infection in (abst) 759
Renal Tubular Sodium, in polycystic kidney disease . 247
Renal Vascular Resistance
and cyclosporin (abst) 662
endothelium-derived relaxing factor in (abst) 641
in adult polycystic kidney disease (abst) 688
Renal Vasodilatation, amino acid induced (abst) . . . 639
Renal Vein Thrombosis, in membranous lupus nephritis S71
Renin-Angiotensin System in adult polycystic kidney disease (abst) 688
Renin-Angiotensin-Aldosterone System
and atrial natriuretic factor (abst) 694
effects of calcium antagonists 83
Renoparenchymal Hypertension, albumin in (abst) . . 686
Renotropin in nephrectomy 579
Renovascular disease, renal artery stenosis in 481
Renovascular Hypertension, captopril 99mTc-DTPA renography in (abst) 687
Respiratory Failure, CAVHD in (abst) 661
RFLP DRβ Typing, in idiopathic nephrotic syndrome (abst) 656
Rhabdomyolysis, in acute renal failure 461
Rheumatoid Arthritis
glomerulonephritis in 385
non-Hodgkin's lymphoma in 385
Rheumatoid Factor in glomerular bound antigen in chronic serum sickness rats (abst) 678
Saline, in urine profiles (abst) 833
Salt Appetite, in analbuminaemic rat (abst) 314
Salt Sensitivity in essential hypertension (abst) 690
Sandimmun, immunosuppressive potential (abst) . . . 758
Schistosomal Nephropathy, parastitic infection in (abst) 684
Segmental Necrotising Glomerulitis, clinical spectrum of S88
Sendai Virus in IgA nephropathy (abst) 675
Sero-Conversion, in haemodialysis (abst) 709
Serum Amyloid, in haemodialysis (abst) 724
Sexual Function, with recombinant human erythropoietin 204
Shoulder Joint Pain and stiffness in haemodialysis (abst) 709
Siderosis, in heart-valve prostheses 847
Skin
collagen defect of (abst) 670
mast cell proliferation (abst) 701
Skin Disorders in renal allograft recipients 379
Smooth Muscle Cells
cytosolic calcium in (abst) 689
intracellular pH in (abst) 689
Sodium
in chronic renal failure (abst) 471
urinary excretion 82
Sodium Acetate
in hypoxaemia (abst) 704
in lead poisoning (abst) 670
Sodium Balance
in haemodiafiltration S141
in haemodialysis S141
in hyperthyroidism (abst) 696
in modulated dialysis S154
Sodium Content, in CAPD 369
Sodium Excretion

and atrial natriuretic peptide (abst) 692
in diabetic nephropathy 337
in glomerulonephritis 337
in hypothyroidism (abst) 692
Sodium Handling, in idiopathic hypercalcuria (abst) . 652
Sodium Intake
in cystinuria (abst) 652
in hypertension (abst) 692
Sodium-lithium Countertransport, in renal failure (abst) 644
Sodium Modelling, in haemodiafiltration (abst) 716
Sodium Monitoring, in haemodialysis S162
Sodium Reabsorption, in nephrotic syndrome (abst) . 646
Sodium Transport in acromegaly (abst) 688
Solitary Kidney (book review) 404
Sorption Efficiency of haemoperfusion to uraemic toxins (abst) 397
Spinal Cord, compression of 554
Spondylarthropathy, craniocervical amyloidosis in . . 554
Spondyloarthropathy, in haemodialysis 199
Steroids
effect on intestinal absorption of aluminium and calcium 860
in glomerulonephritis S23
in hepatitis B virus 525
in lupus nephritis (abst) 468
in membranous lupus nephritis (abst) 650
in renal transplantation (abst) 756
Streptococcus, in CAPD peritonitis (abst) 897
Subclavian Vein Thrombosis
in haemodialysis 977
recombinant tissue plasminogen activator in 400
Subcutaneous Therapy
erythropoietin 553
recombinant human erythropoietin (abst) 759
Subtotal Nephrectomy, enalapril in (abst) 470
Subtotal Renal Ablation
enalapril in (abst) 673
glomerulosclerosis in (abst) 673
mesangial trafficking in (abst) 673
Sucklings, renal failure in (abst) 395
Sucrose-Rich Diets in Uraemia 923
Superoxide Anion Generation, in haemodialysis (abst) 468–9
Sympathetic Nervous System, and recombinant human erythropoietin (abst) 740
Symvastatin in nephrotic syndrome (abst) 673
Systemic Lupus erythematosus (SLE), hydralazine in (abst) 660
Systemic Vasculitis, endothelin in (abst) 676
Systolic Function, in dialysis 325
Tamm-Horsfall Protein
in hypertension (abst) 471
in renal stone disease (abst) 472
TCR Vβ T Cells in Chronic Renal Failure (abst) . . . 685
T-Cell Proliferation, cyclosporin A in 1038
T-Cell Subsets in uraemia (abst) 684
T Cells in CRF (abst) 685
Tetanus Toxoid, in IgA nephropathy (abst) 303
Thallium-Technetium Parathyroid Scanning (abst) . . 311
Thickened Joint Capsules and Tendons in dialysis related amyloidosis (abst) 727
Thin-membrane Nephropathy, antiglomerular basement membrane disease associated with 909
in kidney donors (abst) 306
Thrombocytopenia, in dialysis (abst) 469
Thrombolysis of Clotted Central Venous Catheters, recombinant tissue plasminogen activator (R-TPA) in (abst) 709
Thrombosis, in haemodialysis (abst) 707
Thromboxane
in bilateral ureteral obstruction (abst) 302, 659
in uraemia (abst) 668
Thyroid Dysfunction, in Alport's syndrome (abst) . . 645
Thyroid-stimulating Hormone in CRF (abst) 669
Thyroxine, in nephrolithiasis (abst) 471
Tissue Oxygenation, in anaemia 444
Tissue Plasminogen Activator (tPA), in haemodialysis 362
Tissue Plasminogen Activator Inhibitor (PAI), in haemodialysis 362
TNF in proteinuria (abst) 679
Total Parathyroidectomy with autotransplantation (abst) 730
Tranexamic Acid, in diffuse endocapillary glomerulonephritis 152
Transitional-cell Carcinoma, in acquired cystic disease of the kidney 464
Transplant Co-ordination Services 559
Transplant kidney, spontaneous decapsulation 75
Transplant Renal Artery Stenosis (abst) 748
Trypanosomiasis, in immunologically mediated glomerulonephritis (abst) 304
Tuberculosis in maintenance dialysis 584
Tuberous Sclerosis, renal cysts in (abst) 394
Tubular Cell Necrosis, after cardiac angiography (abst) 662
Tubular Cells, HLA-DR expression in 903
Tubular Function in chronic renal failure (abst) 665
Tubulointerstitial Disease in chronic lymphocytic leukaemia 616
Tumour Enucleation, renal function after (abst) . . . 651
Tumour Necrosis Factor
and mononuclear leukocytes (abst) 718
effect of membrane characteristics 270
in cuprophan haemodialysis (abst) 700
in haemodialysis (abst) 312, 724
in peritoneal dialysis (abst) 718
in renal allograft rejection (abst) 747
Ulcerative Colitis
and glomerulonephritis 628
idiopathic interstitial nephritis in 901
Ultrafiltration
atrial natriuretic peptide in (abst) 691, 693
calcitriol in (abst) 736
haemodynamic effects of body temperature variation (abst) 716
in CAVH or CAVHD 1031
Ultrasound
in acute renal failure (abst) 649
of parathyroid glands (abst) 733
Uninephrectomy (UNX), in spontaneously hypertensive rats (abst) 315
Uraemia
adaptation to anaemia 604
aluminium overload in 945
autonomic nervous system dysfunction in S98
autonomic neuropathy in S128
betathromboglobulin in (abst) 668
blood serum concentrations in (abst) 469
calcitriol in 1013
$Cl^-/NaCO_3^-$ anion exchanger in 1018
effect on natural killer cells 437
endothelin in (abst) 695
fibrinopeptide A in (abst) 668
hyperparathyroidism in S128

intermyocardiocytic fibrosis in 39
nephroangiosclerosis in (abst) 665
platelet abnormalities in (abst) 664
reflux nephropathy in (abst) 655
sucrose-rich diets in 923
T cell subsets in (abst) 684
thromboxane B_2 in (abst) 668
vessel subendothelium in (abst) 664
Uraemic Cardiomyopathy, Doppler echocardiography (abst) 711
in haemodialysis (abst) 706
Uraemic Myopathy, magnetic resonance spectroscopy in (abst) 392
Uraemic Neuropathy, in chronic renal failure (abst) . 646
Urea Distribution Volume (abst) 702
Urea Excretion and protein intake 552
Urea Kinetics, dialysis prescription (abst) 894
(abst) 697
direct calculation of (abst) 703
in CAPD (abst) 896
in dialysis (abst) 710
in haemodialysis 347
single pool algorithm 214
Ureagenesis in acute renal failure (abst) 663
Urinary Albumin Excretion, effect of acute protein load 572
Urinary Nitrogen Excretion, effect of acute protein load 572
Urinary Protein Excretion, in paediatric patients (abst) 657
Urinary Tract Infection
diagnostic and therapeutic aspects (abst) 466
fimbriae in (abst) 466
in renal transplantation (abst) 759
P1 blood group antigen and non-secretor phenotype in (abst) 760
Urine profile
diatrizoate in (abst) 833
iohexol in (abst) 833
saline in (abst) 833
UV Irradiation
in essential hypertension 906
influence on plasma vitamin D metabolites 906
Uveitis, in adolescents (abst) 399
UW Solution in kidney transplantation (abst) 754
Valvular Regurgitations, in chronic renal failure (abst) 711
Vancomycin
in CAPD peritonitis 235
with highly permeable dialysis membranes 697
Vascular Access
Hemasite device in 508
in haemodialysis (abst) 710
long term success rate of snuff-box (abst) 704
Vascular Disease, in renal replacement (abst) 300
Vascular Stability, impact of high blood flow S109
Vasculitic Syndromes, ANCA in (abst) 684
Vasculitis
antineutrophil cytoplasmic antibody in (abst) 309
myeloperoxidase autoantibodies associated with (abst) 298
treatment and monitoring S53
Vasoconstriction, cyclosporin A-induced (abst) 689
Vein Grafts, as arteriovenous fistulas (abst) 703
Venous Compliance in dialysis (abst) 708
Ventricular Function in dialysis (abst) 705
Verapamil, in compensatory renal growth 777
Vesicoureteric Reflux, renal functional reserve in (abst) 655
Vessel Subendothelium in uraemia (abst) 664
Visual Disorders, desferrioxamine in 945
Vitamin D
in chronic renal failure (abst) 732
in nephrotic syndrome (abst) 648
in predialysis (abst) 731
in refractory secondary hyperparathyroidism (abst) . 732
influence of UV irradiation 906
VLDL
effect of beclobrate 588
effect of carnitine 588
Water Excretion, in hypothyroidism (abst) 692
Water Handling, in polycystic kidney disease 247
Water Reabsorption, in nephrotic syndrome (abst) . . 646
Water Soluble Contrast Media (abst) 659
Wegener's Granulomatosis
antineutrophil cytoplasmic autoantibodies in (abst) . 296
cyclophosphamide pulse therapy in (abst) 648
White Blood Cells. *See* Leukocytes
Whole Body Filtration Coefficient in haemodialysis (abst) 712
X-Irradiation
in allograft rejection (abst) 306
in haemolytic-uremic syndrome (abst) 306
X-ray Fluorescence Analysis, glomerular filtration rate (abst) 638
Xanthine-Metabolising Enzymes in adriamycin nephrosis S63
Zinc
in chronic renal failure (abst) 392
in glomerulonephritis (abst) 393
Zinc Deficiency, in haemodialysis (abst) 705